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Abstract 
This thesis analyses the impact of the NHS Bowel Cancer Screening Programme (BCSP) since 
its national implementation. A regional cancer registry (Northern Colorectal Cancer Audit 
Group, NORCCAG, database) and the regional BCSP database were combined to obtain the 
full screening history for all patients diagnosed with a colorectal cancer (CRC) in the North 
East of England, out of the population eligible for screening. 
The CRCs in the screening population between April 2007 and March 2010 were identified 
and classified into four groups: control (diagnosed before first screening invite), screen-
detected, interval (diagnosed between screening rounds, after a negative screening 
episode), and non-uptake (declined screening). Patient demographics, tumour 
characteristics and survival were compared between groups. 
In all, 511 out of 1336 (38.2%) CRCs were controls; 825 (61.8%) were in individuals invited 
for screening of which 322 (39.0%) were screen-detected, 311 (37.7%) were in the non-
uptake group, and 192 (23.3%) were interval cancers. Compared with the control and 
interval cancer group, the screen-detected group had a higher proportion of men, left 
colon tumours, and superior survival, implying the guaiac-based faecal occult blood test 
(FOBt) is more effective at detecting cancers in these groups. There was no difference in 
demographics, tumour location/stage, or survival between control and interval groups. 
A cost-effectiveness analysis of altering the screening pathway by lowering the minimum 
criteria for an abnormal FOBt was performed and raises potential opportunities that the 
screening programme could develop in order to minimise on the number of missed 
cancers. 
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…screening is an admirable method of combating disease, since it 
should help detect it in its early stages and enable it to be treated 
adequately before it obtains a firm hold on the community. 
J. M. G. Wilson & G. Junger, Principles and Practice of Screening 
for Disease, World Health Organisation, Geneva, 1968. 
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Chapter 1 Colorectal Cancer: Résumé 
of the Literature 
 2 
  
1.1 Incidence 
Colorectal cancer is a major public health problem. In 2007, there were around 17,100 new 
cases diagnosed in men and 14,400 in women making it the third most commonly 
diagnosed cancer in the United Kingdom (excluding non-melanoma skin cancers). Cancer 
Research UK estimates that men have a 1 in 16 risk and women a 1 in 20 lifetime risk of 
being diagnosed with bowel cancer. In 2008 around 13,300 people died from colorectal 
cancer giving it the second highest mortality rate in the UK. 
Colorectal cancer incidence increases with increasing age of the patient. More than four 
out of every five new cases are diagnosed in people aged 60 and over. This peaks in the 70-
79 age group in men and in the over 75’s in women [1].  
In 2008, 1.23 million new cases of colorectal cancer were diagnosed worldwide. Incidence 
rates vary with geographical location with the lowest incidence occurring in South Central 
Asia, and Middle African countries. The highest rates are in Europe, North America and 
Australasia [2].  
1.2 Epidemiology 
1.2.1 Sex 
More than 100 people are diagnosed with colorectal cancer every day in the UK. Colorectal 
cancer affects more men than women, at a ratio of 1.56 over all ages (European age-
standardised rates), affecting 70 men and 56 women per 100,000 population in the UK [2, 
3].  
This difference in frequency is mirrored when the disease is subdivided into colon cancer 
and rectal cancer. The crude rates of cases of colon cancer per 100,000 persons are 42 and 
38, with the rates for rectal cancer being 28 and 19, for men and women respectively. 
The rates of advanced neoplasia (a cancer or adenoma at least 10 mm in diameter, with 
high-grade dysplasia, villous or tubulovillous histologic characteristics, or any combination 
thereof) are also independently associated with male sex (adjusted odds ratio, 1.73; 95% 
confidence interval, 1.52 to 1.98; p<0.001)[4]. 
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1.2.2 Age 
The rates of bowel cancer are linked with age, increasing as you get older. The vast majority 
of cases occur after the age of 60, a total of 84% of all new diagnoses. Figure 1.1 below 
shows the distribution of cases with age at diagnosis [2]. 
In the population aged 80 and over, the post-operative mortality is much higher than that 
of patients aged less than 65 (16% vs. 0.7%) [5]. The likelihood of an octogenarian being fit 
enough to survive a major bowel resection will be low, given their higher degree of frailty 
and co-morbidities [6]. By screening the population aged 60-74, with the long lag time 
between normal colonic mucosa and a colorectal carcinoma, it is hoped that the incidence 
of cancers in this elderly age group will decrease. However, as the mean age of the UK 
population becomes greater, there will be an increasing number of patients aged 75 and 
over who will be able to undergo the stress of a colorectal cancer resection. For these 
patients, survival rates have been shown to be acceptable regardless of age [6]. 
11.0% of cases in men and 10.4% of cases in women occur in the age group of 50-59 years 
(rate of 66.6 in men and 50.4 in women per 100,000 population). This age group has been 
included in several mass population studies and recommended as a possible starting point 
for screening, but was not included in the English bowel cancer screening programme due 
to resource constraints [7]. 
In the younger population (aged 40 and below), the incidence of colorectal cancer is rare, 
accounting for 2.3% of all cancers. However, this figure is increasing (from 1.4% in 1990-
1999 to 3.0% from 2000-2009 in one UK study) [8]. Although predisposing factors such as 
inflammatory bowel disease and genetic cancer conditions (FAP and Lynch syndrome) 
make up a larger proportion of cancers than in the older age group (16%), sporadic 
tumours still comprise the majority of these cancers, with a family history of colorectal 
cancer being attributed to the rest (22.7%)[9]. 
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Figure 1.1 Number and incidence rates of colorectal and anal cancer by age group [2]. 
 
1.2.3 Family History 
A family history of colorectal cancer is associated with a greater risk of developing a similar 
cancer. Approximately 20% of colorectal cancers, excluding hereditary conditions (such as 
Lynch Syndrome, and Familial Adenomatous Polyposis, FAP) or inflammatory bowel 
diseases are linked with a family history of the condition. Patients must have either one 
first-degree relative diagnosed with a colorectal cancer aged under 45, or two first-degree 
relatives of any age, to have an increased risk (16-25% for men, 10-15% for women)[10]. 
 
1.2.4 Socioeconomic Status 
In men, there is a direct correlation between the incidence of colorectal cancer and level of 
social deprivation. In both the 1995-1999 and 2000-2004 time periods, there was a 
statistically significant (p=0.02 & p=0.001 respectively) drop in incidence when men move 
from lower to higher socioeconomic groups. Incidence rates were 11% higher in the most 
deprived groups compared to the most affluent. However, this variation is not observed for 
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women [11]. This could be due to a dietary influence and/or increased rates of smoking and 
alcohol use that are associated with lower socioeconomic groups. 
 
1.2.5 Smoking 
There is a well-established link between smoking and the risk of many different types of 
cancer, and this is also the case for colorectal cancer, although not as marked an effect as 
with some other cancers (e.g. lung).  
A meta-analysis performed in 2008 and published in the Journal of the American Medical 
Association, JAMA, looked at 106 observational studies, from which a relative risk of 1.18 
(95% confidence interval, 1.11-1.25) and an absolute risk increase of 10.8 cases per 100,000 
person-years (95% confidence interval, 7.9-13.6) was derived. There was also a dose 
dependent increase in risk, with a greater chance of developing colorectal cancer, the 
greater the number of pack years of an individual (however, this was only statistically 
significant after 30 pack-years). From 17 cohort studies analysed, the pooled risk was 1.25. 
They also found that for both incidence and mortality, the effect was greater with rectal 
cancers compared with colon cancers [12]. 
 
1.2.6 Diet 
In countries such as Japan where their residents diets have rapidly shifted from a 
“traditional” diet with steamed rice as the staple food, to “modernized” or “Westernised” 
with an excessive amount of protein and animal fat, there has been marked increase in the 
incidence of colorectal cancer [13]. For Japanese males (in two of the three regional 
registries), there has been greater than a 90% increase in incidence between 1963 and 
2002 [14]. 
 
1.2.7 Medication Use: Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Aspirin and 
Statins 
For both rheumatoid (RA) and osteoarthritis (OA) patients, there is a significant decrease in 
the risk of developing a colorectal cancer. For RA patients, the standardized incidence ratio 
(SIR) for males is 0.87 (95% CI 0.7–1.1), and for females is 0.71 (95% CI 0.6–0.9). For OA 
patients, for males the SIR is 0.88 (95% CI 0.8 –1.0) and for females the SIR is 0.84 (95% CI 
0.8–0.9) [15]. The reasons behind this are thought to be due to non-steroidal anti-
inflammatory drug (NSAID) use. 
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Non-steroidal anti-inflammatory drugs are thought to decrease the risk of colorectal cancer 
by inducing programmed cell death, known as apoptosis, of cancer cells as well as inhibiting 
the production of prostaglandin, which is “known to promote tumour angiogenesis and cell 
proliferation” [16]. Shadman et al. (2009) found a 30% decrease in colorectal cancer risk 
(odds ratio 0.70, 95% confidence interval 0.56-0.88) in patients who had ever used NSAIDs, 
but only for those patients who were currently taking them. 
Aspirin use is also associated with improved survival from colorectal cancer, after diagnosis. 
However, this was only statistically significant for those patients whose cancers 
overexpress the enzyme COX-2 compared with tumours with weak or absent expression 
(multivariate hazard ratio, 0.39 vs. 1.22) [17]. 
It is also associated with a reduced risk of colorectal cancer (pooled odds ratio 0.62, 95% CI 
0.58-0.67, p<0·0001) [18], a reduced risk of Dukes’ D cancers (odds ratio 0.52, 95% CI 0.35-
0.75, p=0.0006), and of a reduced risk of developing distant metastases on follow up, after 
diagnosis (HR 0.26, 95% CI 0.11—0.57, p=0.0008) [19]. As part of the CAPP2 randomised 
trial, 600mg of aspirin per day for an average of 25 months, produced a hazard ratio for 
colorectal cancer of 0.41 (95% CI 0.19-0.86, p=0.02) against placebo [20]. 
There is some disagreement as to whether the use of statins (3-Hydroxy-3-methylglutaryl 
CoA reductase inhibitors) increases or decreases a patient’s risk of colorectal cancer. A 
meta-analysis of the subject was performed in 2006 of which 27 randomized controlled 
trials of statin use were included. Criteria for inclusion were a mean duration of follow-up 
of at least 1 year, enrolment of a minimum of 100 patients, and reporting of data on either 
cancer incidence or cancer death. Out of 6662 incident cancers and 2407 cancer deaths, 
statins did not reduce the incidence of cancer (odds ratio, 1.02; 95% confidence interval, 
0.97-1.07) or cancer deaths (odds ratio, 1.01; 95% confidence interval, 0.93-1.09) [21]. 
1.3 Genetics 
1.3.1 Hereditary Cancer Syndromes 
There are several genetic theories as to the cause of colorectal cancer. These originate 
from work done looking at the hereditary cancer syndromes, of which the most common 
are Lynch Syndrome (aka Hereditary Non-Polyposis Colorectal Cancer, HNPCC), and Familial 
Adenomatous Polyposis, FAP. It is through FAP investigation that the adenoma-carcinoma 
sequence was postulated for the development of colorectal cancers. 
The Bowel Cancer Screening Programme’s aim is not only to identify colorectal cancers at 
an early stage, but also to identify, remove and stage adenomatous polyps. This is to 
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prevent the postulated natural progression of colorectal adenomas into carcinomas, 
thereby decreasing the incidence rate and mortality from colorectal cancer. Adenoma 
progression to a carcinoma takes an average of 5.5 years for large polyps (>1cm) and up to 
10 years for smaller polyps [22]. 
 
1.3.2 Lynch Syndrome (aka Hereditary Non-Polyposis Colorectal Cancer, HNPCC) 
Lynch Syndrome is the most common of the hereditary colon cancer syndromes and 
accounts for between 1-6% of all cases of colorectal cancer [23]. Lynch Syndrome is an 
autosomal dominant condition and is thought to be due to mutations in five DNA mismatch 
repair genes; hMSH2, hMLH1 (most common), hPMS1, hPMS2 and hMSH6. In those 
persons who have mutations in both copies of the above genes, there is an ever increasing 
amount of DNA sequence errors. This is primarily in seen in segments of DNA containing 
multiple, short, repeated sequences known as a microsatellites [24]. 90% of colorectal 
cancers and 80% of colorectal adenomas display microsatellite instability (MSI) – the 
widespread expansion or contraction of these short sequences of DNA [25]. Those with the 
trait have an 80% lifetime risk of developing a colorectal cancer, which tends to develop at 
a younger age compared to sporadic cancers. Whilst the total number of colorectal polyps 
found in sufferers tends not to be greatly increased; the polyps are of a larger size and 
more dysplastic [26]. Lynch Syndrome is also associated with other types of cancer, most 
commonly endometrial cancer, but also ovarian, gastric, biliary and urinary tracts. 
Diagnosis of this condition was initially with the Amsterdam criteria [27, 28] and then with 
the Bethesda guidelines [29]. An overview of the current revised Bethesda guidelines are 
shown here: 
1. Colorectal cancer diagnosed at age <50 years. 
2. Synchronous or metachronous colorectal or other Lynch Syndrome associated 
tumours regardless of age. 
3. Colorectal cancer diagnosed at age <60 years with histologic findings of infiltrating 
lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet ring 
differentiation or medullary growth pattern. 
4. Colorectal cancer in ≥1 first-degree relative(s) with a Lynch Syndrome tumour, with 
one of the cancers being diagnosed at age <50 years. 
5. Colorectal cancer diagnosed in ≥2 first- or second-degree relatives with Lynch 
Syndrome tumours, regardless of age. 
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Known Lynch Syndrome patients undergo frequent colonoscopies starting from 10 years 
before their youngest known relative was diagnosed, to detect and to remove polyps, as 
well as diagnosing colorectal cancers. They are also offered screening for the other cancers 
associated with Lynch Syndrome, e.g. endometrial aspiration. 
 
1.3.3 Familial Adenomatous Polyposis, FAP 
Familial adenomatous polyposis syndrome, FAP, is also an autosomal dominant condition. 
It is characterised by the presence of over 100, sometimes over 1000 colorectal polyps.  It 
accounts for approximately 1% of all cases of colorectal cancer. 
It is caused by a mutation in the adenomatous polyposis, APC, gene, located on 
chromosome 5. This mutation causes uncontrolled growth of colorectal adenomas starting 
from a young age, mean of 16 yrs. These polyps are histologically identical to polyps found 
in non-FAP sufferers. It is from this knowledge that the theory of the adenoma-carcinoma 
sequence came about. 100% of patients with FAP will go on to develop colorectal cancer, 
where it is thought that the adenomas have an increasing amount of dysplasia over time 
before developing into adenocarcinoma cells. 
Again, FAP is associated with other cancers such as papillary thyroid cancer, 
hepatoblastoma, and adrenal hyperplasia/carcinoma. Treatment for these patients is with 
prophylactic colectomy, normally performed during adolescence, as well as screening for 
the above associated cancers. 
Mutations in the APC gene have also been suggested to have a role in the development of 
sporadic colorectal cancers. In up to 80% of sporadic cancers, somatic mutations of the APC 
gene are found. This would suggest their involvement in initiating tumourigenesis. [30]. 
 
1.3.4 Adenoma-Carcinoma Sequence 
This is the theory that colorectal cancers will develop from a colorectal adenoma. Evidence 
for this hypothesis is described here.  
Adenomas exhibit variation and differences (dysplasia) from normal mucosa in their 
cytological and architectural features. The degree of dysplasia they possess, ranges from 
mild to severe. Often seen are areas of focal severe dysplasia within an otherwise 
mildly/moderately dysplastic adenoma. The epidemiology of adenomas and carcinomas are 
significantly similar with correlating distributions by site, as well as a similar changing 
distribution with the populations’ age. As with dysplastic adenomas, within 57% of early 
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colorectal cancers (T1, limited to the submucosa), the carcinoma can be seen adjacent to 
adenomatous tissue. In the small number of patients in which they have declined 
treatment for their adenoma, follow-up has shown that there is cancer at the same site as 
the adenoma. The importance of this sequence is that it is theoretically possible to prevent 
the development of a colorectal cancer by screening a population for adenomas and 
removing them, therefore preventing their progression. There are, however, descriptions 
of colorectal cancers appearing ‘de novo’, i.e. not from an adenoma, this can be seen in 
chronic inflammatory bowel disease, where a cancer can arise from “within a plaque of 
dysplastic epithelium showing villous change” [31].  
 
1.3.5 Mismatch Repair Genes and Microsatellite Instability 
Microsatellite instability has an important role in the pathogenesis of colorectal cancers. Its 
finding within a large proportion of ‘interval bowel cancers’, has been suggested as a 
possible indictor of fast growth of these tumours, giving an explanation as to why they are 
diagnosed after a recent examination of a patients large bowel. This will be discussed 
further in the section on interval cancers. 
Mismatch repair, MMR, genes act to maintain the integrity of the genome by correcting 
DNA base pairing errors in newly replicated DNA. There are 7 MMR genes (MLH1, MLH3, 
PMS1, PMS2, MSH2, MSH3 and MSH6, spread over 5 chromosomes.  When there is a 
defect in one these genes, repeated accumulation of errors spread across the genome, 
termed microsatellite instability, MSI. 
Whilst an abnormality of a MSI is found in 90% of HNPCC cancers, it is also found in 
approximately 15% of non-familial colorectal cancers [32]. However, a Korean paper found 
that those patients whom had a colorectal cancer resected were not at greater risk of 
developing an adenoma or advanced adenoma at their follow up colonoscopies 1 and 3 
years post operatively. By performing this review of the histology of these patients, they 
diagnosed 11.6% of patients who were found to have a high level microsatellite instability 
with Lynch Syndrome [33]. 
MSI instability has also been found to be a prognostic factor in colorectal cancer [34]. In a 
recent meta-analysis looking at whether MSI could be viewed as a predictive factor in 
effectiveness of chemotherapy, the authors “showed that there was no survival difference 
among MSI-High patients whether or not they received chemotherapy, whereas MSS 
patients had a better response to chemotherapy, suggesting that MSI could be considered 
as a predictive marker of chemoresistance” [35]. However, for those patients undergoing 
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chemotherapy for colorectal metastases, a similar meta-analysis showed no difference in 
response as to whether patients had MSI or not found as part of their cancers [36]. 
1.3.6 BRAF/KRAS Mutations 
The Ras/Raf/MEK/ERK signalling pathway plays an important role in the regulation of cell 
proliferation, differentiation, and survival. An activating mutation in the RAF gene, BRAF, 
leads to unregulated cell growth and tumour proliferation. Mutations of the BRAF gene 
have been reported in 9.5–23.5% of all sporadic colon cancers and are strongly associated 
with microsatellite instability (MSI) in sporadic colon cancers [37]. In a study by Samowitz 
et al. “the BRAF mutation was seen in 5% (40 of 803) of microsatellite-stable tumours and 
51.8% (43 of 83) of microsatellite-unstable tumours. In microsatellite-stable tumours, this 
mutation was related to poor survival” [38]. 
 
1.3.7 CIMP (CpG island methylator phenotype) Status 
There is a third theory in the development of a colorectal cancer, along with APC/KRAS 
gene malformations and microsatellite instability. This is known as CpG island methylator 
phenotype, or CIMP, where abnormal DNA methylation leads to silencing of CpG rich genes 
causing the development of a colorectal cancer. 
A study by Sanchez et al. looked at the prevalence of MSI, CIMP status as well as BRAF and 
KRAS mutations in colorectal cancer histology. They found that CIMP-High was found in 
21.2% of tumours and MSI-High in 21.0%. The CIMP-H tumours tended to present in an 
older age group, 10 years later than CIMP-negative tumours. 
MSI-H/CIMP-H tumours had a higher rate of BRAF mutation (72%) than the other groups 
(p<0.001). 34.0% of microsatellite stable tumours had KRAS mutations compared with only 
13 per cent of MSI-H tumours (p<0.001) [39].  They did not find that CIMP status was linked 
to a worse outcome, as has been reported in other studies [40, 41]. 
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1.4 Chapter Conclusion 
In this chapter, the incidence of colorectal cancer has been discussed, broken down into 
differences between gender and age. Patient and environmental factors have been 
reviewed in their effect on the risk of developing a colorectal cancer. These include a family 
history of a cancer, smoking and alcohol consumption, diet, and certain medication use 
(non-steroidal anti-inflammatory drugs, aspirin, and statins).  
Finally, the genetics of colorectal cancer development through the widely accepted adeno-
carcinoma sequence has been covered. The specific genetic mutations that increase the 
likelihood of developing a cancer are included (micro-satellite instability, CIMP status, 
mismatch repair genes and BRAF/KRAS mutations). These have particular importance as 
have been associated with the development of fast growing, interval colorectal cancers, 
which will be discussed in a later chapter. 
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Chapter 2 Screening: General 
Background 
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2.1 Screening Definition 
The UK National Screening Committee defines screening as “a process of identifying 
apparently healthy people who may be at increased risk of a disease or condition. They can 
then be offered information, further tests and appropriate treatment to reduce their risk 
and/or any complications arising from the disease or condition” [42]. 
In 1968, Wilson & Jungner put forward their criteria for a screening programme [43]: 
1. The condition sought should be an important health problem. 
2. There should be an accepted treatment for patients with recognized disease. 
3. Facilities for diagnosis and treatment should be available. 
4. There should be a recognizable latent or early symptomatic stage. 
5. There should be a suitable test or examination. 
6. The test should be acceptable to the population. 
7. The natural history of the condition, including development from latent to declared 
disease, should be adequately understood. 
8. There should be an agreed policy on whom to treat as patients. 
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed) 
should be economically balanced in relation to possible expenditure on medical 
care as a whole. 
10. Case-finding should be a continuing process and not a “once and for all” project. 
Screening clinical trials are expensive and harder to carry out compared with standard 
trials. Patient recruitment is more challenging as subjects are healthy, asymptomatic 
individuals, of which large numbers are required, with a long lag time between intervention 
and outcome (predominantly disease specific mortality). A screening programme puts 
subjects at risk of complications from the test, or from the treatment of a screen detected 
condition. There are also risks of over-diagnosis, or false-negative results among each 
programme. 
2.2 Cervical Screening 
Cervical screening was the first screening programme that caused both an increase in the 
incidence of a condition, but also a decrease in its mortality rate. This was due to the fact 
that the screening test was able to pick up cancers that were “in situ” and therefore had an 
excellent prognosis following surgery [44]. 
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The Papanicolaou (Pap) smear test was first described in 1943 and the test used in cancer 
detection centres across the United States. Cervical screening started in England in 1964, 
however it was not until the 1980’s, when the screening interval was changed to every 
three years, and a national call and recall system was introduced, did the uptake rate 
increase significantly. In 1988, the coverage of the target age group was at 42%, however 
this rose to 85% in 1994 [45]. The introduction of the programme occurred despite there 
never being a randomised controlled trial comparing outcomes of a screened population 
against a non-screened population [46]. 
The cervical screening programme has been criticised due to the high rates of interval 
cancers secondary to inadequate sampling or reporting error. An Australian study reported 
an interval cancer rate of 13.2% of all cancers diagnosed, with only 7.7% of interval cancer 
slides re-reviewed that were deemed truly negative and of a high quality [47]. Within the 
NHS Cervical Screening Programme, the interval cancer rate for invasive cervical cancers 
was 45.2% in one UK region between 1985-1996, of which 49.1% were after negative 
cytology. On reviewing of the cytology of these slides, 41.1% were confirmed as negative, 
11.0% were deemed inadequate, 17.0% were felt to be low-grade dyskaryosis, and 31.0% 
as high-grade dyskaryosis. The authors attribute these high rates due to “no rapid review or 
preview of negative smears; there was no external quality control; there were no standards 
for cytology reporting rates”. Initially, a certificate of competence for cytology screeners 
was not mandatory for qualified biomedical scientists. However, such measures have since 
been introduced [48]. 
2.3 Breast Screening 
The NHS Breast Screening Programme began in 1988, employing single view 
mammography and inviting women aged 50–64 years for screening once every three years. 
By 2005, the programme changed to using two-view mammography with 1.3 million 
women aged 50–70 years screened annually. This number equates to approximately 75% of 
those invited. In the UK, it costs £75 million per year, or £45.50 per woman screened [49].  
Possibly due to the halo effect, women with symptomatic breast cancer are typically 
presenting with smaller tumours than before 1988. Screening for breast cancer also has an 
impact on other treatment modalities with a substantially greater proportion of women 
with breast cancer receiving chemotherapy and/or hormonal therapy than before 1988.  
Mammographic screening between the ages of 50 and 70 years reduces mortality from the 
malignancy. The International Agency for Research on Cancer (IARC) concluded that the 
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25% reduction in mortality seen in the trials of mammographic screening, based on an 
‘intention to treat’ analysis, implies a reduction in breast cancer mortality of about 35% for 
women who are screened regularly. The current NHS breast screening programme 
diagnoses about 10,000 breast cancers annually and saves an estimated 1400 lives each 
year in England [50]. 
A Cochrane review published in 2009 reviewed breast cancer screening with 
mammography [51]. They identified and reviewed 8 randomised trials comparing 
mammographic screening with no mammographic screening. Out of these 8 trials, the 
authors judged that 3 were adequately randomised (Canada 1980, Malmö 1976 and UK age 
trial 1991), and 5 were suboptimally randomised but still included in the analysis [Göteborg 
1982, New York 1963, Stockholm 1981, Two- County 1977 and the extension of the Malmö 
trial, MMST II 1978). The three adequately randomised trials did not find a statistically 
significant effect of mammographic screening on deaths ascribed to breast cancer, relative 
risk (RR) 0.93 (95% CI 0.79 to 1.09) after 7 years and RR 0.90 (95% CI 0.79 to 1.02) after 13 
years. The four suboptimally randomised trials found a beneficial effect: RR 0.71 (95%CI 
0.61 to 0.83) after 7 years and RR 0.75 (95% CI 0.67 to 0.83) after 13 years. The combined 
risk reduction for all seven trials was 0.81 (95% CI 0.72 to 0.90) after 7 years and 0.81 (95% 
CI 0.74 to 0.87) after 13 years. All-cause mortality was not significantly reduced. 
Significantly more breast operations (mastectomies plus lumpectomies) were performed in 
the study groups than in the control groups: RR 1.31 (95% CI 1.22 to 1.42) for the two 
adequately randomised trials; RR 1.42 (95% CI 1.26 to 1.61) for the suboptimally 
randomised trials. 
When data from 40,075 Norwegian women with invasive breast cancer were analysed, 
comparing mortality rates between the screened and non-screened group, against a 
historical non-screened group [52]. This showed a reduction in death rate of 7.2 deaths per 
100,000 person-years in the screened group (RR 0.72, 95% CI 0.63 to 0.81, p<0.001), and by 
4.8 deaths per 100,000 person-years (RR 0.81, 95% CI 0.71 to 0.93, p<0.001). The authors 
surmise that the reduction in mortality due to screening alone was 2.4 deaths per 100,000 
person-years (1/3 of the total reduction). The introduction of multi-disciplinary teams in 
the management of patients with breast cancer between the historical and contemporary 
groups is suggested as being the predominant factor in the mortality reduction seen. In 
addition to this, new treatment modalities were introduced between groups, namely 
sentinel lymph node biopsies. From the editorial accompanying the above Norwegian 
paper, the impact of breast screening was outlined: “If you screen 2500 women over the 
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age of 50 for 10 years, then one breast cancer death might be avoided at the cost of 1000 
false alarms and between five and 15 women being over-diagnosed and treated needlessly 
with surgery, radiotherapy, and chemotherapy” [53, 54]. In the UK, for women aged 40-55, 
the mortality risk reduction from breast cancer screening moves from 0.41% to 0.35%, a 
difference of 0.062%. Therefore, the number needed to be screened to avoid one death is 
1610. At age 60, the number needed to be screened is still 259 to avoid one death [49]. 
 
No screening programme is without risks to those patients being screened. The main risk 
with any programme is likely to be the implications of a false positive result, including both 
physical and psychological effects. The Cochrane review reports that those women who 
had a false positive result were “twice as likely to suffer psychological consequences three 
years later than women who received a clear result after their last mammogram”. The 
authors conservatively estimate that the rate of overdiagnosis is 30% with more than 10% 
of these women experiencing marked psychological distress due their false positive result. 
Controversy around breast cancer screening revolves around early breast cancers and 
ductal carcinoma in situ (DCIS). Approximately 20% of screen detected cancers in the UK 
during 2009/2010 were DCIS [55]. There is a debate regarding how this should be managed, 
as this pre-malignant condition may never become an invasive cancer in the patient’s 
lifetime. Even if it does, low grade DCIS will only become a low grade invasive cancer, which 
again may not be attributable to a patient’s cause of death. 
Jørgensen & Gøtzsche reviewed whether these risks described above are accurately 
represented on websites by interest groups [56]. They reviewed 13 websites from advocacy 
groups and 11 from government institutions, all of which whom recommended 
mammographic screening, and 3 from consumer organisations who questioned it 
(p=0.0007). They reviewed whether specific topics were covered in each of the websites, 
such as lifetime risk of developing breast cancer, survival rate, number needed to treat, 
overdiagnosis and overtreatment. The authors found that the websites from professional 
advocacy groups had poor information and was “severely biased in favour of screening”. 
The consumer organisation’s websites were “much more comprehensive and balanced”. In 
2009, Baum et al. called upon the patient information leaflet “Breast Screening: the Facts” 
to be rewritten as the full risks and benefits were not accurately conveyed to the public 
[54]. 
The cost effectiveness of the Breast Cancer Screening Programme has been reviewed by 
Pharoah et al. [57]. They calculated that screening was associated with a cost of £20,800 
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per quality adjusted life year (QALY) gained. This equates to 9.2 days gained per person 
time survival. However, in only 45% of cases did the QALY gained of screening fall below 
NICE’s cut-off level of £20,000, with 12% of cases screening being associated with a 
reduction on QALYs. 
The Independent UK Panel on Breast Cancer Screening published their findings and 
recommendations in the Lancet in 2012 [58]. They primarily reviewed 11 randomised trials 
where on meta-analysis the relative risk of breast cancer specific mortality of screened 
individuals against controls was 0.80 (95% CI 0.73 to 0.89). It accepted that overdiagnosis 
did occur, but estimates as to its effect have been exaggerated in previous studies. 
However, they calculate that for every breast cancer death prevented through screening, 
there were three overdiagnosed cases identified and treated. This equates to a 1% chance 
of women aged 50-52 years having an overdiagnosed cancer during the next 20 years. 
Despite this, they conclude that the UK breast screening programme “confers significant 
benefit and should continue”. 
2.4 Chapter Conclusion 
In this chapter, the background to screening has been discussed along with details of other 
screening programmes that are currently in use in the UK. 
There has been recent controversy regarding breast and cervical screening. Breast 
screening has been shown to have a high rate of false positive results leading to significant 
emotional stress to individuals who undergo surgical treatment. Cervical screening suffers 
from a significant rate of false negatives, particularly for cervical cancer, due to several 
different parts of its screening programme where errors may occur. 
The need for a robust screening tool that is easy to perform, with reliable and accurate 
results is crucial for an effective screening programme. It must be well accepted by the 
public, leading to a high uptake rate. Such a program must be evidence based, with proven 
outcomes on meta-analyses. 
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Chapter 3 Colorectal Cancer: Patient 
Presenting Features 
 
 
 
 19 
  
3.1 Symptoms of Colorectal Cancer 
Patients with a colorectal cancer may present to a healthcare professional with symptoms 
relating to the location of the lesion. 
A large number of patients will be asymptomatic with their cancer, but, of those that are 
symptomatic, their related symptoms can be split into rectal, distal to the splenic flexure 
and proximal to the splenic flexure cancers. Early bowel cancers are unlikely to cause a 
patient symptoms, therefore the problems described below are more likely to be caused by 
more advanced colorectal cancers (Dukes C/D), in particular weight loss and iron deficiency 
anaemia [59]. 
Pre-screening, the frequencies of initial symptoms that patients have presented with due 
to a resectable colorectal cancer are shown below. Some patients may present with more 
than one symptom [60]. 
 
 Abdominal pain (including pain secondary to bowel obstruction or bowel 
perforation) – 44% 
 Change in bowel habit – 43% 
 Haematochezia or melaena – 40% 
 Lethargy – 20% 
 Anaemia without other gastrointestinal symptoms – 11% 
 Weight Loss – 6% 
 
The prognosis of patients who present with different symptoms has been reviewed by 
Steinberg et al. [61]. They showed that if you present with abdominal pain secondary to 
bowel obstruction then you have a significantly worse prognosis compared to presenting 
without an obstruction (p=0.003 for survival). This effect is stays true after correcting for 
age, gender and Dukes’ stage. A similar result is seen with bowel perforation. 
 
From the systematic review and meta-analysis by Ford et al., the table below shows both 
the sensitivity and specificity of individual symptoms that are caused by a colorectal cancer 
[62]. 
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Symptom 
Sensitivity (95% 
CI) 
Specificity (95% 
CI) 
Positive likelihood 
ratio (95% CI) 
Negative 
likelihood ratio 
(95% CI) 
Rectal bleeding 64% (55-73%) 52% (42-63%) 1.32 (1.19-1.47) 0.76 (0.66-0.87) 
Change in bowel 
habit 
41% (23-60%) 69% (58-78%) 1.29 (1.05-1.59) 0.82 (0.66-1.01) 
Anaemia 17% (5.5-33%) 90% (87-92%) 1.43 (0.75-2.74) 0.96 (0.87-1.06) 
Weight loss 22% (14-31%) 89% (81-95%) 1.96  (1.25-3.08) 0.91 (0.84-0.98) 
Diarrhoea 19% (1-54%) 80% (63-93%) 0.74 (0.34-1.62) 0.98 (0.85-1.13) 
Iron deficiency 
anaemia 
23% (2-57%) 87% (83-91%) 1.38 (0.48-3.94) 0.88 (0.68-1.13) 
Abdominal Mass 5% (2-9%) 97% (96-98%) 1.47 (0.68-3.19) 0.99 (0.95-1.02) 
Dark red rectal 
bleeding 
15% (3-34%) 96% (93-98%) 3.83 (2.62-5.61) 0.88 (0.75-1.04) 
Table 3.1 Sensitivity and specificity of symptoms in relation to a colorectal cancer [62]. 
 
The table shows that the difficulties in diagnosis for primary care physicians as those 
symptoms with a high specificity for a colorectal cancer (an abdominal mass and dark red 
rectal bleeding), have a poor sensitivity (i.e. only a small proportion of colorectal cancers 
will present with these symptoms). 
3.2 Difficulties in Diagnosis 
Due the fact that symptoms relating to colorectal cancer are typically related to more 
advanced tumours, there is considerable difficulty in making a diagnosis of a cancer at an 
earlier stage. There are also other conditions that can cause the same symptoms as a 
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colorectal cancer, potentially delaying diagnosis. Using rectal bleeding as an example, its 
major causes in a Dutch general practice setting are shown in the following table: 
 
Causes of PR Bleeding Frequency 
Haemorrhoids 55% 
Anal fissure, perianal abscess 15% 
Diverticulosis/diverticulitis 15% 
Malignant neoplasm colon/rectum 4% 
Chronic enteritis/colitis 2.5% 
Table 3.2 Causes of per rectal bleeding [63] 
  
The incidence of rectal bleeding is estimated to be: “20 per 100 people per year, the 
'consultation incidence' in general practice approximately six per 1000 and the incidence of 
referral to a medical specialist is estimated to be about seven per 10,000 per year” [63]. In 
a population based cross-sectional study in Denmark out of a total of 13,777 randomly 
selected persons aged 20 years and older, 5.7% (CI 5.2% to 6.3%) reported blood in bowel 
movements within the preceding 12 months, emphasising the widespread prevalence of 
this cancer alarm symptom [64]. 
An analysis of a large primary care database carried out by Hamilton et al. reviewed the 
symptoms of patients with colorectal cancer in the two years preceding their diagnosis 
[65]. Between the years of 2001 and 2006 (i.e. pre-screening), 5,477 patients with 
colorectal cancer were matched against 38,314 controls. 
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Clinical Feature 
Positive Likelihood 
Ratio (95% CI) 
Odds Ratio (CI) 
Symptoms   
Constipation 2.6 (2.4 to 2.7) 2.1 (1.9 to 2.3) 
Diarrhoea 3.2 (3.0 to 3.4) 2.4 (2.1 to 2.7) 
Change in bowel habit 5.5 (5.2 to 5.8) 14 (12 to 17) 
Rectal bleeding 6.0 (5.7 to 6.3) 20 (17 to 23) 
Weight loss   
5.0–9.9% 1.6 (1.4 to 1.8) 1.2 (0.99 to 1.5) 
≥ 10% 2.9 (2.6 to 3.1) 2.5 (2.1 to 3.0) 
Abdominal pain 3.5 (3.3 to 3.7) 3.9 (3.6 to 4.3) 
Investigations   
Haemoglobin (g/dl)   
<12.0 4.4 (4.2 to 4.6)  
12.0–12.9  1.7 (1.5 to 1.9) 
11.0–11.9  2.8 (2.4 to 3.2) 
10.0–10.9  5.9 (4.8 to 7.2) 
9.0–9.9  9.3 (7.1 to 12) 
< 9.0  18 (14 to 25) 
Mean red cell volume < 80 fl 2.8 (2.4 to 3.1) 6.5 (5.3 to 7.9) 
Diagnoses and Risk Factors   
Irritable bowel 
syndrome 
2.4 (2.1 to 2.8)  
Diabetes 1.2 (1.1 to 1.3)  
Obesity 1.0 (0.93 to 1.1)  
Table 3.3 Likelihood and odds ratio of clinical features in the diagnosis of colorectal 
cancer [65]. 
 
The positive predictive value (PPV) rises with age, especially after the age of 60, as well as 
with male sex. The highest values are for rectal bleeding and change in bowel habit. For 
men over 60 years, rectal bleeding PPVs ranged from 2.4% to 4.5%, with women being 2-
3%. Constipation, diarrhoea, abdominal pain and weight loss all have low positive 
predictive values of less than 1.5%. This study shows that most colorectal cancers present 
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with low risk symptoms, with the chance of these symptoms being due to a colorectal 
cancer being very low. 
3.3 Distribution of Colorectal Cancers 
Figure 3.1 shows the distribution of colorectal cancers in the UK between 2007 and 2009. It 
should be noted that approximately 60% of tumours diagnosed are distal to the splenic 
flexure. This is likely to have implications in the presentation of the majority of patients, 
and also the ability of a screening test to detect these cancers. 
 
 
Figure 3.1 Distribution of colorectal cancers [2] 
 
However, there has been a change over time towards more proximal, right-sided cancers as 
shown in the table below. 
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Site % CRC/site 1976–78 % CRC/site 1990–97 
Proximal To Splenic Flexure 23.6 36.7 
Distal To Splenic Flexure 27.2 27.1 
Rectal 44.4 31.9 
Unknown 4.8 3.5 
Multiple 0.0 0.8 
Table 3.4 Percentage Distribution over time of Colorectal Cancers in Northern Ireland 
[66].  
 
This change in distribution may be due to changes in dietary habits, physical activity, or 
other lifestyle factors as well as increased diagnostic activities affecting most age groups 
among women [67]. 
Rabeneck et al. performed a review of population-based cancer registries in the United 
States comparing the incidence of both right and left-sided colorectal cancers between 
1978 and 1998. They found that although there seems to be an increase in the proportion 
of right-sided cancers compared to left, this is actually because the incidence of left-sided 
cancers is decreasing. For right-sided cancers in whites, the age adjusted incidence rate 
during 1978-1980 was 15.1 per 100,000, moving to 15.0 per 100,000 during 1996-1998. In 
left-sided cancers in whites, the age-adjusted incidence rate during 1978-1980 was 15.6 per 
100,000 which fell to 12.6 per 100,000 during 1996-1998 [68].  
 
3.3.1 Rectal Cancers  
Patients will present with symptoms such as rectal bleeding that can be bright red in colour 
for rectal cancers, to a darker red for slightly more proximal lesions. 
They may have some obstructive symptoms such as change in their bowel habit towards 
constipation or the feeling of incomplete emptying after they have opened their bowels. 
Occasionally, they may present to an emergency department with a complete bowel 
obstruction, not being able to pass flatus or open their bowels. 
 
3.3.2 Cancers Distal to the Splenic Flexure 
Bleeding is a more prominent feature, although it may be of a darker red colour compared 
to rectal cancers. A change in bowel habit towards constipation is more likely [69]. 
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3.3.3 Cancers Proximal to the Splenic Flexure 
Again, patients may present with a change in their bowel habit, although this may be more 
towards diarrhoea. This is because faeces are more liquid in the proximal colon and are 
therefore less likely to be associated with obstructive symptoms. If these patients do 
present with an obstruction, vomiting may be more of a prominent feature. A palpable 
abdominal mass has a greater association with proximal cancers. For all colorectal cancers, 
patients will have symptoms common to all cancers such as weight loss, decreased 
appetite, malaise, etc.  Patients may have been found to be anaemic, often incidentally, 
which may represent blood loss from their cancer. 
Caecal and ascending colon tumours have a greater daily blood loss than tumours at other 
sites. The geometric mean levels of blood loss for caecal and ascending colon cancers are 
9.3 ml/day, 1.5 ml/day for transverse and descending colon, 1.9 ml/day for sigmoid colon, 
and 1.8 ml/day for rectum. Blood loss is independent of the stage of the cancer [70]. 
3.4 Symptoms and Stage of Colorectal Cancer 
Although one might expect duration of a patients symptoms to be longer in more 
advanced cancers, this has been shown not to be the case. In a review of 194 patients 
with colorectal cancer and their presenting symptoms, there was no association 
(p=0.94) between the duration of symptoms and the stage of cancer. Some patients 
with Dukes’ Stage A cancers had had symptoms for 2 years whereas; some patients 
with Stage D cancers had had symptoms for less than 2 weeks. Majumdar found no 
evidence of confounding of the duration-stage relationship by any one symptom [69]. 
3.5 Atypical Presentations of Colorectal Cancer 
9.2% of colorectal cancers present with metastases at time of diagnosis [2]. These patients 
may present with symptoms relating to the location of the spread of disease. Colorectal 
cancers spread via the lymphatic system to local and regional lymph nodes, 
haematogenous spread via the portal system to first the liver, then lungs, bone and brain. 
Symptoms caused by this spread may be right upper quadrant pain due to liver capsule 
stretch from a liver metastases, or bone pain [60].  
Rarely, colorectal cancers can present with an infectious disease related to either the 
complications of the cancer or its spread. The table below summarises possible diagnoses: 
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Intra-Abdominal 
Infections 
 
Peritonitis 
Abscesses ( abdominal wall, 
retroperitoneal hepatic, 
perinephric, appendiceal) 
Urinary tract infections and sepsis 
due to colovesical fistulae 
Extra-Abdominal 
Infections 
Due to Spread of 
Organisms along 
Intra-Abdominal 
Tissue Planes 
Non-traumatic crepitant cellulitis 
Non-traumatic myonecrosis 
Empyema 
Due to Presumed 
Bacteraemia from a 
Necrotic Tumour 
Sepsis due to bowel flora 
Meningitis 
Suppurative thyroiditis 
Endocarditis 
Pericarditis 
Pulmonary microabscesses 
Septic arthritis 
"Metastatic" non-traumatic 
myonecrosis 
Fever of unknown origin 
Table 3.5 Atypical presentation of a colorectal cancer [71] 
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3.6 “Asymptomatic” Colorectal Cancers 
 The natural history of colorectal cancers is such that they go through different symptom 
phases: 
 
       
 
 
 
 
 
 
 
 
Figure 3.2 Phases of symptoms for a colorectal cancer. MTT, minimum time to treatment 
that can be achieved after onset of symptoms; A, asymptomatic phase; B, time between 
onset of symptoms and earliest possible treatment; C, early symptomatic phase; D, late 
symptomatic phase [72]. 
 
In the NHS, processes have been put in place to try and reduce the minimum time to 
treatment, ranging from health promotion campaigns to raise awareness of the symptoms 
of colorectal cancer, to increasing the speed that patients can be seen and treated once a 
referral from their general practitioner has been made. The authors state that at present, 
there are average delays of between 4-9 months, which has not significantly changed over 
the last 60 years. 
The above phases do not seem to correlate with the stage of disease. Early colorectal 
cancers can present with significant symptoms and, conversely, advanced cancers can 
remain relatively ‘asymptomatic’ [73]. 
As mentioned with regards to rectal bleeding, only a small percentage of the population 
with this symptom will present to their general practitioner, and then even a smaller 
percentage will be referred to secondary care. Within screening programmes, all patients 
who undergo the relevant examinations are deemed to be asymptomatic for the disease 
that is being screened for. There is an assumption that patients within the appropriate age 
group will have sought the advice of their relevant health care professional regarding any 
Biological Onset Onset of Symptoms Death or Cure 
A B C D 
‘Window of Opportunity’ for 
earlier diagnosis to be of benefit 
MTT 
Asymptomatic Phase Symptomatic Phase 
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symptoms they may be having, and subsequently undergo further tests to confirm or 
exclude a particular disease. 
Harmston et al. reviewed questionnaires regarding any symptoms suffered by 200 patients 
who were diagnosed with a colorectal cancer as part of the English arm of the Bowel 
Cancer Screening Programme pilot study [74]. They found that 70% of patients had 
significant symptoms (change in bowel habit, rectal bleeding, and peri-anal symptoms). The 
distributions of these are shown in the graph below (Figure 3.3). 59% of patients had two 
or more symptoms. 
 
Figure 3.3 Distribution of Symptoms for Screen-detected Cancers in the English Screening 
Pilot [74]. 
 
Interestingly, a large proportion of “early” cancers had these significant symptoms as 
shown in the table below. 
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 Rectal 
Bleeding 
Change in 
Bowel 
Habit 
Tenesmus Peri-Anal 
Symptoms 
Abdominal 
Pain 
Urgency 
Dukes A 59.6% 28% 35% 14% 24.5% 47.4% 
Dukes B 35.7% 24.2% 31.4% 14.3% 18.6% 27.1% 
Dukes C1 50% 22.5% 43.5% 16% 19.4% 35.4% 
Dukes C2 45.4% 9.1% 36.4% 27.3% 9.1% 63.6% 
Table 3.6 Symptom prevalence by Dukes Stage [74]. 
 
The difficulty in drawing conclusions from this is that the authors do not state whether 
there was any other pathology that was concurrent with the patients’ cancer that might be 
contributing to their symptoms, e.g. haemorrhoids with the symptom of rectal bleeding. 
A similar review of the Scottish arm of the national colorectal cancer screening pilot was 
performed where all those patients with positive faecal occult blood tests completed a 
symptom questionnaire. Although lower gastro-intestinal symptoms were common among 
the patient group (78% of 563 participants had one or more symptoms), there were no 
significant associations found between any of these symptoms and the findings on 
colonoscopy. Likewise, the total number of symptoms was not predictive of neoplasia 
(colorectal adenoma or carcinoma) [75]. 
3.7 Chapter Conclusion 
As described in the section above, the diagnosis of a colorectal cancer is a challenging one. 
For those patients who do have a colorectal cancer, any possible symptoms attributed to it 
can be vague or absent. Symptoms that are potentially attributable to a cancer can also be 
caused by a range of benign gastro-intestinal pathologies. Even for those patients who do 
have a colorectal cancer and are symptomatic with this, a large proportion will not seek 
medical advice, instead undergoing screening examinations. It is unclear at what point this 
group of patients would eventually seek the advice of their general practitioner, in the 
absence of a screening programme, or whether they would continue to manage their 
symptoms by themselves. 
The NHS Bowel Cancer Screening Programme helps to identify the population with a 
colorectal cancer in which they are asymptomatic with their cancer, or have symptoms but 
have not actively sought medical attention. 
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Chapter 4 Investigation of Lower 
Gastrointestinal Symptoms 
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4.1 Introduction 
Investigation for a suspected colorectal cancer can take the form of many different types of 
investigation. These are now usually endoscopic, such as a flexible sigmoidoscopy and 
colonoscopy, with the majority of patients requiring no further investigation. Other tests 
are radiological, such as a CT scan or occasionally a plain abdominal X-Ray for patients 
presenting with abdominal pain. Increasingly, stool and blood tests precipitate large bowel 
investigations with the increasing public awareness of bowel cancer. Given the range of 
investigations, there have been a number of studies that have looked into using each of 
these as possible screening tests for colorectal cancer. This section describes each of the 
examinations and gives an overview of the important literature regarding screening studies 
using either each of them alone or in combination with other tests. 
The “History” of the nature of the patients’ problem will first be taken by their healthcare 
professional. This will involve enquiring into the severity and duration of each individual 
symptom, focusing on any “alarm” symptoms that might be caused by a colorectal cancer. 
A physical examination should be carried out, including a digital rectal examination. This is 
to look for a palpable abdominal or rectal mass which greatly increases the suspicion of a 
cancer. Appropriate blood tests should be carried out, in particular looking for iron-
deficiency anaemia. This is due to occult blood loss from colorectal neoplasia which causes 
iron deficiency that is sufficiently severe to diminish erythropoiesis and cause the 
development of anaemia [76]. 
Each hospital NHS Trust will have referral guidelines for those with gastro-intestinal 
symptoms. These may be based upon the National Institute for Clinical Excellence 
guidelines published in 2004 [77], however these have been criticised for being “too 
restrictive and … intended partly to ration limited diagnostic resources”, when an analysis 
of the predictive value of colorectal cancer related symptoms is performed [78].  
If the suspicion of a colorectal cancer is high, a “two-week” referral to secondary care is 
sent. The patient may then be seen in either an outpatient clinic or go straight for further 
investigations as listed below. 
4.2 Flexible Sigmoidoscopy 
This is a form of endoscopic examination of the large bowel. The procedure involves using 
an endoscope to visualise the large bowel from the rectum up to the splenic flexure 
(proximal descending colon). It differs from a colonoscopy in that the endoscopist does not 
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examine the whole length of the large bowel, visualising approximately 60cm from the anal 
verge. 
Patients must undergo bowel preparation, either in the form of an enema or oral laxative, 
prior to the procedure to better visualise the bowel, as well as not eating or drinking for 
several hours prior to the procedure. Each hospital trust may have slight differences in the 
advice given prior to the procedure. The advantages of a flexible sigmoidoscopy over a 
colonoscopy are that it is better tolerated, safer, less painful, quicker, and has a lower 
complication rate.  Sedation is not routinely given for a flexible sigmoidoscopy. 
As discussed in Chapter 3, there is much discussion as to how best to identify those 
patients presenting to their general practitioner who have a colorectal cancer. Once a 
referral has been made to a colorectal clinic for a suspected cancer, there is further debate 
as to which choice of investigation should be used. 
Thompson et al., attempted to identify which patients would be better suited having a 
flexible sigmoidoscopy, and which patient should have their whole colon visualised [79]. Of 
15,363 patients analysed, 94.1% had one or more symptoms suggestive of a colorectal 
cancer (rectal bleeding, change in bowel habit, abdominal pain, iron deficiency anaemia or 
an abdominal mass). 98.9% of patients underwent a flexible sigmoidoscopy, of which 34.8% 
were then referred for whole colon imaging. Of the 946 patients that were diagnosed with 
a colorectal cancer, 86.2% had a rectal or sigmoid cancer. In 922 (97.5%) patients, this was 
diagnosed by flexible sigmoidoscopy (788) or subsequent whole colon imaging (134). There 
were 24 (2.5%) missed cancers. The authors conclude that only 0.2% of patients who 
present to a surgical outpatient clinic with symptoms of rectal bleeding, change in bowel 
habit, or abdominal pain without iron deficiency anaemia or abdominal mass, will have a 
cancer proximal to the sigmoid colon. If flexible sigmoidoscopy is negative, and the patient 
does not have anaemia, abdominal mass, severe symptoms or other significant factors on 
flexible sigmoidoscopy, then the residual risk of a colorectal cancer is less than an 
asymptomatic patient who has not had a flexible sigmoidoscopy.  
The authors suggest a referral pathway that incorporates the fact that 95% of colorectal 
cancers will be detected by flexible sigmoidoscopy in patients without iron deficiency 
anaemia or an abdominal mass. 
 
4.2.1 Screening with Flexible Sigmoidoscopy 
Given the above benefits over colonoscopy, there have been a number of studies which use 
flexible sigmoidoscopy to screen for colorectal cancers. 
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A multi-centre randomised controlled trial based in England sent questionnaires to 368,142 
men and women aged 55-64 years to establish their interest in a one-off flexible 
sigmoidoscopy screening examination [80]. This was on the background of two pilot studies 
[81]. 194,726 (52.9%) responded positively, of which 170,432 were randomised into the 
intervention group or control group at a ratio of 1:2. Participants were invited for a 
colonoscopy if they were found to have any of the following at flexible sigmoidoscopy: 1cm 
or larger polyp; three or more adenomas; tubulovillous or villous histology; severe 
dysplasia or malignant disease; or 20 or more hyperplastic polyps above the distal rectum. 
Of the 57,237 allocated to the screening group, 40,674 (71.1%) attended their offered 
flexible sigmoidoscopy. 95% of patients were discharged after a negative exam with 2,131 
(5.2%) of patients being referred for a colonoscopy, with the remainder entering a 
surveillance programme. There were 706 colorectal adenocarcinomas identified in the 
intervention group and 1,818 in the control group. After 11 years of follow up, there was a 
significant reduction in all site CRC incidence (HR 0.67, 95% CI 0.60-0.76), although this 
reduction was only significant for distal cancers. All-cause mortality was unchanged 
between the intervention screened group and control group; however, there was a 
significant reduction in verified deaths attributable to CRC (HR 0.56, 95% CI 0.45-0.69). 
The authors conclude that flexible sigmoidoscopy screening is a safe and practical test and, 
when offered only once to people between ages 55 and 64 years, confers a substantial and 
long lasting protection from colorectal cancer. 
In a separate UK based study, when flexible sigmoidoscopy screening was offered as a 
service rather than as part of a research study, uptake remained high at 67%. The authors 
give the reasons that the examination was taken up well “because the entire study 
population was invited without the two-stage invitation procedure”. As may be expected, 
“people living in more socioeconomically deprived areas were more likely to decline the 
offer of screening or not respond to the invitation” [82]. 
A large, population based randomised controlled trial from Norway, compared the 
incidence and mortality from colorectal cancer in patients aged between 55-64 [83]. The 
age range was chosen to maximise ability of the study to show the desired primary 
endpoint, due to the relative population size and colorectal cancer incidence at this range. 
Out of 13,823 people invited for a one-off flexible sigmoidoscopy, half were additionally 
asked to undergo an immunochemical FOB test. Of the 13,653 people eligible for screening, 
8,846 underwent an examination, giving an attendance rate of 64.8% (67% with exclusion 
of those not examined owing to exclusion criteria). In total, 33 out of 71 colorectal cancers 
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were screen-detected, giving a significant 59% reduction in incidence of total colorectal 
cancer and 76% reduced incidence of rectosigmoid cancer among attenders, per protocol 
analysis (an analysis prone to selection bias). However, whilst there was a reduction in 6 
year mortality (27% from total colorectal cancer and 37% from rectosigmoid cancer), this 
was not significant on statistical analysis. Interval cancers were found to have equivalent 
outcomes to the control group. 
As part of the SCORE (Screening for COlon REctum) one-off Italian flexible sigmoidoscopy 
screening trial, of the 17,148 subjects assigned to the intervention group of a one-off 
flexible sigmoidoscopy, followed by a colonoscopy for any patient found to have large distal 
polyps (>5 mm), three or more adenomas, one adenoma with villous component greater 
than 20%, a high-grade dysplastic polyp, inadequate bowel preparation harbouring at least 
one polyp, and for those found to have invasive CRC [84]. It is important to note that the 
criteria for referral for a colonoscopy in the Norwegian and Italian trials were at a lower 
threshold than the UK RCT, and hence their colonoscopy rates were higher. 9,911 (57.8%) 
subjects were examined by flexible sigmoidoscopy. Of these, 9,387 (94.71%) subjects were 
discharged, 55 (0.55%) were referred for surgery (43 CRCs, 10 large adenomas, and two 
perforations: one during flexible sigmoidoscopy and one during total colonoscopy), 395 
(4.0%) were referred for a subsequent surveillance colonoscopy, whereas the remaining 74 
(0.74%) did not comply with the recommended colonoscopy assessment. 54 subjects were 
detected with 57 CRCs (44 in the rectum and sigmoid colon, four in the descending colon, 
and nine in the proximal colon). In an intention-to-treat analysis, the authors report an 18% 
reduction in CRC incidence in the intervention group, with an improved stage profile of the 
cancers and adenomas detected. However, there was still an interval cancer rate. Of 126 
subjects diagnosed with a colorectal cancer that were screened, 54 (42.8%) of these were 
identified at the flexible sigmoidoscopy. This means that over half of cancers were not 
detected due to this screening intervention, which includes 32.4% of distal colon cancers, 
over the median 10.5 year follow up period. Although there was no difference found in the 
incidence of proximal cancers between those screened and not screened, the authors do 
not state when precisely these non-screen-detected cancers (for both proximal and distal 
lesions) were diagnosed in the intervention group. Therefore, we do not know whether the 
proportion of cancers were present at the time of the intervention, in the population that 
had no polyps that necessitated a subsequent colonoscopy. 
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4.3 Colonoscopy 
A colonoscopy is an endoscopic examination of the entire length of the large bowel. 
Patients must undergo bowel preparation in order to establish adequate views of the 
bowel wall. During the procedure, patients often require either, or a combination of, 
intravenous analgesia and intravenous sedation, or inhaled analgesia (e.g. entonox, a 50/50 
mix of nitrous oxide and oxygen). A colonoscopy naturally takes longer than a flexible 
sigmoidoscopy and has a higher (albeit low) complication rate. If a suspected cancer is 
found, the lesion can be tattooed endoscopically to aid identification of the lesion at 
operation. This tattooing is becoming increasingly important with the increase in 
laparoscopic bowel resections, as the surgeon can no longer manually feel for the lesion 
within the bowel. Colonoscopy itself is poor at identifying locations of lesions, with up to 
21% being incorrectly recorded [85]. 
 
4.3.1 Screening with Colonoscopy 
There has been much discussion regarding the frequency that a colonoscopy should be 
carried out. Lansdorp-Vogelaar et al., attempted to individualise the frequency of 
examination by sex and race of the population. Their proposed individualisation is to have 
white men undergo 4 screenings from age 53 to 74 years every 7 years; black men: 5 
screenings from age 47 to 75 years every 7 years; white women: 4 screenings from age 53 
to 77 years every 8 years and black women: 5 screenings from age 47 to 75 years every 7 
years. However, when compared with their current local 8-yearly guidelines, there are only 
0.0002 additional life-years gained, at $9.09 lower costs per person [86]. 
Whilst Imeriale et al. [87] suggested a 5 year interval for colonoscopy screening, Singh et al. 
believe that this should be extended to 10 years following a negative colonoscopy with the 
standardised incidence ratio for colorectal cancer being 0.28 (95% CI, 0.09-0.65) at 10 years 
[88]. 
A study published by from the EPAGE (European Panel on the Appropriateness of 
Gastrointestinal Endoscopy) group, involved 561 colonoscopies that were performed for 
screening purposes, i.e. asymptomatic patients with a range of increase in risk for 
colorectal cancer, over a range of ages. Of these screening colonoscopies, 336 (59.9%) were 
for indications that were uncertain appropriateness with 80 (14.3%) being performed for 
inappropriate indications. 74 (13.2%) patients were diagnosed with colorectal neoplasia 
including 4 (0.7%) cancers and 70 (12.5%) adenomatous polyps [89]. 
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4.4 Newer Types of Colonoscopy 
The standard colonoscopy examination involves using a white light colonoscope. This uses 
air insufflation with a fibre-optic image being transmitted to a video monitor, viewed by the 
endoscopist. In order to improve the detection rate for colorectal neoplasia, newer 
methods of examination using endoscopic techniques are being evaluated. Below is an 
overview of these techniques, and the evidence to support their use. 
 
4.4.1 Wide-Angle Colonoscopy 
This type of colonoscopy uses a high definition (HD), wide angle endoscopy in the detection 
of colorectal neoplasia. A randomised controlled trial of 390 patients comparing HD, wide 
angle colonoscopy vs. standard colonoscopy was carried out by Tribonias et al., with the 
primary outcome of polyp detection [90]. The HD, wide angle colonoscopy group was found 
have a superior rate of all type and size polyp detection (SC 1.31 ± 1.90; HD 1.76 ± 2.31; 
p=0.03) and of polyps <5mm in size (SC 0.10 ± 0.36; HD 0.25 ± 0.61; p=0.003). No 
differences in detection were found between medium (5-10mm) size or large (>10mm) size 
polyps. 
 
4.4.2 Chromoendoscopy 
Chromoendoscopy or chromocolonoscopy is a type of lower gastro-intestinal endoscopic 
examination which is aimed at, in particular, increasing the identification of flat or 
depressed neoplasia, deemed harder to detect with conventional methods. 
Chromoendoscopy works by spraying a dye (indigocarmine) at the bowel wall in an attempt 
to better identify lesions. Kahi et al. [91] compared high-definition chromocolonoscopy 
versus high-definition white light colonoscopy for patients referred for screening 
colonoscopies. Out of 660 patients randomised into two groups, the number of patients 
with at least one adenoma (55.5% vs. 48.4, p=0.07), and the number of adenomas per 
patient (1.3±2.4 vs. 1.1±1.8, p=0.07) were marginally higher in the chromocolonoscopy 
group. There were no significant differences in the number of advanced adenomas per 
patient (p=0.3) or the number of advanced adenomas <10mm per patient (p=0.4). 
Chromocolonoscopy detected significantly more flat adenomas per patient (p=0.01), 
adenomas <5mm in diameter per patient (p=0.03), and non-neoplastic lesions per patient 
(p<0.0001). The main problem with this technique is that it is labour intensive and time-
consuming [92]. 
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A Cochrane review of chromocolonoscopy of four studies all carried out prior to Kahi et 
al.’s, concluded that this technique will yield positive results for significantly more patients 
with at least one neoplastic lesion (OR 1.61, 95% CI 1.24-2.09) and significantly more 
patients with three or more neoplastic lesions (OR 2.55, 95% CI 1.49-4.36) [93]. They 
criticised the studies for not publishing their results of biopsies that proved to be of normal 
colonic tissue, hence making estimates of the specificity of the technique impossible. They 
suggest that this technique may have the most marked benefit for patients with 
inflammatory bowel disease and Lynch Syndrome. 
 
4.4.3 Narrow Band Colonoscopy 
Narrow band imaging uses a narrowed light source with wave lengths centred at 415nm 
(blue) and 540nm (green). Light at these wavelengths penetrates through the mucosa and 
submucosa and is absorbed by haemoglobin thereby enhancing the appearance of 
microvessels. The theory that lesions have a greater level of angiogenesis means that they 
should be more easily detectable, regardless of their shape. 
In a tandem colonoscopy study using narrow band imaging versus the standard white light 
colonoscopy, there was a miss rate in 17 of 135 patients (12.6%) in the narrow band 
imaging group versus 17 of 141 (12.1%) in the white light group [94]. All missed neoplasms 
were tubular adenomas with 78% of these ≤5mm. The authors felt that their high detection 
rate of neoplasms (49% of patients) was the reason that there was no difference seen 
between the two imaging modalities. 
The DISCARD (Detect InSpect ChAracterise Resect and Discard) study used high-definition 
white light colonoscopy, followed by narrow-band imaging (without magnification or 
chromoendoscopy) to compare whether these modalities could accurately assess polyp 
characterisation, and hence follow up period, against histological assessment [95]. In 
polyps <10mm in size, 186 out of 198 adenomas (sensitivity 0.94, 95% CI 0.90-0.97) were 
accurately diagnosed, along with 55 of 62 hyperplastic polyps (0.89, 95% CI 0.78-0.95). The 
implications of the use of these techniques may mean savings in both time and cost by 
avoiding histological examination of a large number of these polyps. 
 
4.4.4 Autofluorescence Imaging 
A similar technique to narrow band imaging, except different wavelengths are used: 
ultraviolet (<400nm) or short visible light (mostly blue) to produce autofluorescence light. 
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The autofluorescence of neoplastic mucosa differs from that of normal colonic mucosa and 
so appears a different colour when the above light is shined upon it [92]. 
4.5 Chapter Conclusion 
Flexible sigmoidoscopy and colonoscopy play pivotal roles in the current diagnosis of 
colorectal cancers. Despite an effective screening programme, there will always be patients 
who present through their general practitioner with symptoms attributable to a colorectal 
cancer, which are investigated with the above tools. This chapter has covered the evidence 
behind screening with flexible sigmoidoscopy, and the debate on the time intervals for 
repeat colonoscopies. 
Newer forms of colonoscopy, including chromoendoscopy and narrow band imaging, have 
been discussed. These techniques may have a role to play in diagnosis and management of 
small polyps found on either screening or non-screening colonoscopies. 
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Chapter 5 The Faecal Occult Blood 
Test, FOBt 
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5.1 Background of the test 
The test is a dehydrated, guaiac acid faecal occult blood test (FOBt). The test was 
developed after the finding by Van Deen that gum guaiac, a natural resin extracted from 
the wood of Guaiacum officinale, can detect occult blood. Guaiac had previously been used 
from the early 1500’s as a treatment for syphilis, a treatment that continued until the early 
19th Century [96]. 
The test is based on the properties of guaiac to turn to a blue-coloured compound when 
oxidised by hydrogen peroxide. The haem portion of haemoglobin, if present in the faecal 
specimen, has peroxidise activity which catalyses the oxidation of alpha guaiaconic acid 
(active component of the guaiac paper) by hydrogen peroxide (active component of the 
developer) to form a highly conjugated blue quinone compound [97]. 
Patients are sent three tests per kit and are given the following instructions with the test: 
 For accurate test results, apply samples from bowel movements collected on three 
different days to slide.  
 Do not collect sample if blood is visible in your stool or urine (e.g., menstruation, 
active haemorrhoids, urinary tract infection). Contact your doctor. 
 For the most accurate test results collect each stool sample before contact with the 
toilet bowl water. You may use any clean, dry container. 
 Return completed slides to your doctor or laboratory no later than 14 days after 
your first sample collection. 
 Protect slides from heat, light, and volatile chemicals (e.g., ammonia, bleach, 
bromine, iodine and household cleaners). 
 Remove toilet bowl cleaners from toilet tank and flush twice before proceeding. 
They are given the following information regarding medication: 
 For seven days before and during the stool collection period, avoid non-steroidal 
anti-inflammatory drugs such as ibuprofen, naproxen or aspirin (more than one 
adult aspirin a day). 
 For three days before and during the stool collection period, avoid vitamin C in 
excess of 250 mg a day from supplements, and citrus fruits and juices. 
They are given the following information regarding diet: 
 For three days before and during stool collection period, avoid red meats (beef, 
lamb and liver). 
 Eat a well-balanced diet including fibre such as bran cereals, fruits and vegetables. 
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5.2 Screening with Faecal Occult Blood Tests 
There are four main mass population-based screening studies that have used faecal occult 
blood tests to screen a population with the aim of diagnosing early, pre-symptomatic 
colorectal cancer. These were based in Nottingham in the UK, Funen in Denmark, 
Minnesota in the USA and, Goteborg in Sweden. The features of each of these are 
described below. 
 
5.2.1 The Nottingham Trial 
The Nottingham trial began in 1981 with subjects aged between 45-74 (identified by GP 
records) being randomly assigned to test and control groups, continuing to 1991. Subjects 
allocated to the intervention arm were offered biennial faecal occult blood tests. These 
tests were guaiac-based and un-rehydrated. The results of the trial was published over 
several papers [98-101], culminating in a paper showing follow up results over a median of 
19.5 years (1,296,712 person-years in intervention group, 1,296,614 person-years in 
control group) [102]. 
In the preliminary phases of the trial, the Hemoccult test was shown to give false positive 
results secondary to dietary intake. Foods that contain natural peroxidase activity, such as 
broccoli, cauliflower, banana, and parsnip, as well as red meat (beef, lamb, black pudding) 
that contains animal haemoglobin can cause a positive reaction. Dietary restrictions, as well 
as repeating weakly positive tests were introduced following a study of repeating a 
selection of positive tests within the Nottingham pilot study with dietary restrictions [103]. 
The subjects who had a repeat negative test were asked to repeat a FOB test after three 
months and then endoscopically investigated if it was positive. Out of 31 positive tests, 
there were 4 cancers and 20 adenomas detected. This emphasised the need for regular and 
repeated testing due to the intermittent nature of polyps/cancers bleeding. 
By the end of the allocation period, 152,850 subjects had undergone between three and 
five screening rounds. The trial methodology was altered as time and resources progressed. 
At the beginning of the study, no dietary restrictions (apart from vitamin C tablets) were 
imposed. Those with a positive FOB test were invited for an outpatient appointment, 
flexible sigmoidoscopy and double contrast barium enema. 
In 1983, a cohort in the same age group was sent the FOB test, as well as an immunological 
FOB test. Those with a positive test, either FOBt or iFOBt, were investigated as above. 
In 1984, those who completed the Hemoccult test from the first cohort were offered 
rescreening by a repeat FOB test. Those with a positive result were offered a repeat 
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examination with flexible sigmoidoscopy and barium enema, and were also asked to 
complete a 6-day Hemoccult test with dietary restrictions. 
151,975 subjects were suitable for analysis after a median follow-up of 19.5 years (range 
0.0-28.4 years, IQR 10.2). 76,056 subjects were in the intervention arm and 75,919 in the 
control arm. The uptake was 59.6% of at least one screening test with 38.2% completing all 
FOB tests offered. FOBt positivity was 2.3%. In the intervention arm, of a total of 2,279 
colorectal cancers diagnosed, there were 236 (10.4%) screen-detected cancers (83 after 
first invitation - 51% Dukes’ A, 21 in later invitation – 29% Dukes’ A, and 132 at re-screen - 
37% Dukes’ A), 959 (42.1%) cancers in non-responders (8% Dukes’ A) and, 1,037 (45.5%) 
interval cancers. Of the interval cancers, 173 were diagnosed between screening rounds 
within two years, with 864 being diagnosed after two years. This is likely the reason for the 
high rate of interval cancer. There were 2,354 cancers diagnosed with the control arm, of 
with 11% were Dukes’ A. 314 of 2279 (14%) cancers diagnosed in the intervention arm 
were of Dukes’ Stage A.  
In addition to cancer detection, a total of 2,291 adenomas were removed at colonoscopy in 
the intervention arm with 1,484 from the control arm. 615 of the screen-detected 
adenomas were greater than 10mm in size. 
The absolute reduction in mortality from CRC was 1.66 per 1000 persons, meaning 602 
persons (95% CI 339-2648) who need to be invited for screening for an average of 6 years 
to prevent one death over 20 years. 
 
5.2.2 The Funen Trial 
Between August 1985 and September 1986, 30,970 individuals aged between 45 and 74 
years of age were offered the un-rehydrated Hemoccult FOBt, along with 30,968 controls 
[104]. They were all inhabitants in the county of Funen, Denmark. Of these, 20,695 (67%) 
completed the test. There were 215 patients with positive tests, all of whom were invited 
to undergo a colonoscopy examination. Of the 209 patients who underwent subsequent 
examination, 123 cases of colorectal neoplasia (37 carcinomas and 86 adenomas) were 
found. Only 8 individuals had no colorectal pathological findings. The authors included 
diagnoses of diverticulosis and haemorrhoids as a positive colonoscopic finding, although 
accept that these may not have been the cause for a positive FOBt. 
There were 9 cases of interval colorectal cancer, following a negative FOB test. In the 
control group colorectal neoplasia was diagnosed in 76 persons. The cancers within the 
screening group had a large proportion of Dukes’ A cancers compared to the control group 
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(19 vs. 2). There were 11 vs. 19 Dukes B cancers in the screening and control groups 
respectively. There was a greater proportion of more advanced cancer which had distant 
spread in diagnosis in the control group versus the screening group (8 vs. 2). 
In 1996, Krongborg et al. published the results of the follow up study from their pilot study 
described above [105]. Having excluded those individuals from the pilot study, they 
randomised 137,485 persons aged 45-74 into a screening group (30,967 persons), control 
group (30,966 persons) and un-enrolled group (75,552). Only the control and intervention 
group were followed up. The authors estimated that a study and control group of size 
30,000 subjects in each was sufficient to give an adequate power in detecting a significant 
reduction in CRC mortality by 25%. The un-enrolled group represented the excess 
population not required as part of the study, but would have potentially been eligible for 
inclusion. 20,672 (67%) submitted an un-rehydrated Hemoccult test (having restricted their 
diet) from the first screening round, >90% completed repeat biennial tests. There were a 
total of 481 cancers in the screening group identified (120 following positive FOB test, 18 
before invitation for test, 195 in non-responders and 148 interval cancers), with 483 in the 
control group. There was a total of 413 adenomas ≥10mm in the screening group versus 
174 in the control group. As with the Nottingham study, the colorectal cancers were of a 
significantly earlier stage in the screening group (Dukes A – 22 vs. 11%, p<0.01). The overall 
cumulative survival in patients with colorectal cancer was significantly higher in the 
screening group versus the control group (p<0.01), with a reduction of 18% in colorectal 
cancer mortality. The mortality rate from CRC (including complications from treatment) 
was 0.89 per 1000 person-years in the control group, and 0.73 in the screening group. 249 
of 6303 deaths (4.0%) were due to CRC in the control group, with 205 of 6228 deaths 
(3.3%) in the screening group.   
 
5.2.3 Other FOBt trials 
There have been numerous other trials looking at faecal occult blood tests. The Minnesota 
study showed a reduction in cumulative 18 year colorectal cancer mortality by 33% in the 
annual FOB screening group compared to the control group (rate ratio: 0.67; 95% CI 0.51–
0.83) and a 21% reduction in the biennial FOB screening group (rate ratio: 0.79; 95% CI 
0.62–0.97) [106]. A criticism of this study is that subjects volunteered for the study, 
meaning it is not a true population-based screening study. 
Another notable study is Faivre et al.’s from Burgundy, France [107, 108]. A population 
based-study between 1988 and 1998 including 91,199 individuals aged 45-74, who 
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underwent biennial FOB tests. They showed a 33% reduction in colorectal cancer mortality 
in those who underwent at least one round of screening test versus the control group 
(mortality ratio: 0.67, 95% CI 0.56-0.81). In the whole screening group, colorectal cancer 
mortality was significantly lower than the control group (mortality ratio: 0.84, 95% CI 0.71–
0.99). 
Other studies have also shown a reduction in mortality due to the use of an annual or 
biennial FOB test [109, 110]. Meta-analyses of the studies from Nottingham, Funen, 
Minnesota and Burgundy showed an overall reduction in mortality due to colorectal cancer 
of 14-16% [111, 112]. A Cochrane review [113] from 2008 reviewed the Nottingham, 
Funen, Minnesota and Goteborg  trials [114, 115]. They found a combined relative risk 
reduction of 16% of colorectal cancer mortality (relative risk 0.84, 95% CI 0.78-0.90). There 
was a 25% relative risk reduction (relative risk 0.74, 95% CI 0.66-0.84) in those who 
underwent at least one round of the screening test. 
However, in a paper by Autier et al., the effect on colorectal cancer mortality due to only 
the FOB screening test was reviewed, i.e. not including the interval cancers mortality rates 
from the screening arm as a whole [116]. By doing this, the absolute reduction in mortality 
decreases from 16% to 12% and is no longer statistically significant (p>0.05). The authors 
state that this effect is disease awareness of colorectal cancer. However, I would argue that 
this effect should be considered part of the screening programme. With the primary aim of 
the screening test to identify colorectal cancers and adenomas at an earlier stage so that 
they can be treated, if this means that a population of patients presents out with a 
screening programme and are subsequently diagnosed with a colorectal cancer, then the 
endpoint is still the same. This is reflected in the fact that 47% of interval cancers in the 
Nottingham study are of Dukes A or B (compared with 44% of controls). 
The cost-effectiveness for introducing a biennial FOB test in terms of the Disability adjusted 
life years (DALYs) and the years of life lost (YLLs) averted was reviewed in Australia, and 
deemed to be suitable for introduction [117]. 
The risks associated with the Nottingham randomised controlled trial was reviewed by 
Robinson et al. [118]. There were seven (0.5%) complications of the colonoscopy, of which 
6 required surgical intervention. There were 5 deaths within 30 days of surgery for a 
screen-detected cancer, but no post 30 day cancer related deaths post-surgery. 
5.3 Summary of Mass Population Studies 
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A difficulty in interpreting the differing mass population studies is the different 
methodology and screening tests that have been used by the groups involved. Tables 5.1 
and 5.2 below summarises the screening methodology for each of the four main trials, as 
well as the incidence of colorectal cancer in each group. Table 5.3 shows the positivity of 
the FOBt and its calculated sensitivity.  
These tables have been adapted from the Cochrane review (published in 2008 and updated 
in 2011) [113], with results from the median 19.5 year follow up from Nottingham added 
[102]. 
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Table 5.1 Methodology and uptake of FOBt screening. A = annual screening; B = biennial screening; NR = not reported. 
Study Country Screen Frequency Age Range (yr) 
Length of 
Follow-Up (yr) 
No. of Screening 
Rounds 
Attending First 
Screening (%) 
At Least 
One Round 
(%) 
Funen [105] Denmark Biennial 45–75 17 9 66.8 NR 
Goteborg [110] Sweden Biennial 60–64 15.5 2 63.0 70.0 
Minnesota [119] U.S. 
Annual/ 
Biennial 
50–80 18 
11 (A) 
6 (B) 
NR 
75.0 (A) 
78.0 (B) 
Nottingham [102] U.K. Biennial 45–74 19.5 6 53.4 59.6 
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Table 5.2 Number and incidence rate of colorectal cancer by study. NR = not reported. 
Table 5.3 Type of FOBt, positivity rate and predictive value for colorectal cancer and adenoma.
Study 
No. of CRC Cases Incidence Rate of CRC Cases 
Screening Group Control Group Screening Group (py) Control Group (py) 
Funen [105] 889/30,967 874/30,966 2.06/1,000 2.02/1,000 
Goteborg [110] 252/34,144 300/34,164 NR NR 
Minnesota [119] 852/31,157 507/15,394 32–33/1,000 39/1,000 
Nottingham [102] 2,279/76,056 2,354/75,919 1.77/1000 1.83/1000 
Study Rehydration Positivity Rate (%) Sensitivity (%) 
Positive Predictive Value 
(CRC) (%) 
Positive Predictive Value 
(Adenoma) (%) 
Funen [105] No 0.8–3.8 55.0 5.2–18.7 14.6–38.3 
Goteborg [110] 
Yes 1.7–14.3 82.0 NR NR 
No 1.9 NR NR NR 
Minnesota [119] 
Yes 3.9–15.4 92.2 0.9–6.1 6.0–11.0 
No 1.4–5.3 80.8 5.6 NR 
Nottingham [102] No 1.2–2.7 57.2 9.9–17.1 42.8–54.5 
 48 
  
 
Table 5.4 below shows the number and rate of mortality related to colorectal cancer. When 
all-cause mortality was reviewed in the Nottingham study, no significant difference was 
found between intervention and control group.  
 
Study 
No. of CRC Deaths Mortality Rate 
Mortality 
Reduction 
(%) 
Screening 
Group 
Control Group 
Screening 
Group (py) 
Control 
Group (py) 
Funen [105] 363/30,967 431/30,966 0.84/1,000 1.00/1,000 16 
Goteborg 
[110] 
252/34,144 300/34,146 NR NR 16 
Minnesota 
(A) [119] 
121/15,570 
177/15,394 
0.67/1,000 
1.00/1,000 
33 
Minnesota 
(B) [119] 
148/15,587 0.79/1,000 21 
Nottingham 
[102] 
1,176/76,056 1,300/75,919 0.91/1000 1.00/1000 13 (18*) 
Table 5.4 Number and rate of deaths for each study. A = annual screening; B = biennial 
screening: NR = not reported; py = person years. *when adjusted for non-compliers of 
screening. 
 
As described in Chapter 1, risk factors in the development of a colorectal cancer are also 
risk factors for many other conditions such as ischaemic heart disease and other types of 
cancer. Therefore, with the extended follow up data published on the Nottingham study, it 
is unsurprising that equivalent all-cause mortality rates were found. 
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Chapter 6 Interval Cancers 
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6.1 Introduction 
Interval cancers can be classified into two groups: 
 
1. A cancer relating to the biology of the cancer. 
This group represents cancers that are aggressive in their growth, going through the 
adenoma-carcinoma sequence at an accelerated rate. It has been postulated that this may 
be due to the genetic make-up of this group of tumours. 
 
2. A cancer relating to a false negative diagnostic test. 
This type of interval cancer is related to the sensitivity of a test, i.e. the proportion of false 
negative test results. Within colorectal cancer screening, there are relatively large numbers 
of false negative faecal occult blood tests, due to the poor sensitivity of the test. There has 
also been research published on post colonoscopy interval cancers. 
 
With regards to colorectal cancer, an interval cancer may belong to one, or both categories. 
Both of these groups will be discussed in this chapter. 
 
6.2 The Biology of Interval Cancers 
As discussed in Chapter 1, there are a series of genetic abnormalities that are associated 
with colorectal cancer development. 
Microsatellite instability (MSI) is thought to play a key role in the pathogenesis of colorectal 
cancers. Lesions with MSI are associated with interval colorectal cancers. The reasons for 
this are multifactorial. The lesions themselves are associated with rapid growth, and 
therefore may develop between examination procedures [120]. Also, these lesions are 
more frequently found in the right colon, and are of a serrated sessile structure, making 
them harder to detect at colonoscopy [121]. Hawkins et al. compared benign polyps from 
cancer resection specimens in patients with and without microsatellite instability (n=29 in 
each group). They found that  individuals with cancers showing MSI were more likely to 
have at least one serrated polyp than the control group (OR 4.0, 95% CI 1.1-14.2; p=0.03), 
but the frequency of non-serrated adenomas was the same in both groups (p=0.52) [122].  
Sawhney et al. compared 51 interval cancer specimens against 112 non-interval cancers. 
They reported that 30.4% (95% CI 19.0%–44.9%) of interval cancers displayed MSI vs. 
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10.3% (95% CI 5.5%–18.1%) of non-interval cancers (p=0.003). After adjusting for age, 
subjects with an interval cancer were 3.7 times more likely (95% CI 1.5-9.1) to show MSI 
than non-interval cancers. The association between MSI and interval cancers was found to 
be more pronounced in the distal colon, despite a greater proportion of interval cancers 
being found in the proximal colon (61% vs. 40%, p=0.02). The authors found no difference 
in stage of interval cancers, with their survival rates being similar. 
CIMP gene markers have been implicated in the development of interval bowel cancers. In 
a study by Arain et al., the CIMP status of interval bowel cancers (which they defined as 
those which had developed within 5 years of a negative colonoscopy), was compared 
against the CIMP status in matched non-interval colorectal cancers. The interval cancers 
were significantly more proximal, smaller, had similar 5-yr survival rates, but showed no 
variation in stage. 57% vs. 33% were found to be positive for CIMP (p=0.004). They also 
showed that the interval cancers were significantly more likely to have microsatellite 
instability (29% vs. 11%, p=0.004) [123]. 
 
6.3 Interval Cancers Related to Diagnostic Test Sensitivity 
6.3.1 Interval Colorectal Cancers Post Faecal Occult Blood Test 
In a review of the Nottingham, Funen and Minnesota trials, an attempt to evaluate the 
sensitivity of the Hemoccult test was made [124]. The authors took into account the natural 
progression of a small adenoma to a large adenoma, then from a preclinical cancer of 
varying stage to a clinical cancer of varying stage. The sensitivity of the test is 33% if it is 
assumed that this is the same for all stages of cancer; 13% for Dukes’ A cancers to 66% for 
Dukes’ D cancers if it is assumed that the sensitivity varies according with cancer stage, and 
51% versus 19% when clinical stage versus earlier stage is assumed. With an estimated pre-
clinical cancer duration of 6.7 years, the highest sensitivity, with the best ‘goodness-of-fit’ 
is within an average of 2.5 years before diagnosis, where the sensitivity becomes 50%. The 
sensitivity of the test also seems to become greater with age (up to age 72 for men and 75 
for women) [125].  
The above shows that it is likely that the majority of interval cancers are related to the 
overall poor sensitivity of the guaiac based faecal occult blood test. By rehydrating the test, 
its sensitivity improves. However, this leads to a greater proportion of false positive results, 
which will require extra resources (in both time and money) to cope with the increase in 
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screening colonoscopy. A more detailed description of interval cancers, as part of this study 
and related studies, is included in the discussion. 
 
6.3.2 Interval Colorectal Cancers Post Colonoscopy 
Colonoscopy is termed the gold standard for detecting neoplastic lesions. The reasons for 
missing neoplasia that is present at time of test (i.e. a false negative) can be split into two 
groups. These are either because of performing an incomplete procedure, i.e. not 
intubating the caecum; or by not visibly seeing/treating a lesion within the reach of the 
colonoscope. 
To determine factors that might influence a colonoscopy being carried out that does not 
reach the caecum, a population-based study performed in Ontario, Canada reviewed all 
incomplete colonoscopies. Out of 331,608 colonoscopies, 43,483 (13.1%) were incomplete. 
The statistically significant variables for incomplete procedures were older age group (odds 
ratio [OR] 1.20 per 10-year increment; 95% CI 1.18–1.22), female gender (OR 1.35; 95% CI 
1.30–1.39), a history of prior abdominal surgery (OR 1.07; 95% CI 1.05–1.09), or pelvic 
surgery (OR 1.04; 95% CI 1.01–1.06). Those procedures that were performed in a private 
office setting were 3 times more likely to be incomplete (OR 3.57; 95% CI 2.55–4.98). For 
patients undergoing a colonoscopy in an academic centre, the completion rate for high 
volume endoscopists (5th quintile, 641-1569 procedures) was the same, no matter what 
speciality (internal medicine, surgery, gastroenterology) [126]. 
As mentioned, even when the endoscopist visualises the whole colon, there is still a false 
negative rate. A review of the Surveillance, Epidemiology, and End Results (SEER)-Medicare 
database of 57,839 patients aged ≥69 years, diagnosed with a colorectal cancer between 
1994 and 2005, showed that the 7.2% had undergone a prior colonoscopy between 6 to 36 
months earlier. Predictors of interval cancers were found to be proximal colon location 
(distal colon: OR 0.42, 95% CI 0.39-0.46; rectum: OR 0.47, 95% CI 0.42-0.53), greater 
patient comorbidity (OR 1.89, 95% CI 1.68-2.14 for 3 comorbidities), a previous diagnosis of 
diverticulosis (OR 6.00, 95% CI 5.57-6.46), and previous polypectomy (OR 1.74, 95% CI 1.62-
1.87). Risk factors at the endoscopist level included a lower polypectomy rate (OR 0.70, 
95% CI 0.63-0.78 for the highest quartile), higher colonoscopy volume (OR, 1.27, 95% CI 
1.13-1.43), and specialty other than gastroenterology (colorectal surgery: OR, 1.45, 95% CI 
1.16-1.83; general surgery: OR 1.42, 95% CI 1.24-1.62; internal medicine: OR 1.38, 95% CI 
1.17-1.63; family practice: OR 1.16, 95% CI 1.00-1.35). Although patients with a previous 
diagnosis of carcinoma in situ were excluded from the analysis, there was no mention as to 
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the proportion of patients who underwent a polypectomy for a dysplastic lesion at their 
index colonoscopy. Given that a previous polypectomy was seen as a risk factor for the 
development of an interval cancer, and the inclusion of patients who underwent a 
colonoscopy up to three years prior to diagnosis, it is likely that there may be a proportion 
of patients who had high risk polyps removed, and had their cancer diagnosed at the 
planned surveillance colonoscopy. Their definition of an interval cancer therefore appears 
flawed. The study should have excluded any patients whose index colonoscopy had any 
degree of abnormality. 
A study as part of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Group  
repeated a flexible sigmoidoscopy 3 years after a negative examination [127]. Of 11,583 
individuals without a polypoid mass or lesion on initial examination, 9,317 (80.4%) 
returned. The mean age was 65.7 years with 61.6% being men. Of these 9,317, 1,292 
(13.9%) had a repeat flexible sigmoidoscopy where a polyp or mass was detected. 64.4% 
had 1 abnormal lesion (polyp or mass) identified, 19.7% had 2, 7.8% had 3, and 8.1% had 4 
or more abnormal lesions found. The largest polyp size, estimated by the endoscopist, was 
at least 1 cm in 5.5%, between 0.5 and 0.9 cm in 21.6%, and 0.5 cm or smaller in 73.0%. In 
the distal colon, 292 (3.1%) of 9317 had an adenoma or cancer with 78 (0.8%) being classed 
as an advanced adenoma or cancer. 847 participants underwent a colonoscopy following 
their abnormal flexible sigmoidoscopy which increased the yield of advanced adenoma and 
cancer to 4.1% and 1.3% respectively. 
This study raises the question as to whether some of these lesions were new lesions or 
whether they had been missed on the initial examination. Whilst it is possible that these 
are new lesions, other studies where a “tandem colonoscopy” has been carried out have 
shown that it is possible to miss lesions. 
In a bid to determine the sensitivity of a colonoscopy examination, tandem colonoscopy 
studies have been performed.  In a study by Hixson et al., subjects underwent two back-to-
back colonoscopies [128]. At the first colonoscopy, all polyps/tumours were removed or 
biopsied. The colonoscopy was then repeated by a second examiner, who attempted to 
identify all lesions ≥1cm in size. Any lesions identified on the 2nd colonoscopy that had not 
been seen on the first exam were deemed ‘missed’. Out of 90 patients, there were 63 
lesions ≥1cm, none of which were missed (95% CI 0%-4.6%). 58 of the polyps were found to 
be neoplastic, with 5 being hyperplastic. As would be expected, 37 (63.8%) of the 
neoplastic polyps were distal to the splenic flexure. There were 163 neoplastic polyps 
≤9mm in size of which 14.7% were missed on initial examination. The authors do not 
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comment as to the location of the missed polyps. As the likelihood of a polyp being 
malignant increases with its size, the authors conclude that colonoscopy is an extremely 
effective tool at identifying larger lesions, but repeat colonoscopies should be carried out 
for patients with multiple smaller polyps.  
A similar back-to-back study of 183 colonoscopies, with varying patient positions and 
endoscopists for the 2nd exam, showed a miss rate of 27% for adenomas ≤5mm, 13% for 
adenomas 6-9mm, and 6% for adenomas ≥1cm. Right-sided adenomas were missed more 
frequently than left (27% vs. 21%), although not significantly [129]. However, a separate 
study has shown that right sided tumours are more likely to be missed compared to left 
sided tumours [130], of which the risk of missing a metachronous non-advanced 
(Ptrend<0.001) and advanced (Ptrend<0.07) adenomas was associated with patients with a 
higher BMI [131].  
The possible reasons for missing a colorectal cancer have been looked at by identifying 
interval cancers within a colonoscopy screening programme. A paper published in the New 
England Journal of Medicine in 2010, used a multivariate Cox proportional-hazards 
regression model to evaluate the influence of particular quality indicators for colonoscopy 
on the risk of interval cancer [132]. They looked at 50,148 subjects from the National 
Colorectal Cancer Screening Program in Poland for the period from October 2000 through 
to December 2004. The study looked at the adenoma detection rate for each of the 186 
endoscopists, as well as their caecal intubation rate, and whether they were statistically 
significant in the rate of interval cancers. There were 42 interval cancers diagnosed, of 
which two independent risk factors for interval colorectal cancer were identified: the 
endoscopists rate of adenoma detection (p=0.008) and the subject's age (p=0.005). The 
rate of caecal intubation was not significantly associated with the risk of interval colorectal 
cancer (p=0.50), as has been previously thought. An individual rate of adenoma detection 
below 20.0% was significantly associated with an increased risk of interval colorectal 
cancer, as compared with a detection rate of 20.0% or more (p=0.02). Older patients (≥60) 
within the study were also associated with a greater risk of developing an interval cancer. 
The Polyp Prevention Trial (PPT) from the United States, found an incidence rate of interval 
cancer following colonoscopy being 1.2/1000 person-years of observation. A history of an 
advanced adenoma was the only factor significantly associated with the risk of an interval 
cancer (p=0.04) [133]. 
There is an on-going debate as to when, or even if, a colonoscopy should be repeated after 
a completely negative examination. A study by Brenner et al. found that in 593 patients 
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after a mean of 11.9 years post negative colonoscopy (no cancers or adenomas identified), 
no subsequent cancers were detected. The rate of advanced adenoma (defined as 
presence of adenoma with at least 1 of the following features: >1 cm in size, tubulovillous 
or villous components, high-grade dysplasia) was 0.38, 0.34, 0.38, and 0.53 among 
participants with a negative colonoscopy conducted 1-5, 6-10, 11-15, and >16 years 
previously respectively [134]. In a paper by the same group of health professionals, they 
suggest that those patients who have a negative screening colonoscopy may not need a 
repeat exam for a minimum of 20 years [135]. 
Imperiale et al. performed a repeat colonoscopy on 1256 participants aged ≥50 years old 
that had a negative colonoscopy 5.34±1.34 years (mean ± 1SD) previously. At this repeat 
colonoscopy, no cancers were found (95% confidence interval, 0 to 0.24%). One or more 
adenomas were found in 201 persons (16.0%) with a total of 19 advanced adenomas (of 
which 10 (52.6%) were distal to the splenic flexure), were found in 16 persons (1.3%). The 
authors conclude that a 5 year rescreening interval is supported by this paper, however, 
they did not include in their analysis a number of patients whom had a repeat colonoscopy 
outside of the study in which neoplasia was found. These patients will have increased the 
total percentage of neoplasia detected [87]. 
 
6.4 Chapter Conclusion 
Interval cancers in any form of screening programme or cancer diagnosis test are crucial to 
review in detail. The causes as to why a cancer is not detected at the time of the test allow 
for both a better understanding of the condition and how it develops over time, as well as 
identifying possible areas for improvement of the test, to minimise on future missed 
cancers.  
Public opinion and confidence behind the medical profession relies on having robust 
examinations with high sensitivities. As discussed above, there are possible genetic and test 
factors that influence whether a colorectal cancer is missed by the screening programme. 
Given the relatively low sensitivity of the guaiac FOBt, compared to the high sensitivity of a 
colonoscopy, it is expected that the majority of interval cancers will be after a normal FOBt. 
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Chapter 7 The UK Bowel Cancer 
Screening Pilot 
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7.1 Study Design 
The UK bowel cancer screening pilot study began in 2000 and was based in Tayside, 
Grampian and Fife in Scotland and the West Midlands in England. Screening began at the 
Scottish site on 31st March 2000 and at the English site 6th September 2000 with a total of 
486,355 people offered screening at the two sites by the time of its completion after 2 
years. 
The pilot had a similar format to that of the randomised controlled trials with FOBt kits sent 
out to all patients in the age group 50-69 on a two yearly basis. After a positive result, 
patients were sent out an appointment with a screening nurse where they were offered a 
colonoscopy examination. 
Results from the 2nd year of the study are summarised below [136]. 
 
Demographic Responders, n (%) 
None 259402 (56.8) 
England 105878 (58.6) 
Scotland 153524 (55.4) 
Male 118617 (52.1) 
Female 140785 (61.4) 
Male: <55 yrs 33104 (47.2) 
Male: 55-59 yrs 30779 (51.2) 
Male: 60-64 yrs 26992 (55.0) 
Male: ≥65 yrs 27742 (57.3) 
Female: <55 yrs 38964 (58.2) 
Female: 55-59 yrs 37054 (62.6) 
Female: 60-64 yrs 32105 (64.9) 
Female: ≥65 yrs 32662 (61.7) 
Table 7.1 Number & Percentage of Responders from Both Sites 
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Figure 7.1 Percentage of responders by demographic. 
 
These values represent a similar number to those seen in the Nottingham trial. 
7.2 Faecal Occult Blood Test Results 
The pilot study group sent a questionnaire to a sample of the population from each of the 
following groups: Phase 1 non-responders, Phase 1 negatives, Phase 3 negatives, FOBt 
positives, and cancer positives. The different phases represent the repeat FOBt after 
inconclusive initial tests. 
The results from all the groups combined were that 40% didn’t carry out any exercise, 20% 
were current smokers, 60% obese/overweight according to their body mass index (BMI) 
and 40-50% had a low fibre intake. 
FOBt non-responders were: more likely to be current cigarette smokers than all responder 
groups, more likely to report a low fibre intake than phase 1 negatives and were more 
likely to perceive that bowel cancer would lead to death and pain, would limit their social 
and personal relationships and put their financial security at risk. They were less likely than 
all other groups to report knowing someone with bowel cancer or a family history of bowel 
0
10
20
30
40
50
60
70
80
90
100
R
es
p
o
n
d
er
 %
 
 59 
  
cancer and were less likely to believe that the FOBt would give them peace of mind and 
reduce the chances of dying from bowel cancer. 
FOBt positives and cancer positives were more likely than all other groups to report a blood 
relative with bowel cancer. 
The study group analysed each responder based on their deprivation index. They found 
that people who were from more deprived areas were less likely to take up FOBt, saw 
themselves at higher risk of developing bowel cancer, perceived bowel cancer as more 
serious (in terms of physical pain and damage to financial security), and had a low 
perceived ability to complete the kit. The authors suggest that non-completion of the FOBt 
may be an avoidance response to the fear of a positive result. These viewpoints were 
mirrored for the younger age groups. Non-completion in the younger age group was 
thought to be due to constipation, lack of time and storage problems, which were more 
commonly reported. 
7.3 Colonoscopy within the Pilot Study 
Uptake of colonoscopy amongst FOBt positives was 82.2%. Only 1.5% did not undergo 
colonoscopy because they were deemed medically unfit. Of the 16.3% that did not attend 
(DNA), 20% were under therapy or polyp follow-up, 8% had had a recent endoscopy, 2% 
had no colon and 6% intended to have a private colonoscopy. Correcting for these gives an 
alternative estimate of colonoscopy uptake of 87%.  
The DNA rate was higher in England (20.8%) than in Scotland (14.0%), higher amongst all 
ethnic minorities (over 25%) and amongst those from areas of higher deprivation. 
From similar surveys performed as with the FOB test, people undergoing colonoscopy in 
England were more likely to have consulted a clinic nurse, whilst those in Scotland were 
more likely to have consulted their GP.  
Perceptions of the colonoscopy experience amongst attendees were very positive. More 
than 90% of people attending colonoscopy felt they had adequate information about the 
meaning of their FOBt result and the colonoscopy procedure prior to attendance. 
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Table 7.2 Number and percentage of uptake of colonoscopy by demographic. 
 
 
Figure 7.2 Uptake of colonoscopy by demographic. 
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Demographic Colonoscopy Uptake, n (%) 
England 1227 (77.5) 
Scotland 2463 (84.3) 
Male 2272 (82.2) 
Female 1418 (81.4) 
Male: < 55 yrs 436 (80.3) 
Male: 55-59 yrs 524 (84.5) 
Male: 60-64 yrs 610 (84.0) 
Male: ≥ 65 yrs 702 (80.3) 
Female: <55 yrs 278 (85.8) 
Female: 55-59 yrs 321 (80.9) 
Female: 60-64 yrs 362 (80.4) 
Female: ≥ 65 yrs 457 (79.9) 
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7.4 Colonoscopy Results 
Abnormalities were classified as:  
 Non-malignant adenoma 
o polyp where lack of malignancy is confirmed by pathology data  
 Malignancy 
o polyp cancer which is known from pathology data to have been completely 
removed 
 Invasive colorectal cancer  
o all other cancers whose removal is incomplete or not known 
 Neoplasia  
o sum of all three categories above 
Subjects with more than one polyp and/or cancer were classified according to their most 
severe condition. The overall neoplasia rates in those with a positive FOB test result was 
402 per 1,000. 
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Neoplasia of subjects completing 
FOB testing, n (%) 
Neoplasia of subjects testing 
positive, n (%) 
Neoplasia of subjects with 
colonoscopy performed, n (%) 
  England Scotland England Scotland England Scotland 
Age (years) 
<55 91 (0.32) 174 (0.43) 91 (29.45) 174 (31.18) 91 (37.60) 174 (36.86) 
55-59 121 (0.41) 248 (0.70) 121 (34.28) 248 (37.35) 121 (43.84) 248 (43.59) 
60-64 183 (0.75) 315 (0.98) 183 (40.94) 315 (43.21) 183 (53.20) 315 (50.16) 
≥65 209 (0.94) 442 (1.24) 209 (44.00) 442 (45.52) 209 (57.26) 442 (55.67) 
 
Gender 
Male 399 (0.82) 822 (1.27) 399 (42.18) 822 (45.24) 399 (53.77) 822 (53.73) 
Female 205 (0.37) 357 (0.45) 205 (32.13) 357 (32.31) 205 (42.27) 357 (38.26) 
 
Deprivation 
Category 
1/2 147 (0.49) 246 (0.76) 147 (40.27) 246 (44.57) 147 (52.50) 246 (51.14) 
3 102 (0.51) 217 (0.68) 102 (39.08) 217 (36.59) 102 (47.44) 217 (42.38) 
4 195 (0.67) 239 (0.87) 195 (42.58) 239 (40.17) 195 (53.87) 239 (46.77) 
5 67 (0.62) 93 (0.91) 67 (30.45) 93 (36.61) 67 (40.61) 93 (45.37) 
6/7 83 (0.68) 62 (0.86) 83 (33.33) 62 (32.29) 83 (45.60) 62 (41.89) 
Table 7.3 Results following FOBt and colonoscopy
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Over half of the cancers that were found within the pilot screening programme were of an 
early stage (up to and including Dukes B) as shown in the pie chart below. 
 
Figure 7.3 Stage of screen-detected tumours. 
7.5 Adverse Consequences of the Screening Pilot 
Out of 3600 people who underwent a colonoscopy examination as part of the pilot 
screening programme the number of adverse effects are as follows: 
 10 (0.28%) patients were admitted overnight for post-procedure bleeding or 
abdominal pain, and then discharged the next day 
 13 (0.36%) patients re-admitted for bleeding or abdominal pain 
 2 (0.06%) patients suffered a bowel perforation 
 1 (0.03%) patient in England died post colonoscopy (although this was not 
attributed to the colonoscopy itself, but their co-morbidities) 
 3 (0.08) patients died post-surgery on their cancers picked up by the screening 
colonoscopy (secondary to their ischaemic heart disease) 
These complication rates are similar to those in the published literature regarding 
colonoscopy [137]. 
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7.6 Chapter Conclusion 
In this Chapter, the pilot bowel cancer screening programme has been reviewed. Uptake of 
the FOBt, its positivity levels, and cancer detection rates are equivalent to that seen in the 
mass population trials. The pilot study added key information regarding the population 
who do not take up the screening test, along with adverse consequences of the screening 
programme. It also demonstrated equivalent results from Scotland, which had not been 
part of any FOBt screening studies. This finding is key to the initiation of a nationwide 
programme. 
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Chapter 8 The NHS Bowel Cancer 
Screening Programme (BCSP) 
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8.1 Background 
The bowel cancer screening programme formally began in April 2006. This followed UK and 
Scandinavian research undertaken in Nottingham and Funen in the 1980’s (which is 
discussed in Chapter 5) and then based on a pilot service in Coventry, Warwickshire and 
Scotland. The planned roll out of a screening programme was due to be phased region by 
region over a three year period, with the entire eligible UK population covered by 2009. 
8.2 Aims & Objectives of the Screening Programme 
Taken from the NHS BCSP guidebook [138], the aims and objectives of the programme are 
to: 
 identify and invite eligible men and women for screening  
 enable people to make an informed choice about whether or not to participate in 
the screening programme  
 provide clear information quickly to people with either normal or abnormal FOBt 
results  
 diagnose a significant proportion of cancers at an early stage  
 minimise anxiety among participants in the programme  
 make the best use of screening resources  
 maintain minimum standards of screening and continually strive for excellence  
 involve and give feedback to the population covered by the programme  
 develop the staff who deliver the screening service  
 continue research into screening for and diagnosis and treatment of colorectal 
cancer. 
8.3 The Screening Process 
The NHS BCSP offers a guaiac based faecal occult blood test, FOBt, to all men and women 
aged between 60 and 69 every two years. Initially, anyone aged over 69 could request a 
FOBt kit. From February 2010, the age group was extended up to 75. 
Each FOBt kit has six samples within it. If a participant has six negative samples, the test is 
deemed negative, and a repeat kit will be issued in two years time. If the result is unclear, 
classed as one to four positive samples, then either one or two complete repeat kits are 
then sent to the patient. A second unclear or abnormal test kit and the episode is deemed a 
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positive result. If two subsequent test kits both have zero of six positive windows, the 
episode is classed as negative and the patient re-invited for screening in two years time. If 
five or six samples are positive, either on initial or repeat test, the test is deemed positive 
and the patient is invited to attend a nurse led clinic. 
At this appointment, the screening nurse discusses the abnormal test result and its 
implications. They will complete a medical history assessment and make a decision 
regarding the suitability for the patient to undergo a colonoscopy. At that session, the 
screening nurse can make the appointment for the patient to return for the colonoscopy 
examination. If there are concerns about the fitness of a patient to undergo a colonoscopy, 
they are referred to a screening colonoscopist. These patients will alternatively be offered a 
CT colonography examination in these circumstances. 
From the colonoscopy, the possible results are as follows: 
 
 
Figure 8.1 Outcomes after screening colonoscopy, Polyp surveillance guidelines [139]. 
8.4 Bowel Cancer Screening In the North East of England 
Bowel cancer screening using the FOBt began in February 2007, with full uptake in the 
region by April 2008. There are four programme hubs from which the screening 
programme within their catchment area is co-ordinated. These hubs are Tees, South of 
Tyne, North of Tyne and County Durham & Darlington. Within the programme hubs are 12 
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primary care trusts: Hartlepool, North Tees, Middlesbrough, Redcar & Cleveland, County 
Durham, Gateshead, South Tyneside, Sunderland, Darlington, Newcastle, North Tyneside, 
and Northumberland Care Trust. 
Each hub is responsible for issuing and monitoring screening invitations, including 
despatching test kits, issuing results and arranging screening nurse practitioner 
appointments. 
8.5 Data Storage 
Data is stored on a central database that can be accessed on a regional and national level. 
There is a service level agreement between the NHS Cancer Screening Programme and NHS 
Connecting for Health Service Management for the support and infrastructure of IT systems 
within the programme. A web based data recording system is used, with access via the 
Open Exeter system [140]. All data items except invite and FOBt data are primarily entered 
by the screening nurse practitioners. 
8.6 Data Items 
Table 8.1 shows a summary of all the data that is stored on the BCSP database. From this 
dataset, data obtained from the regional database was split into four categories as shown 
in the below figure: 
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Figure 8.2 Data obtained from regional BCSP database. 
 
Also obtained were the overall numbers of invites sent and uptake of an offered FOBt, the 
proportion of each FOBt result, the uptake of SSP appointments and uptake of a screening 
colonoscopy within the study time period. 
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Table 8.1 Data Items Collected within the Bowel Cancer Screening Database
Data Headings Data Items 
Patient Demographics 
Gender 
ASA Grade 
Drinks Alcohol 
Smoking 
Allergy Cause Of Death 
Screening Reason for Cease/Change    
Episode Status Closure Type Recall Method 
Communications Communication Records    
Test Kit 
Episode Type 
Individual Window Result 
Spoilt Reason 
 
Overall Result 
 
Technical Failure Reason 
Practitioner Clinic 
Appointment Type 
Attendance? 
Information Given 
Symptom Confirmation Symptom 
Type 
Decision to Proceed 
Medical History Confirmation 
Cancellation Reason 
Healthy Eating And Symptom 
General Health 
Fit For Colonoscopy 
MDT Outcome 
Diagnostic Test 
Type 
Diagnostic Test Result 
Distant metastases Bone 
Distant metastases Liver 
Distant metastases Lung 
Distant metastases Other 
Final Pre-treatment TNM category 
Radiology Complication 
Radiology Diagnosis 
Radiology Fail Reason 
Radiology Location 
Result CT Scan 
Result Endoanal Ultrasound Result 
1
st
 MRI Scan T Stage 
Result 1
st
 MRI Scan N Stage 
Result 2
nd
 MRI Scan T Stage 
First MRI Scan Margin Threatened 
Colonoscope Inserted 
Colonoscope Extent 
Fail Reason 
Complication Early 
Complication Late 
Result 
Neoplasia 
Histology 
ICD10 
Cancer Type 
Cancer Differentiation 
Lymphovascular Invasion 
Cancer Location 
Polyp Carcinoma 
Polyp Type 
Polyp Class 
Polyp Dysplasia 
Polyp Excision Complete 
Polyp Location 
Polyp Lymphovascular Invasion 
Polyp Stalk Invasion 
Polyp Sub Type 
Polyp Therapy Device 
Polyp Therapy Modality 
Polyp Therapy Success 
Modified Dukes Staging 
T Category Pathological 
N Category Pathological 
M Category Pathological Excision 
Margin 
Circumferential Margins Excision 
Margin Positivity Of Cut Colon Or 
Rectum Margin 
Perforation Or Serosal Involvement 
Synchronous Cancer Sites 
Cancer Therapy Modality 
Cancer Therapy Success 
Procedure Primary Procedure Name OPCS Procedure Type Stoma Procedure Reason No Surgery Performed 
Chemotherapy Chemotherapy Trial Teletherapy Trial   
Colonoscopy Quality 
Assurance 
Bowel Prep 
Comfort Exam 
Comfort Recovery 
Evaluation 
Extent 
Outcome 
Retro 
 
Sedation Exam 
Sedation Recovery 
Patient Discharge Type Confirmed Follow Up   
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8.7 Chapter Conclusion 
The NHS Bowel Cancer Screening Programme aimed to repeat the benefits found in the 
preliminary studies and pilot programme. It has a comprehensive data collection system, 
predominantly collected by screening nurse practitioners. This chapter summarises the 
screening process and data items that will be used in this study’s analysis. 
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Chapter 9 Northern Region Colorectal 
Cancer Audit Group (NORCCAG) 
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9.1 Background 
The Northern Region Colorectal Cancer Audit Group, NORCCAG, was started in 1997 by a 
group of colorectal surgeons, oncologists and pathologists from the region. The stated aim 
was “to improve the treatment, care and outcome of patients with colorectal cancer” 
[141]. It is currently funded by the strategic health authority and employs an audit co-
ordinator and an audit clerk. There is IT support from an external company, Xentec, who 
are experienced in medical databases. Attached to the group currently are two clinical 
research fellows.  
It primarily acts as a data collection and analysis group for all colorectal cancers known to 
the gastrointestinal multi-disciplinary team meeting in the Northern Region of England. 
This area stretches from Wansbeck General Hospital in Northumberland down to the 
Friarage Hospital in North Yorkshire, and from South Tyneside across to Carlisle Hospital in 
the North West, a population of approximately 3.1million. It covers one cancer network 
(North of England Cancer Network), encompassing 9 Trusts, 11 MDT’s and 17 District 
General Hospitals. 
Prior to 2005, NORCCAG collected the data of approximately 1400 patients with colorectal 
cancer per annum.  This number has increased to around 1800 per annum with a change of 
data collection. All data from submitted surgical, pathological and oncological forms are 
collated by the audit team. All deaths are flagged by the Office of National Statistics to the 
audit group. 
9.2 Format of Audit Programme  
9.2.1 Audit Staff 
There are 2 full-time audit co-ordinators who visit MDTs, co-ordinate data submissions and 
review case notes. They maintain the database and ensure data quality through both 
external & internal data validation, assist with data analysis and feedback outcomes to 
units on request through presentations. Outcomes are also presented to the Cancer 
Network and the Regional Chapter of the Association of Coloproctology. 
 
9.2.2 Steering Group 
A multidisciplinary steering group oversees the management of the audit and consists of a 
chairman, 2 secretaries, a surgical representative from each of the 17 participating 
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hospitals, pathologists, clinical and medical oncologists, medical gastroenterologists and 
clinical geneticists. Advice from other specialists is co-opted as required. This group is large 
as the essence of the audit is that it is organised by the audit participants. 
 
9.2.3 Dataset 
The NORCCAG dataset was previously divided into 3 subsets, collected on separate forms; 
 Patient Management Form; demographics, waiting times & staging investigation 
data items.  Completed by the NORCCAG staff, previously with the support of some 
MDTs. 
 Surgical Form; operative data items.  Completed by the operating surgeon or the 
NORCCAG staff from the operation note. 
 Pathology Form; pathology data items.  Completed by the reporting pathologist or 
the NORCCAG staff from the pathology report. 
 
 
 
Figure 9.1 Flow chart representing storage of data on NORCCAG database. 
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During 2009/10, the database was revised and updated to include newer data items on 
liver and lung resection and to ensure consistency of data items and data definitions with 
those of the NBOCAP dataset. 
 
9.2.4 Data Capture 
In previous years, data capture has been entirely reliant on case note review.  Whilst this is 
a robust method, the difficulty inherent in obtaining paper notes has been a major obstacle 
and resulted in an increasing retrospective dataset, due in part to the limited resources of 
the group. In 2006, NORCCAG’s role changed with colorectal cancer data recording being 
relinquished to each individual trust.  Data submitted to the National Bowel Cancer Audit 
Project (NBOCAP) was downloaded and imported into the NORCCAG database. From here 
it could be validated for accuracy and completeness. NORCCAG continues to aid some 
trusts in collecting and submitting data by reviewing data upload files and assisting with 
filling in missing data items. It also provides a training role to audit clerks in each trust. 
 
9.2.5 Data Quality 
The NORCCAG staff are experienced with colorectal cancer data items and trained to 
extract information from clinical notes and systems. There is rigorous internal and external 
data validation to ensure data quality. 
 
9.2.5 Data security 
The audit co-ordinators and the chairman of the Steering Group are responsible for data 
security and maintaining confidentiality. Ethical approval for the project was obtained from 
the Multi-Centre Research Ethics Committee in August 1999.  The Caldicott Guardians in all 
17 hospitals have approved NORCCAG. The audits support under Section 60 of the Health 
and Social Care Act to use patient identifiable information was approved after amendments 
to standard consent forms. 
 
9.2.6 Data Confidentiality 
The audit data is owned by the audit participants represented by the Steering Group which 
delegate the day to day working of the audit to the chairman, secretaries and audit 
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facilitators. There is no patient identifiable data released and each surgeon and unit are 
given a code known only to the surgeon, the relevant unit and the audit facilitators who 
have signed a declaration of confidentiality. Precedent for disclosure of unit identifiable 
data has been set by the National Lung Cancer Audit (LUCADA), the National Head and 
Neck Cancer Audit (DAHNO), the Society for Cardiothoracic Surgery and the Healthcare 
Commission, but previously the NORCCAG membership have voted against disclosure of 
what is currently incomplete, and non-risk adjusted outcomes data. 
9.3 Chapter Conclusion 
This Chapter shows the set-up of the Northern Colorectal Cancer Audit Group (NORCCAG) 
database. As with the BCSP database, the data items which will be used in this study are 
summarised.   
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Chapter 10 Aims of the Project 
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10.1 Introduction 
The project is a large scale epidemiological study of all colorectal cancers within the Bowel 
Cancer Screening Programme in the Northern Region of England. 
The purpose of this MD is to examine in detail patients diagnosed with colorectal cancer 
since the national bowel cancer screening programme was implemented. 
There are three important research questions: 
 
1. How effective is the current screening programme? 
This section will look at the rates of detection of colorectal cancers in the population who 
were offered screening. Patient demographics, level of deprivation, tumour location and 
stage profile of the cancers detected, how they were managed and the outcomes for those 
patients will be compared between each of the four patient classification groups shown 
below. The null hypothesis for this section will be: 
‘There is no difference in survival rate between subjects diagnosed with a colorectal cancer 
between those who were offered screening, and those who weren’t.’ 
 
2. What are the reasons behind the rates and outcomes of interval and non-uptake 
cancers? 
By comparing the screen-detected group with the interval cancer group, an explanation will 
be sought for patient and tumour characteristics that may influence the positivity of the 
FOBt in diagnosing a colorectal cancer. For those diagnosed with a colorectal cancer who 
did not take up the FOBt, any relationship between uptake and level of deprivation will be 
analysed. The null hypothesis for this section will be: 
‘There is no difference in the patient demographics, tumour characteristics, and survival 
rate between screen detected and interval/non-uptake colorectal cancers.’ 
 
 
3. How can we improve on the screening process? 
This section will look at the implications of changing the classification of an abnormal result 
according to the window positivity of the faecal occult blood test. Other possible areas for 
improvement to the screening process will also be discussed. 
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Within the bowel cancer screening programme, the cases of colorectal cancers can be split 
into four groups as shown below (shaded): 
 
 
Figure 10.1 Classification of Study Groups 
10.2 Colorectal Cancer Occurring in the Non-Uptake Group 
This group of patients comprises those persons who decline to undergo part, or all, of the 
screening process. This might be refusal to submit a FOB result, approximately 40-50% of 
the population eligible for screening. As discussed from the pilot study, these patients tend 
to be in the younger age groups, of a lower socioeconomic group, and male. 
Reasons that were given to the pilot study group for non-completion of the FOB test were 
that the test itself was “disgusting”, “unhygienic”, “difficult to use”, and “difficult to store” 
[136]. 
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A smaller group of patients (approx. 13%) will be those who have a positive FOB test, and 
then decline the offered colonoscopy examination. This can be with or without seeing the 
screening nurse practitioner. The main reason for not undergoing a colonoscopy from the 
pilot study was simply unwillingness to have the procedure. 
10.3 Interval Cancers 
The possible reasons behind the diagnosis of an interval cancer have been discussed in 
Chapter 6. Given that the bowel cancer screening programme has three parts to it, there 
are therefore three situations where interval cancer might occur. 
The first type occurs in patients who have a negative FOBt and are then diagnosed with a 
colorectal cancer within two years of the test, i.e. before they are due to have their next 
round of FOB testing. This group will account for the largest proportion of interval cancers 
and classified as a false negative screening test. 
The second type occurs in patients who have a positive FOB test and subsequently have a 
negative colonoscopy, and are then diagnosed with a cancer within two years of the 
colonoscopy. This group is classed as a false negative colonoscopy. 
The final group of patients occurs in those who have a non-cancerous adenomatous polyp 
found on colonoscopy and are then put in a surveillance programme, to be diagnosed with 
a cancer before they are due for their planned surveillance colonoscopy. This group will 
most likely have undergone a false negative colonoscopy, although a rapidly growing 
cancer is also a possibility. 
10.4 Screen-Detected Cancers 
This group of patients are those that who are diagnosed as a direct result of the screening 
investigations. They will have received a positive FOB test result, followed by a colonoscopy 
where their colorectal cancer was diagnosed. Screen-detected cancers can also include 
those diagnosed on the planned surveillance colonoscopy. 
In the Nottingham study, within the screening arm of the trial: “of the 893 cancers… (CRC 
incidence of 1·49 per 1000 person-years), 236 (26·4%) were detected by FOB screening, 
249 (27·9%) presented after a negative FOB test or investigation, and 400 (44·8%) 
presented in nonresponders” [100]. 
10.5 Control Group 
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Within this study there is a fourth control group. This is the population of patients who 
were diagnosed with their colorectal cancer within the time frame and age range of the 
above groups, but before they completed their first screening episode. Included in this 
category are all patients who were diagnosed with a CRC before they received the 
screening invite, or were diagnosed through symptomatic services before a planned 
screening colonoscopy (even if they submitted a positive FOBt). 
This control group was available for analysis due to the long lag time in the roll-out of the 
programme through the North East of England in inviting the whole population who were 
eligible to be screened. Completion of the initial invitation to be screened lasted nearly two 
years. Although this may seem like a prolonged time period, it was necessary as otherwise 
the programme would have been inundated with subjects requiring a colonoscopy. Given 
the limited resources within the region, this would have potentially led to those with a 
positive FOBt result waiting prolonged periods for their endoscopy. 
10.6 Chapter Conclusion 
This study aims to establish the performance of the NHS BCSP since its national 
implementation. This involves comparing the intervention (population offered screening) 
group against the control group, and then reviewing the outcomes of the patients detected 
through the screening programme against those not detected by the screening programme 
(either due to a false negative test result, or by non-uptake of the test). An explanation of 
the possible reasons behind the false negative test results, and methods to minimise these 
will be put forward.  
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Chapter 11 Methods 
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11.1 Study Location 
The study took place in the North East of England. The geographical area that NORCCAG 
covers has been described in the Chapter 9. From the description of the two databases, it is 
evident that they cover slightly different populations. NORCCAG also encompasses the 
population that the Cumberland Infirmary in Carlisle and the West Cumberland Hospital in 
Whitehaven serve. 
As the bowel cancer screening regional hub for Cumbria is based in Rugby and therefore 
includes patients that will not be registered on the NORCCAG database, all patients who 
sent their screening tests to the North West England regional hub were excluded. By doing 
this, it allows the total numbers of screening invites/responses, the total number of 
screening nurse practitioner appointments and colonoscopies to be obtained. This gives 
the denominator for many of the planned analyses. 
The exclusion was performed by reviewing the cancer unit that each patient was registered 
with on the NORCCAG database, and excluding those with a Cumbria hospital identifier. A 
secondary method was reviewing the postcode of each patient, and excluding any 
beginning with “CA”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.1 The North East of England. [142] 
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11.2 Regional Population Demographics 
The population of the North East is approximately 2.6million (5.0% of England’s 
population), making it the smallest region in England. It is also one of the slowest growing 
populations in England (from 2001 to 2010 it grew by 2.6% vs. 5.6% for England). In mid-
2010, 17.2% of the North East population was aged 65 or older (447,200 people). This 
proportion compared to other English regions is shown in the figure below. [143] 
 
 
Figure 11.2 Percentage of population aged 65 and over, 2010 and 2030. 
 
The total number of the North East population who are eligible for screening (aged 60-74 
years) is expected to grow over the next 25 years as shown in Figure 11.3 [144].
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Figure 11.3 Predicted total numbers of North East England population aged 60 to 74. [144] 
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The North East is also one of the most deprived regions in England. By using data from the 
English Indices of Deprivation Report of 2007, it is possible to show this against other 
English regions, as demonstrated in the chart below. 
 
 
Figure 11.4 Percentage of Lower Super Output Areas (LSOAs) In Each Region Falling In 
‘Most Deprived 20% Of LSOAs In England’. [145] 
 
The below table shows how the North East of England ranks with the rest of England when 
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Social Indicator Average Rate/Percentage 
North East in Relation To 
Other English Regions 
Disposable Household 
Income 
£327 per week Lowest 
Crime 
650 per 10,000 adults 
against the person 
Lowest 
Income 
24 % (6.2 million) in 
households below the 
poverty threshold 
 
Adults with Disabilities 15% Highest 
One Person Households 30% Amongst the Highest 
Lone Parent Households 7.7% Amongst the Highest 
Median House Price £120,000 Lowest 
Rented Accommodation 23% 2nd Highest 
Unemployment 9.3% Amongst the Highest 
Life Expectancy at birth 
77.2 for males, 81.2 for 
females 
Amongst the Lowest 
Smoking >20 
cigarettes/day 
10% of men and women Amongst the Highest 
Alcohol consumption on 
five or more days/week 
18% men,  9% women Lowest 
Table 11.1 Comparison of North East Social Indications against other English regions [146] 
 
North East industry traditionally had a high proportion in coal mining. In 2007, 17% of the 
region’s gross value added (GVA, a measure of economic output of a region) was from 
manufacturing (UK average 13%). 19% of the GVA was from real estate, renting and 
business activities (UK average 24%) [147]. 
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11.3 Study Population 
Subjects selected for the analysis were the population eligible for screening as part of the 
national programme. Inclusion criteria were defined as: 
 Date of diagnosis of cancer between 1st April 2007 and 31st March 2010. 
 Aged 60 to 69 years on date of diagnosis. 
As mentioned, the North East region bowel cancer screening hub began screening in 
February 2007. To allow time for the initial invites to be sent out and kits returned, the 
study period began on the 1st April 2007. At the time of data extraction, the NORCCAG 
database was complete up until 31st July 2010 therefore a three year time period was 
selected. Dates of diagnosis of each patient’s cancer were used as an inclusion criterion, 
with the final dates extending to the 31st March 2010. 
In February 2010, the age range for screening was increased to 74. Given the relatively slow 
distribution of invites and the lag time between invite and possible diagnosis, it was felt 
that there would be a minimal number of patients diagnosed in the two month period of 
age extension, in the older age bracket. Therefore, the age at diagnosis criteria was kept 
between 60 and 69. This also minimises on the potential differences in outcomes that may 
be associated with an older age group, as they may be more likely to have a greater level of 
comorbidities, compared to the younger age group. There may also be differing views on 
management choice for a 75 year old compared to a 60 year old, i.e. endoscopic resection 
and follow up vs. segmental bowel resection. 
11.4 Permissions 
As part of my role as a clinical research fellow, I was granted automatic access to the 
NORCCAG database. The clinical supervisor for my post is the chairperson of NORCCAG, 
Miss Sarah Mills. 
The study design and methodology was endorsed by  members of the Northern Region 
Endoscopy Group (NREG), a collaborative research network representing over 300 
endoscopists [148]. The vice chairman of NREG is Dr Matt Rutter who is also the chairman 
of the bowel cancer screening programme evaluation committee. This committee grants 
access to the national BCSP database. Dr Rutter reviewed the project plan and agreed to 
release of the appropriate screening data, but felt that this could be satisfactorily obtained 
from the regional hub database, instead of the national hub. 
All bowel cancer screening research should be reviewed by the National Information 
Governance Board (NIGB) [149]. Their ethics and confidentiality committee review 
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applications related to the processing of health and social care information under section 
251 of the NHS Act 2006. An application was made and reviewed by their committee who 
responded explaining that formal approval was not required as long as there was pseudo-
anonymization of the two databases. 
Pseudo-anonymization includes removing all identifiable data items from the database and 
replacing them with non-identifiable items. The only data item that remained on the 
NORCCAG dataset was NHS number. This was therefore replaced with a study number 
(A1000 to A2556). A list of NHS numbers with their corresponding study numbers (and no 
other data items) was sent to the hub analyst at the regional BCSP hub, Mr Colin Taylor. Mr 
Taylor then returned the appropriate BCSP data using this study number, and removing the 
NHS number. This meant that there was no patient identifiable data on any of the files that 
contained analysis data. 
As discussed, there are eight NHS trusts which comprise 13 hospitals that are part of the 
North East screening hub. These are: 
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Figure 11.5 Hospitals and Trusts within the North East Bowel Screening Hub. 
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Through the research and development team at Northumbria Health Care Trust, I obtained 
a list of all R&D managers in each of the above trusts. Each one of these was individually 
contacted to obtain access to medical records and their IT systems to allow data validation. 
The response from each of the trusts was variable. As the project was deemed a service 
evaluation (see below), certain research and development departments felt that it was not 
part of their role to aid me in gaining access to their data. This meant a great deal of time 
wasted in emailing the trusts to get their advice on whom to contact to gain access to their 
computer systems. 
Although the initial email explaining the nature of the project was sent out in December 
2010, it took until July 2011 to gain full access to each of the trust’s data. Each trust varied 
in the proof they required to grant this access. For example, South Tees NHS Foundation 
Trust was happy with the details provided in the project plan and was able to grant access 
within one month. However, other trusts required Caldicott approval, copies of criminal 
records bureau (CRB) clearance, ethics approval clearance, and copies of my passport 
before granting access. Many of the R&D facilitators informed me that they do not often 
deal with service evaluations and so weren’t familiar themselves as to what was required. 
The above process proved to be one of the biggest hurdles faced in carrying out this study.   
 
11.5 Ethics and Consent 
A service evaluation is “designed and conducted solely to define or judge current care” and 
is developed to answer “what standard does this service achieve?” [150]. A service 
evaluation has no current reference standard, with the intervention being currently in use. 
There should be no randomisation or allocation instilled. 
The project was reviewed by the University of Durham School of Medicine and Health 
Research and Ethics Committee and approved. 
To confirm that this study fell within the service evaluation category, the local NHS 
Research and Ethics Committee was contacted. They reviewed the project plan and agreed 
that formal ethical approval was not required. 
However, as this study progressed, it became apparent that although this project started 
out as a service evaluation of the screening programme, it began to generate research 
hypotheses. Some of these hypotheses could be answered by examining the data available 
in further detail. However, with regards to the use of medication around the time of FOBt 
(Chapter 11.13), extra data was actively sought out that was not included in the original 
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study protocol. These hypotheses were then addressed individually with the aims of the 
project altered to answer more specific research questions. 
 
11.6 Study Materials 
Patient identification from the NORCCAG database took place via two methods. First, all 
patients with a date of diagnosis and age within the inclusion criteria were extracted. One 
of the compulsory data items for entry onto the National Bowel Cancer Audit Project 
database is date of diagnosis. Along with tumour site and NHS number, it forms a unique 
patient identifier for this database. However, it was noted that there were a proportion of 
patients who were missing their date of diagnosis, with only minimal data items entered 
for each patients. 
A search was therefore performed based on the patient’s date of birth in an attempt to 
identify additional patients who may have been eligible for screening. The records of each 
of these were reviewed against each Trust’s IT system to obtain the date of diagnosis. The 
vast majority of these additional patients were patients who were currently being 
investigated for a colorectal cancer and so had incomplete records. 
11.7 Database Validation 
After validation work of the NORCCAG database (Chapter 9), patient records were 
reviewed for errors and missing data. 
By reviewing all incomplete pathology records, it was possible to complete all T, N and M 
stages as well as lymph node status and Dukes stage. From the pathology reports, the type 
of operation was extracted. There were a number of patients with duplicate procedures, an 
initial endoscopic excision (i.e. a polypectomy) who went on to have a segmental bowel 
resection. In these instances, the bowel resection was treated as the operative procedure 
(even if no residual tumour was found post polypectomy).  
All cases of Dukes D cancer were reviewed as it was found that if there was a degree of 
uncertainty on the staging investigations, they were sometimes incorrectly recorded as 
having metastatic spread of the cancer. 
Missing patient postcodes, GP codes, and ASA grades (where available) were supplemented 
from hospital computer records. 
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11.8 Postcode Deprivation Data 
Using the patient’s postcode, it was possible to obtain deprivation indices for each patient. 
This was performed by using the GeoConvert data from the Economic & Social Research 
Council (ESRC) Census Programme website [151].  A text file of all patient postcodes was 
uploaded which provided the Lower Super Output Area (LSOA) for each area. Through this, 
it was possible to derive what the score and rank of each LSOA was according to the English 
Indices of Deprivation from 2007. There are 32,482 LSOAs in England. The LSOA ranked 1 
by the Indices of Multiple Deprivation (IMD) 2007 is the most deprived and that ranked 
32,482 is the least deprived. The IMD 2007 was constructed by combining the seven 
transformed domain scores, using the following weights: Income (22.5%), Employment 
(22.5%), Health Deprivation and Disability (13.5%), Education, Skills and Training (13.5%), 
Barriers to Housing and Services (9.3%), Crime (9.3%), Living Environment (9.3%). The 
above data was obtained from the Communities and Local Government website [152]. 
11.9 Combining Databases 
As described in Chapter 8, the data from the bowel cancer screening programme was 
provided in several parts: Invitation data, FOB results, SSP appointment data and, 
Colonoscopy results. 
 
Using the study number and episode ID as identifiers, the invites and FOB results data was 
combined using Microsoft Access® 2010. This was then exported into a Microsoft Excel® 
2010 file for initial analysis. 
As each patient potentially had submitted several tests over different screening episodes, 
their FOB results could be spread over numerous rows. Therefore, each patient was 
reviewed in turn against their date of diagnosis to identify which screening episode was the 
correct one prior to their diagnosis. The results of their FOB kits were then put onto a single 
line in excel under the column headings: FOB kits 1-3, Earlier kits 1-3, and Later kits 1-3. 
For each kit, the overall result and total number of positive windows was recorded, as well 
as the date returned to the regional hub. 
By streamlining the data to a single row, reviewing it against the FOB test results and the 
patient’s date of diagnosis, it was possible to classify patients into their respective cancer 
groups on a preliminary basis. 
A similar process of condensing the SSP appointment data and colonoscopy results onto a 
single row in Excel was performed. 
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Once complete, it was possible to combine the NORCCAG database with the BCSP database 
and postcode deprivation data. This was performed using study numbers as identifiers and 
combining the three datasets into one. Once completed, the data was transferred into SPSS 
version 19·0® (SPSS Inc., Chicago, Illinois, USA). 
11.10 Classification of Data Items in SPSS 
To aid analysis, each data type was given numerical codes and grouped where appropriate. 
The full list of steps can be seen in Appendix 1. To summarise, these included using: 
 American Society of Anaesthesiologists (ASA) physical status grade as a surrogate 
for severity of patient comorbidities, being dichotomised into two groups of 1-2, 
and 3-5.  
 Tumour location was dichotomised on being distal to the splenic flexure or 
proximal (up to and including the splenic flexure). 
 Deprivation level was then dichotomised into two groups; whether or not the 
patient lived in one of the 10% most deprived areas within England.  
 Coding of medication use to within 2 months of carrying out a FOBt. 
 All resective surgery grouped into one category. 
 All palliative procedures (stents, bypass operation, etc.) grouped together. 
 Local excisions included all endoscopic polypectomies and trans-anal resection of 
tumours. 
 The modified Dukes’ staging classification (Stages A to D) was used to stage each 
tumour.  
 Dukes C1 and Dukes C2 cancers were combined to form Dukes’ C cancers. 
 Lymph node harvests grouped into greater than or less than 12 lymph nodes for 
resective surgery. 
 Creation of 30-day mortality variable. 
11.11 Classification of Study Group 
The two databases were combined to allow classification of patients into their respective 
groups of control, interval, non-uptake and screen-detected cancers. Figure 11.6 is a flow 
chart that summarises the process of allocation for each subject, into their appropriate 
classification groups. 
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 Figure 11.6 Flow chart representation of allocation to each study group. 
 
All subjects who were found to have a positive FOBt result were identified from the 
combined database. This subject group were then reviewed to ensure they had attended a 
SSP appointment, and had undergone a screening colonoscopy. Screen-detected cancers 
had to submit a positive FOBt, attend a screening nurse practitioner appointment and 
undergo a screening colonoscopy to be included in this group. All patients who were 
referred to symptomatic services with a histological diagnosis of a cancer, or with a 
suspicion of a cancer that had not been confirmed histologically by endoscopic biopsy were 
included in this group. The hospital records for each patient who had submitted a positive 
FOBt, but did not undergo a screening colonoscopy were reviewed. If they dropped out 
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from the programme, they were classified as a non-uptake cancer. If they were diagnosed 
with a CRC before they were due to undergo the next part of their screening tests (either 
repeat FOBt or screening colonoscopy), and had not been part of a previous round of 
screening, then they were classified into the control group. An example of this is if a subject 
submitted a positive FOBt, but then was admitted to hospital as an emergency with a 
bowel obstruction, before they due to have their planned screening colonoscopy.  
The above scenario for inclusion into the control group, ties with its definition: A subject 
who was diagnosed with their colorectal cancer through symptomatic bowel cancer 
services, prior to completion of their first screening round. Therefore, even if they 
submitted a positive FOBt result (n=19), they were still classed as a control if they did not 
complete the planned screening round.  
Interval colorectal cancers were classed as a cancer diagnosed between screening rounds, 
after a negative screening episode (either FOBt or colonoscopy). 
Non-uptake cancers were in patients who declined a part of the screening process: the 
FOBt, a SSP appointment or a screening colonoscopy. 
11.12 Data Analysis 
As described above, the control group was available for analysis due to the lag time in 
programme implementation across the study region. This is the only time in the history of 
the screening programme where such a group will be available for comparison, since it has 
been introduced nationally. It was assumed that this control group were uninfluenced by 
the screening programme, as none had completed a screening episode at the time of their 
diagnosis. To ensure that this is the case, analysis of the impact of different variables on 
survival of the control group will be performed. These variables are widely accepted as 
being independent factors in altering (or not altering) the outcome of cancer patients, and 
include gender, ASA grade, and deprivation level. The effect of these variables on the 
intervention group will also be reviewed, to ensure both groups are influenced by the 
above in the same way. 
To achieve the above aims, the following classification groups were compared against each 
other: 
 Control vs. Intervention  
 Control vs. Screen detected 
 Control vs. Non-uptake 
 Control vs. Interval 
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 Screen detected vs. Interval 
Between the above groups, Pearson Chi-squared tests were used to look for significant 
differences in proportions for variables of deprivation, gender, ASA grade, and tumour 
location. Kruskal-Wallis test was used for Dukes’ stage analysis as an ordinal variable, with 
log rank Mantel-Cox test used for survival analysis. Ages were compared with Students t-
test. Results will be displayed in tabular form, with Kaplan-Meier survival curves shown to 
demonstrate any differences in survival. Subgroup analyses were performed where 
appropriate. Data were analysed using SPSS version 19·0® (SPSS Inc., Chicago, Illinois, USA). 
Primarily, a comparison between the control group and intervention (those who were 
offered screening) group will be made. This will establish whether the patient 
demographics and tumour characteristics between the two groups are equivalent. If there 
are no significant differences between these groups, then it will mean that the control 
group is valid for use as a comparator.  
 To answer the research question: ‘There is no difference in survival rate between subjects 
diagnosed with a colorectal cancer between those who were offered screening, and those 
who weren’t’, the survival rates will be compared between the control group and the 
intervention group. 
The second research hypothesis: ‘There is no difference in the patient demographics, 
tumour characteristics, and survival rate between screen detected and interval/non-uptake 
colorectal cancers’ will be answered by comparing the screen detected group against the 
interval and non-uptake groups. The interval cancer group will be reviewed in detail to 
establish any areas that would potentially improve the detected rate of colorectal cancers, 
leading to a decrease in false negative FOB results. 
11.13 Medication Use Dataset 
All interval and screen-detected cancer patients were identified along with their GP code. 
From the list of GP codes supplied with the screening invite data, it was possible to obtain 
the GP addresses for all these patients.  
A proforma was designed (see Appendix 2) and sent with an accompanying letter 
(Appendix 3) to each identified GP practice. The proforma asked the practice to complete 
whether their patient(s) had ever taken specific medications, the dates they were taken, 
and whether the patient had undergone a previous cholecystectomy. 
The medications asked about were: 
 Non-steroidal anti-inflammatories (NSAIDs), e.g. diclofenac, ibuprofen 
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 Hormone Replacement Therapy 
 Hormone Antagonists, e.g. tamoxifen 
 Anti-coagulants, e.g. aspirin, warfarin 
A stamped, addressed return envelope was included within the initial letter. This was sent 
out on the 7th February 2012. A reminder letter was sent out on the 7th March 2012 
(Appendix 4). A generic reminder letter was sent out to practices that had not responded 
by the 7th March, and individual letters were sent out for further clarification of missing 
details returned by a number of practices. 
A 2nd reminder letter, with proforma and return envelope was sent out on the 18th May 
2012 to all non-responders (Appendix 5). 
The results were inputted onto the SPSS worksheet, highlighting patients that had been 
taking the relevant medications at, or up to 2 months prior, to returning their FOBt. 
11.14 Chapter Conclusion 
By using a combination of the regional BCSP database, along with the North East’s regional 
cancer registry, it is possible to establish the screening history of all colorectal cancers 
diagnosed in the population eligible for screening. 
Comprehensive data cleansing and consolidation was carried out to create a workable 
dataset, with the combination of all data sources. Methods of statistical analysis have been 
shown. The steps taken to obtain and analyse the medication use of screen-detected and 
interval cancer groups has been shown. 
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Chapter 12 How Effective is the 
Current Screening Programme in 
North East England? 
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12.1 Introduction 
This is a comprehensive study of colorectal cancers in one English region, following the 
implementation of the National Bowel Cancer Screening Programme. By using the 
combination of the NORCCAG database and the BCSP database, an accurate comparison of 
all cancers and their short term outcomes can be demonstrated. 
The North East of England was one of the first regions to achieve complete coverage of its 
entire geographical area. It is therefore an ideal area to analyse the impact of the screening 
programme since its national implementation, in a region that hasn’t been involved with 
any preliminary studies. This allows the true effect of screening to be seen, without any 
influence from previous interventions or media campaigns. 
As described in earlier chapters, clinical mass population studies from Nottingham, Funen, 
Minnesota, Burgundy, and Goteborg, [100, 104-107, 115] have shown that screening 
increases the detection of earlier colorectal cancers, accompanied by an overall 
improvement in survival for screen-detected cancers. Pilot studies performed by Hardcastle 
et al. in Nottingham between 1981 and 1991 showed that there was a 15% reduction in 
cumulative CRC mortality in the screening group, as well a larger proportion being 
diagnosed with earlier bowel cancers (Dukes A). Of the 893 cancers diagnosed in the group 
offered screening (CRC incidence of 1·49 per 1000 person-years), 236 (26·4%) were 
detected by faecal occult blood (FOB) screening, 249 (27·9%) presented after a negative 
FOB test or investigation, and 400 (44·8%) presented in nonresponders [100].  
12.2 Uptake of Screening in North East England 
The below figure shows the total number of invitations to complete the FOB test in the 
study period of 1st April 2007 to 31st March 2010. This is for the population aged 60-69 and 
does not include those who self-referred or any as part of the age extension (70-75). The 
2,463 that were discharged were allocated to this group as they did not complete a full 
round of faecal occult blood tests. 
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Figure 12.1 Overall number of FOB invites, their uptake and results. N=Normal, 
Ab=Abnormal, Un=Unclear. 
 
 
An uptake of 56.0% (54.0% for men and 58.0% for women), is slightly higher than uptake 
rates from national figures (49.6% for men, 54.4% for women) [153]. When uptake was 
divided into deprivation level quintiles for the first one million population screened 
nationally, the North East of England was found to have a better uptake in each five 
divisions compared to other regions in England. 
There were 9,701 screening nurse practitioner appointments made for 9,187 persons after 
a positive FOBt. The maximum number of appointments per person was three. The 
discrepancy of 2 persons between positive results and SSP appointments is unknown, but 
could be due to them being discharged due to not highlighting exclusion criteria prior to 
appointment being made. The attendance rates per appointment number and per person 
are shown in the below figures. 
 
954,302 
Invites Sent 
534,262 
Responded 
522,610 
Negative 
Results 
509,643 
One N Test 
47.17% 
Male 
12,967 U, N, 
N 
55.93% 
Male 
9,189 
Positive 
Results 
1,159 One 
Ab Result 
65.31% 
Male 
538 Un, Ab 
67.10% 
Male 
92 Un, N, Ab 
54.35% 
Male 
5,025 Un, 
Un 
63.10% 
Male 
2,375 Un, N, 
Un 
59.96% 
Male 2,463 
Discharged 
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Figures 12.2 a and b. Numbers of SSP appointments post positive FOBt, total and per 
subject. 
 
There were 9,428 investigations carried out in 8,828 persons which are summarised in the 
figure below. Figure 12.3 shows that colonoscopy is the gold standard for large bowel 
investigation with 90.3% of patients undergoing at least one procedure. 
 
Appointments 
Attended 
Appointments Made 
Total Appointments 
Post Positive FOBt 
9701 Total 
6109 (63.0%) Male 5533 (90.6%) 
3592 (37.0%) 
Female 
3318 (91.2%) 
Appointments 
Attended 
Subject Appointments 
Offered 
Total Subjects Post 
Positive FOBt 
9187 Total 
5760 (62.7%) Male 5505 (95.6%) 
3427 (37.3%) 
Female 
3303 (99.6%) 
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Figure 12.3 Numbers of investigations, total and per subject. 
 
There were 1,884 screening nurse practitioner appointments made post investigation in 
1,608 persons with uptake rates for both shown below. 
 
Total Number of 
Investigations Per 
Subject 
Total Number of Each 
Investigation 
Total Investigations 
9428 
Investigations in 
8828 Subjects 
162 Barium Enema in 160 Subjects 
8419 
Colonoscopies 
in 7968 Subjects 
648 Flexi Sig in 508 Subjects 
148 CT 
Colonography 
in 142 Subjects 
31 CT Scan in 30 Subjects 
20 Limited 
Colonoscopy 
in 20 Subjects 
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Figures 12.4 a & b. Numbers of SSP appointments post investigation, total and per 
subject. 
 
12.3 Study Group 
Within the study period, 1336 patients diagnosed with a colorectal cancer were identified 
as being suitable for analysis. These included 825 (61.8%) in the population that were 
Appointments 
Attended 
Appointments Made 
Total Appointments 
Post Investigation 
1884 Total 
1271 (67.5%) Male 1033 (81.3%) 
613 (32.5%) 
Female 
479 (78.1 %) 
Appointments 
Attended 
Subject Appointments 
Offered 
Total Subjects Post 
Investigation 
1608 Total 
1096 (68.2%) Male 954 (87.0%) 
512 (31.8%) 
Female 
439 (85.7%) 
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offered screening (intervention group), and 511 (38.2%) in the control group. Of the 
cancers that were diagnosed in the group that were offered screening, 311 were in those 
who did not complete the screening tests (non-uptake group), 192 were interval cancers 
and 322 were screen detected. This is shown graphically in Figure 12.5 below.  
 
Figure 12.5. Proportion of cancers by classification group. 
12.4 Control Group vs. Intervention Group 
For an accurate comparison to be made between the three classification groups that were 
offered screening, a comparison must be made between the intervention group and the 
control group. Although the outcomes may differ in the intervention group, the patient 
demographics should be the same for an accurate comparison to be made. 
 
 
1336 Colorectal Cancers 
825 (61.8%) Cancers In 
Population Offered 
Screening 
514 (62.3%) Cancers In 
Population Who 
Completed Screening 
Episode 
192 (37.4%) Interval 
Cancers 
322 (62.6%) Screen-
detected Cancers 
311 (37.7%) Non Uptake 
Cancers 
511 (38.2%) Control 
Group Cancers 
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 Control, n=511 
Intervention, 
n=825 
 
Total, 
n=1336 
Mean Age At Diagnosis (years) 64.97 65.27 65.16 
Gender 
Male 319 (62.4%) 543 (65.8%) 862 (64.5%) 
Female 192 (37.6%) 282 (34.2%) 474 (35.5%) 
Lives in 10% 
Most Deprived 
Areas In 
England 
Yes 60 (11.7%) 113 (13.7%) 173 (12.9%) 
No 451 (88.3%) 712 (86.3%) 1163 (87.1%) 
ASA Grade 
Grouped 
1-2 224 (77.8%) 436 (72.8%) 660 (74.4%) 
3-5 64 (22.2%) 163 (27.2%) 227 (25.6%) 
Tumour Site 
Distal To Splenic 
Flexure 
358 (70.1%) 586 (71.0%) 944 (70.7%) 
Splenic Flexure 
and Proximal 
153 (29.9%) 239 (29.0%) 392 (29.3%) 
Table 12.1 Patient demographics and tumour details for control group and intervention 
group. 
 
 Chi-square 
Degrees of 
Freedom, df 
Significance, 
p value 
Gender 1.586 1 0.208 
Lives in 10% Most Deprived Areas 
In England 
1.070 1 0.301 
ASA Grade 2.543 1 0.111 
Tumour Site 0.144 1 0.705 
Table 12.2 Pearson Chi-Square Tests comparing control group vs. intervention group. 
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The above tables show that gender proportions, ASA grade, deprivation level and tumour 
site were not significantly different between intervention and control groups. 
The influence of the above variables on survival was reviewed for both intervention and 
control groups. The survival curves for each of these are shown below in Figures 12.6 to 
12.8. 
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Figure 12.6 a & b. Survival curve comparing gender for control and intervention groups. 
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Figure 12.7 a & b. Survival curve comparing deprivation level for control group and intervention groups.  
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Figure 12.8 a & b. Survival curve comparing ASA grade for control group and intervention groups. 
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For each variable, a comparison was made between groups. The results of these are shown 
in Table 12.3 below. 
 
 
Control Group Intervention Group All Cases 
Significance, p value 
Gender 
M vs. F 
0.180 0.425 0.706 
Deprivation Level 
Most Deprived 10% 
vs. Rest 
0.024 0.008 0.001 
ASA Grade 
1-2 vs. 3-5 
<0.001 <0.001 <0.001 
Table 12.3 Log Rank (Mantel-Cox) comparison of control group against intervention group 
for each variable, df=1 for all comparisons. 
 
As would be expected, the influences of deprivation level and a patient’s comorbidities 
have a significant effect on their outcome. This effect is seen in both the control group and 
intervention group showing that both groups behave in the same way, based on their pre-
existing patient demographics. 
12.5 Chapter Conclusion 
This chapter shows the total uptake of FOBt screening within the North East of England. 
There was a 1.7% positivity rate of the faecal occult blood test, in those who completed all 
test kits. The total numbers of each kit result are shown. 
The patient demographics and tumour details were found to be equivalent between the 
control group and the intervention group (all groups offered screening). Outcomes in both 
of these groups are influenced by the same risk factors. This means that the comparison 
between the control and intervention groups is a valid one, and allows the effect of 
screening to be established. This will be shown in the next chapter. 
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Chapter 13 The Impact of Screening 
Programme 
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13.1 The Impact of the Screening Programme 
The mass population trials from around the globe have reported on the comparison 
between a control group and the intervention group, with the intervention being the offer 
of screening.  
As shown in the previous chapter, the patient demographics and tumour locations are 
equivalent between groups. The impact of the screening programme can be viewed as any 
change in the stage of tumours detected, and the outcome of the population offered 
screening. These are shown in Table 13.1 below. 
 
 
Table 13.1 Outcomes of the control and intervention groups. 
 
 Control, n=511 
Intervention, 
n=825 
 
Total, n=1336 
Type of 
Surgery 
Resective 405 (79.3%) 666 (80.7%) 1071 (80.2%) 
Local Excision 15 (2.9%) 50 (6.1%) 65 (4.9%) 
Palliative 33 (6.5%) 39 (4.7%) 72 (5.4%) 
No Procedure 58 (11.4%) 70 (8.5%) 128 (9.6%) 
Dukes 
Stage 
A 89 (17.9%) 204 (25.5%) 293 (22.6%) 
B 132 (26.6%) 219 (27.4%) 351 (27.1%) 
C 154 (31.0%) 240 (30.0%) 394 (30.4%) 
D 121 (24.4%) 137 (17.1%) 258 (19.9%) 
30 Day 
Mortality 
Yes 21 (4.1%) 20 (2.4%) 41 (3.1%) 
No 490 (95.9%) 805 (97.6%) 1295 (96.9%) 
 114 
  
 
Figure 13.1 Tumour stage proportions between groups. 
 
As shown in the above table and figure, there were significantly more Dukes’ A cancers and 
significantly fewer Dukes’ D cancers within the intervention group. The choice of 
management between these two groups varies in the use of a local excision (without a 
segmental bowel resection and regional lymphadenectomy). A significantly greater 
proportion of patients in the intervention group were managed this way. 
There were no significant differences found in the 30-day mortality between groups. 
However, over the full follow-up period, the intervention group was found to have a 
superior survival rate (Log Rank Mantel-Cox χ2= 7.352, df=1, p=0.007), as shown in Figure 
13.2 below. 
 
17.90% 
25.50% 
26.60% 
27.40% 
31.00% 
30.00% 
24.40% 
17.10% 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Control Group Intervention Group
Dukes Stage D
Dukes Stage C
Dukes Stage B
Dukes Stage A
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Figure 13.2 Kaplan-Meier survival curves for control group and intervention group. 
 
To determine the reasons behind the improved survival rate due to carrying out screening, 
it is necessary to review each subgroup within the intervention group. As previously 
described, colorectal cancer patients who were offered screening can be categorised into 
three distinct groups. These are screen-detected cancers, interval cancers and non-uptake 
cancers. 
13.2 Screen-Detected Cancers 
There were 1,336 colorectal cancers diagnosed in the study population. The proportions in 
each group are shown in the figure below. This chapter will concentrate on the impact of a 
patient being diagnosed with a colorectal cancer through screening, highlighted in purple 
below. 
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Figure 13.3 Proportion of cancers by classification group. 
 
By comparing the screen-detected cancer group against the control group, it is possible to 
show the implications of detecting a cancer through screening. Table 13.2 below shows the 
demographics and cancer details of both the screen-detected group and the control group. 
1336 Colorectal Cancers 
825 (61.8%) Cancers In 
Population Offered 
Screening 
514 (62.3%) Cancers In 
Population Who 
Completed Screening 
Episode 
192 (37.4%) Interval 
Cancers 
322 (62.6%) Screen-
detected Cancers 
311 (37.7%) Non Uptake 
Cancers 
511 (38.2%) Control 
Group Cancers 
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Figure 13.4 Box plot of time from completion of FOBt to diagnosis for the screen-detected 
cancer group. 
 
The above figure (Figure 13.4) shows that the mean time from completion of the FOBt to 
diagnosis was 1.3 months (Standard Deviation 1.9 months), with 95% of cancers being 
diagnosed within 3.5 months. 
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Control Group, 
n=511 
Screen-
detected 
Group, n=322 
Comparison, 
p Value 
Mean Age (Years) 64·97 64·96 NS 
Gender 
Male 
319 
(62·4%) 
235 
(73·0%) 
0.002 
Female 
192 
(37·6%) 
87 
(27·0%) 
ASA Grade 
1-2 
224 
(77·8%) 
197 
(79·8%) 
NS 
3-5 
64 
(22·2%) 
50 
(20·2%) 
Lives in 10% 
Most Deprived 
Areas In 
England 
Yes 
60 
(11·7%) 
36 
(11·2%) 
NS 
No 
451 
(88·3%) 
286 
(88·8%) 
Tumour 
Location 
Distal To 
Splenic 
Flexure 
358 
(70·1%) 
253 
(78·6%) 
0.007 
Splenic 
Flexure and 
Proximal 
153 
(29·9%) 
69 
(21·4%) 
Dukes Stage 
A 
89 
(17·4%) 
125 
(38·8%) 
<0.001 
B 
132 
(25·8%) 
81 
(25·2%) 
C 
154 
(30·1%) 
89 
(27·6%) 
D 
121 
(23·7%) 
21 
(6·5%) 
T0 
6 
(1·2%) 
5 
(1·6%) 
 
Unknown 
9 
(1·8%) 
1 
(0·3%) 
 
Type of 
Procedure 
Resective 
405 
(79.3%) 
274 
(85.1%) 
<0.001 
Local Excision 
15 
(2.9%) 
38 
(11.8%) 
Palliative 
33 
(6.5%) 
3 
(0.9%) 
No Procedure 
58 
(11.4%) 
7 
(2.2%) 
Table 13.2 Distribution of patient demographics, tumour characteristics and management 
of patients between control and screen-detected cancer groups. χ2 test used in nominal 
variables, students t-test used to compare ages, Kruskal-Wallis test for Dukes stage as an 
ordinal variable. NS=Not significant. 
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Compared to the control group, screen-detected cancers were found more frequently in 
men (p=0.002), distal to the splenic flexure (p=0.007), had a better stage profile (p<0.001) 
with significantly more Dukes’ A cancers and fewer Dukes’ D cancers. A greater proportion 
were treated with local excision (p<0.001).  
 
30-Day 
Mortality 
Group 
Control, n=511 
Non-Uptake, 
n=311 
Interval, n=192 Screen, n=322 
Yes 21 (4.1%) 13 (4.2%) 6 (3.1%) 1 (0.3%) 
No 490 (95.9%) 298 (95.8%) 186 (96.9%) 321 (99.7%) 
Table 13.3 30-day mortality figures for each cancer group. 
 
The above table shows the numbers and percentages of the 30-day mortality for each 
group. Screen-detected cancers have a significantly lower mortality rate compared to each 
other group (χ2=11.4, df=3, p=0.01). However, when this is broken down by type of 
procedure performed for each group (Table 13.4 below), there are no longer significant 
differences for each (Table 13.5). Therefore, it is likely that the overall numbers of local 
excision procedures performed in the screen-detected group, is the predominant factor in 
achieving an extremely low early mortality rate. 
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Type of Surgery 
30 Day 
Mortality 
Group 
Control, n=511 
Non-Uptake, 
n=311 
Interval, n=192 Screen, n=322 
Resective 
Yes 
5 
(1.2%) 
4 
(1.7%) 
1 
(0.7%) 
1 
(0.4%) 
No 
400 
(98.8%) 
236 
(98.3%) 
151 
(99.3%) 
273 
(99.6%) 
Local Excision 
Yes 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
No 
15 
(100.0%) 
8 
(100.0%) 
4 
(100.0%) 
38 
(100.0%) 
Palliative 
Yes 
4 
(12.1%) 
2 
(7.7%) 
3 
(30.0%) 
0 
(0.0%) 
No 
29 
(87.9%) 
24 
(92.3%) 
7 
(70.0%) 
3 
(100.0%) 
No Procedure 
Yes 
12 
(20.7%) 
7 
(18.9%) 
2 
(7.7%) 
0 
(0.0%) 
No 
46 
(79.3%) 
30 
(81.1%) 
24 
(92.3%) 
7 
(100.0%) 
Table 13.4 30 day mortality figures for each cancer group by level of operative 
intervention. 
 
Type of Surgery χ2 Significance, p value 
Resective 2.523 0.471 
Local Excision NA NA 
Palliative 3.782 0.286 
No Procedure 3.760 0.289 
Table 13.5 Chi-squared figures and significance for each level of operative intervention, 
df=3 for all. 
 
As shown by the graph below, screen-detected cancer patients have a superior survival rate 
(Log Rank Mantel-Cox χ2=53.62, df=1, p<0.001), when compared against the control group. 
This is for all-cause mortality. 
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Figure 13.5 Kaplan-Meier survival curves for control and screen-detected cancers. 
13.3 Chapter Conclusion 
By comparing the outcomes of the intervention group and the control group, this study has 
shown that the screening programme has resulted in a more favourable stage profile, with 
significantly more Dukes’ A cancers and significantly fewer Dukes’ D cancers. The 
intervention group were found to have a superior survival curve. 
When the intervention group was split into its three subgroups, the screen-detected cancer 
group were found to have a far superior outcome to the control group, with a marked shift 
in tumour stage. Cancers detected through the screening programme were also found to 
be managed with a greater proportion of endoscopic treatment alone. 
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Chapter 14 Cancers Not Detected 
through the Screening Programme 
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14.1 Introduction 
Colorectal cancers that are diagnosed concurrently, but outside, the screening programme 
can be split into two groups. These are non-uptake cancers and interval cancers. 
Non-uptake cancers occur in the population that do not complete part, or all, of the 
screening process. Within the bowel cancer screening programme, this can occur at several 
stages: the non-uptake of all, or part, of the faecal occult blood test; the non-attendance at 
a screening nurse practitioner appointment (either after an abnormal FOBt result, or 
abnormal investigation), or non-uptake of a screening investigation (likely a colonoscopy, 
which could be after an abnormal FOBt, or as part of surveillance). These cancers are 
highlighted in green in the below figure. 
Interval colorectal cancers are defined as a cancer that is diagnosed between screening 
episodes, after a negative screening investigation. Again, these can be subdivided into post 
FOBt interval cancers (occurring after a normal FOBt), post colonoscopy (or other 2nd line 
investigation) interval cancers or, a cancer that is diagnosed prior to a planned surveillance 
colonoscopy. These cancers are highlighted in orange in the below figure. 
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Figure 14.1 Proportion of cancers by classification group. 
14.2 Non-Uptake Cancers 
The comparison of the non-uptake group and the control group aims to identify whether 
the process of inviting patients to undergo a screening test, will improve their outcomes, 
even if they do not take up the test itself. Each FOBt kit that is sent to subjects contains a 
patient information leaflet that contains information about the screening test and the 
symptoms of a colorectal cancer. 
By inviting a population to take part in a screening programme, it could be expected that 
awareness of colorectal cancer is increased. Therefore, patients may be more likely to see 
their GP’s if they are currently experiencing bowel related symptoms. 
As previously discussed, the aims of this study were not to look into reasons behind non-
uptake of the screening program. Although the demographics of the non-uptake cancer 
group are likely to reflect the demographics of those who do not take up the test and do 
not have a colorectal cancer, we do not have the evidence to support this. 
1336 Colorectal Cancers 
825 (61.8%) Cancers In 
Population Offered 
Screening 
514 (62.3%) Cancers In 
Population Who 
Completed Screening 
Episode 
192 (37.4%) Interval 
Cancers 
322 (62.6%) Screen-
detected Cancers 
311 (37.7%) Non Uptake 
Cancers 
511 (38.2%) Control 
Group Cancers 
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The types of non-uptake cancers are shown in the figure below. The population that 
returned an incomplete number of FOBt kits are included in the non-uptake of FOBt group. 
 
 Figure 14.2 Types of Non-Uptake Cancers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
311 Non-Uptake Cancers 
301 (96.8%) Non-
Uptake/Non-Completion 
of FOBt 
3 (1.0%) Non Uptake of 
SSP Appointment 
7 (2.3%) Non Uptake of 
Colonoscopy 
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Control, n=511 
Non-Uptake, 
n=311 
Comparison, 
p Value 
Mean Age (Years) 64·97 65·32 NS 
Gender 
Male 
319 
(62·4%) 
192 
(61·7%) 
NS 
Female 
192 
(37·6%) 
119 
(38·3%) 
ASA Grade 
1-2 
224 
(77·8%) 
138 
(64·2%) 
<0.001 
3-5 
64 
(22·2%) 
77 
(35·8%) 
Lives in 10% 
Most Deprived 
Areas In 
England 
Yes 
60 
(11·7%) 
60 
(19·3%) 
0.003 
No 
451 
(88·3%) 
251 
(80·7%) 
Tumour 
Location 
Distal To 
Splenic 
Flexure 
358 
(70·1%) 
205 
(65·9%) 
NS 
Splenic 
Flexure and 
Proximal 
153 
(29·9%) 
106 
(34·1%) 
Dukes Stage 
A 
89 
(17·4%) 
43 
(13·8%) 
NS 
B 
132 
(25·8%) 
87 
(28·0%) 
C 
154 
(30·1%) 
95 
(30·5%) 
D 
121 
(23·7%) 
72 
(23·2%) 
T0 
6 
(1·2%) 
2 
(0·6%) 
 
Unknown 
9 
(1·8%) 
12 
(3·9%) 
 
Type of 
Procedure 
Resective 
405 
(79.3%) 
240 
(77.2%) 
NS 
Local Excision 
15 
(2.9%) 
8 
(2.6%) 
Palliative 
33 
(6.5%) 
26 
(8.4%) 
No Procedure 
58 
(11.4%) 
37 
(11.9%) 
Table 14.1 Distribution of patient demographics, tumour characteristics and management 
of patients between control and non-uptake groups. χ2 test used in nominal variables, 
students t-test used to compare ages, Kruskal-Wallis test for Dukes stage as an ordinal 
variable. NS=Not significant. 
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Figure 14.3 Kaplan-Meier survival curve comparing control against non-uptake groups. 
 
Compared to the control group, the non-uptake cancer group had a significantly greater 
proportion of patients from a more deprived area, and with a greater level of co-
morbidities. 
However, these factors did not cause an overall change in survival rate, as may have been 
expected. We have shown in the previous chapter that both a higher ASA grade and a more 
deprived geographical residence have a negative impact on survival. When the control 
group was compared against the non-uptake group, there was no significant difference in 
survival rate found (Log Rank Mantel-Cox χ2=2.16, df=1, p=0.142). 
 
14.3 Interval Cancers 
Interval colorectal cancers are either due to the cancer being missed by the screening test, 
i.e. a false negative or, due to the cancer being fast growing in pathology and hence 
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developing in between screening episodes. If the cancer is of the latter group, we might 
expect patients to be diagnosed with a greater proportion of more advanced tumours, 
which may have already disseminated to regional lymph nodes compared to a control 
population. We might also expect their survival outcomes to be worse. To answer this 
question, a comparison between the interval cancer and control group should be made. A 
confounding factor may be the degree of false reassurance that a negative test brings. This 
is not only for the patient, but also for the patient’s health professional. The possible 
implications of a negative test result brings may be that the patient ignores symptoms 
caused by their bowel cancer, allowing time for the cancer to disseminate prior to 
diagnosis. This may also lead to a worse survival outcome for the patient. 
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Control, n=511 Interval, n=192 
Comparison, 
p Value 
Mean Age (Years) 64.97 65.71 0.002 
Gender 
Male 
319 
(62.4%) 
116 
(60.4%) 
NS 
Female 
192 
(37.6%) 
76 
(39.6%) 
ASA Grade 
1-2 
224 
(77·8%) 
101 
(73.7%) 
NS 
3-5 
64 
(22.2%) 
36 
(26.3%) 
Lives in 10% 
Most Deprived 
Areas In 
England 
Yes 
60 
(11.7%) 
17 
(8.9%) 
NS 
No 
451 
(88·3%) 
175 
(91.1%) 
Tumour 
Location 
Distal To 
Splenic Flexure 
358 
(70.1%) 
128 
(66.7%) 
NS 
Splenic Flexure 
and Proximal 
153 
(29.9%) 
64 
(33.3%) 
Dukes Stage 
A 
89 
(17.4%) 
36 
(18.8%) 
NS 
B 
132 
(25.8%) 
51 
(26.6%) 
C 
154 
(30.1%) 
56 
(29.2%) 
D 
121 
(23.7%) 
44 
(22.9%) 
T0 
6 
(1.2%) 
1 
(0.5%) 
 
Unknown 
9 
(1.8%) 
4 
(2.1%) 
 
Type of 
Procedure 
Resective 
405 
(79.3%) 
152 
(79.2%) 
NS 
Local Excision 
15 
(2.9%) 
4 
(2.1%) 
Palliative 
33 
(6.5%) 
10 
(5.2%) 
No Procedure 
58 
(11.4%) 
26 
(13.5%) 
Table 14.2 Distribution of patient demographics, tumour characteristics and management 
of patients between control and interval cancer groups. χ2 test used in nominal variables, 
students t-test used to compare ages, Kruskal-Wallis test for Dukes stage as an ordinal 
variable. NS=Not significant. 
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When the interval cancer group is compared against the control group, no significant 
differences are found in gender, ASA grade, deprivation level, tumour location, Dukes 
stage, management or survival rate. Survival rates between control and interval cancer 
groups were found to be equivalent (Log Rank Mantel-Cox χ2=0.48, df=1, p=0.489). 
 
 
Figure 14.4 Kaplan-Meier survival curves for control and interval cancers. 
 
14.3.1 Interval Cancers with an Unclear First Test Result 
There are several combinations of an individual FOBt result that leads to an overall positive 
or negative result. These are dependent on the number of positive windows for each test, 
out of a maximum of six. A normal test has no positive windows, an unclear test has 
between one and four positive, with an abnormal test having five or six positive windows. 
The results for screen-detected cancers and interval cancers are shown in the table below. 
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Table 14.3 FOB results for interval and screen-detected cancers 
 
As shown above, 37.4% of cases who completed a screening episode were missed by the 
faecal occult blood test. Of the 192 interval cancers, 15 (7.8%) had a FOBt that had 
between one and four windows positive in the first round of tests. These patients then 
repeated two further tests, both of which had zero of the six windows positive, giving them 
an overall normal result. 
The above table shows the number and percentage of cancers by the total number of each 
test result for interval and screen-detected cancers. A group of patients within the control 
group (n=19) and non-uptake group (n=17) sent a minimum of one test kit back, but did not 
complete the screening process, hence not being allocated to the screen-detected or 
interval cancer group. 
When interval cancers were compared against the population who were offered but did 
not take up screening (non-uptake group), there was no difference found between Dukes 
stage (χ2=0.646, df=3, p=0.422) or survival (χ2=0.156, df=1, p=0.692). It can be concluded 
that completing a negative screening in itself offers no additional benefit in terms of stage 
shift or survival. Kaplan-Meier curves for interval cancers, non-uptake cancers and the 
control group are shown in Figure 14.5.  
 
FOB Result Interval Cancer, n=192 
Screen-detected Cancer, 
n=322 
Normal 177 (92.2%)  
Unclear, Normal, Normal 15 (7.8%)  
Abnormal  83 (25.8%) 
Unclear, Unclear  158 (49.1%) 
Unclear, Abnormal  40 (12.4%) 
Unclear, Normal, Unclear  38 (11.8%) 
Unclear, Normal, Abnormal  3 (0.9%) 
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Figure 14.5 Kaplan-Meier survival curve comparing control against non-uptake and 
interval cancer groups.  
14.4 Incident Screening Round Cancers 
5.6% (46 of 825) of colorectal cancer patients were diagnosed in the incident round of 
screening (diagnosed during the second round of tests), having been offered a FOBt in the 
prevalent round (the first round of tests). 32 of the 46 returned a negative FOBt result, with 
30 returning one normal test kit (0/6 positive windows). The stage profile of each result is 
shown in Table 14.4 below.  
 
 
 
 
 
 133 
  
 
Screen-detected Cancer Interval Cancer 
Earlier Normal 
Test Result, 
n=24 
Earlier Unclear, 
Normal, Normal 
Test Result, n=2 
Earlier Normal 
Test Result, n=6 
Dukes Stage 
A 10 (41.7%) 1 (50.0%) 1 (16.7%) 
B 4 (16.7%) 1 (50.0%) 1 (16.7%) 
C 7 (29.2%) 0 (0.0%) 3 (50.0%) 
D 3 (12.5%) 0 (0.0%) 1 (16.7%) 
Tumour Site 
Distal to 
Splenic Flexure 
16 (66.7%) 2 (100.0%) 4 (66.7%) 
Splenic Flexure 
and Proximal 
8 (33.3%) 0 (0.0%) 2 (33.3%) 
Table 14.4 Stage and site of tumours by earlier test result 
 
Given the length of development of a colorectal cancer, and the range of stages of the 
cancers when they were eventually diagnosed, these cases could be classed as interval 
cancers. There were no cases where a subject had a normal test and then declined further 
screening, to be diagnosed with their cancer through symptomatic services. This would 
have implied a sense of false reassurance that may come with a normal result. However, 
given the small numbers of patients who were diagnosed in their second round of 
screening, it is possible that this group of patient may increase in number in future rounds. 
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Figure 14.6 Horizontal organisation chart of the results of earlier FOB tests by group. 
 
There were no statistically significant differences found in the stage or location of tumour 
between the two types of earlier FOBt results in the patients diagnosed with a cancer 
through screening. 
14.5 Chapter Conclusion 
Within this chapter, the rates and outcomes of cancers not detected through the screening 
programme have been presented. The vast majority of non-uptake cancers were after non 
completion of the FOBt. This cancer group were associated with a greater proportion of 
patients from deprived areas, with a higher level of co-morbidities. Their stage profile and 
survival rate found to be equivalent to that of the control group. 
In the population who took up screening and were diagnosed with a cancer, 37.4% were 
after a negative FOBt result. Of these 7.8% were after an unclear result in their first kit, 
followed by two normal results. The interval cancer group had an equivalent stage profile 
and survival rate as the non-uptake group, as well as the control group. 
46 Earlier Tests 
37 Screen-
detected Cancers 
24 Earlier Normal 
Test 
11 Earlier Non-
Uptake of Test 
2 Earlier Unclear, 
Normal, Normal 
Test Results 
7 Interval Cancers 
6 Earlier Normal 
Tests 
1 Earlier Non 
Uptake of Test 
2 Non-Uptake 
Cancers 
2 Earlier Non-
Uptake of Test 
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There were also a proportion of patients that had a cancer detected in the second round of 
screening, who had a normal result in the first round, two years earlier. They were found to 
have a range of tumour stages. 
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Chapter 15 The Effectiveness of the 
Faecal Occult Blood Test 
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15.1 The Effectiveness of the Faecal Occult Blood Test 
All patients within the screen-detected and interval cancer groups returned a FOBt, with 
screen-detected cancers having a positive result and interval cancers a negative result. No 
interval cancers were diagnosed after a false negative colonoscopy. This means that 37.4% 
of the population who completed a screening episode, had a cancer that was missed due to 
the low sensitivity of the FOBt. This figure does not include cancers that were picked up at 
the next screening round, after a negative screening episode. 
A comparison between screen-detected and interval cancer groups can be viewed as a 
surrogate analysis of the FOB test in detecting a colorectal cancer. The aim of the 
comparison is to identify patient and tumour demographics that might lead to a positive or 
negative FOBt result, in the detection of a colorectal cancer. 
The patient demographics, tumour stage and location, and management of these two 
groups are shown below in Table 15.1. 
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Screen, n=322 
Interval, 
n=192 
Comparison, 
p Value 
Mean Age (Years) 64·96 65·71 0.005 
Gender 
Male 235 (73·0%) 116 (60·4%) 
0.003 
Female 87 (27·0%) 76 (39·6%) 
ASA Grade 
1-2 197 (79·8%) 101 (73·7%) 
NS 
3-5 50 (20·2%) 36 (26·3%) 
Lives in 10% 
Most Deprived 
Areas In 
England 
Yes 36 (11·2%) 17 (8·9%) 
NS 
No 286 (88·8%) 175 (91·1%) 
Tumour 
Location 
Distal To 
Splenic 
Flexure 
253 (78·6%) 128 (66·7%) 
0.003 
Splenic 
Flexure and 
Proximal 
69 (21·4%) 64 (33·3%) 
Dukes Stage 
A 125 (38·8%) 36 (18·8%) 
<0.001 
B 81 (25·2%) 51 (26·6%) 
C 89 (27·6%) 56 (29·2%) 
D 21(6·5%) 44 (22·9%) 
T0 5 (1·6%) 1 (0·5%)  
Unknown 1 (0·3%) 4 (2·1%)  
Type of 
Procedure 
Resective 274 (85.1%) 152 (79.2%) 
<0.001 
Local Excision 38 (11.8%) 4 (2.1%) 
Palliative 3 (0.9%) 10 (5.2%) 
No Procedure 7 (2.2%) 26 (13.5%) 
Table 15.1 Distribution of patient demographics, tumour characteristics and management 
of patients between screen-detected and interval cancer groups. χ2 test used in nominal 
variables, students t-test used to compare ages, Kruskal-Wallis test for Dukes stage as an 
ordinal variable. NS=Not significant. 
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Gender Tumour Location 
Group Comparison, 
p value Screen Interval 
Male 
Distal To Splenic 
Flexure 
191 (81.3%) 79 (68.1%) 
0.006 
Splenic Flexure 
and Proximal 
44 (18.7%) 37 (31.9%) 
Female 
Distal To Splenic 
Flexure 
62 (71.3%) 49 (64.5%) 
NS 
Splenic Flexure 
and Proximal 
25 (28.7%) 27 (35.5%) 
Table 15.2 Proportions of screen and interval cancers by tumour site for men and 
women. 
 
 
Tumour Location Gender 
Group Comparison, 
p value Screen Interval 
Distal To Splenic 
Flexure 
Male 191 (75.5%) 79 (61.7%) 
0.005 
Female 62 (24.5%) 49 (38.3%) 
Splenic Flexure 
and Proximal 
Male 44 (63.8%) 37 (57.8%) 
NS 
Female 25 (36.2%) 27 (42.2%) 
Table 15.3 Proportions of screen and interval cancers by gender for left and right-sided 
tumours. 
 
The above tables show that, for male patients, there is a significantly greater proportion of 
cancers detected through screening that are distal to the splenic flexure (81.3% vs. 68.1%). 
This effect is not significant for female patients, although still present (71.3% vs. 64.5%).  
Similarly, for cancers that are distal to the splenic flexure, there are a significantly greater 
proportion of men that are diagnosed through screening (75.5% vs. 61.7%). This effect is 
not significant for right sided cancers, although the male proportion is still greater (63.8% 
vs. 57.8%). As the numbers become relatively small in each of the subgroups, this is a 
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possible reason why some results are not found to be significant on statistical analysis. A 
larger sample size may (or may not) confirm these findings. 
Screen-detected cancers have a significantly improved survival, compared against the 
interval cancer group (Log Rank Mantel-Cox χ2=50.36, df=1, p<0.001). 
 
 
Figure 15.1 Kaplan-Meier survival curves for screen and interval cancer groups. 
15.2 Outcomes for Screen-Detected and Interval Cancer Groups by 
Dukes Stage 
With significant differences in outcomes between screen-detected and interval cancer 
groups, it is important to determine the reasons behind this. If these differences are solely 
due to a more favourable tumour stage profile, then it should be expected that the 
outcomes for each stage of tumour should be the same between groups. 
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15.2.1 Outcomes for Dukes’ A Cancers 
Initially, a comparison of patient and tumour demographics must be made to ensure that 
there are no pre-existing variables that will have an influence on patient outcome. As 
shown in Chapter 12, a high ASA grade and more deprived residential area have a negative 
impact on survival. These variables for Dukes’ A cancers are shown in the table below.  
 
 
Screen, n=125 Interval, n=36 
Comparison, 
p Value 
Mean Age (Years) 64.75 65.80 NS 
Gender 
Male 87 (69.6%) 20 (55.6%) 
NS 
Female 38 (30.4%) 16 (44.4%) 
ASA Grade 
1-2 70 (77.8%) 19 (73.1%) 
NS 
3-5 20 (22.2%) 7 (26.9%) 
Lives in 10% 
Most Deprived 
Areas In 
England 
Yes 11 (8.8%) 2 (5.6%) 
NS 
No 114 (91.2%) 34 (94.4%) 
Tumour 
Location 
Distal To Splenic 
Flexure 
108 (86.4%) 30 (83.3%) 
NS 
Splenic Flexure and 
Proximal 
17 (13.6%) 6 (16.7%) 
T Stage 
pT1 86 (68.8%) 22 (61.1%) 
NS 
pT2 39 (31.2%) 14 (38.9%) 
Type of 
Procedure 
Resective 87 (69.6%) 32 (88.9%) 
0.02 
Local Excision 38 (30.4%) 4 (11.1%) 
Palliative 0 (0.0%) 0 (0.0%) 
No Procedure 0 (0.0%) 0 (0.0%) 
30 Day 
Mortality 
Yes 0 (0.0%) 0 (0.0%) 
NS 
No 125 (100.0%) 36 (100.0%) 
Table 15.4 Demographics, tumour stage and location, and management for screen and 
interval Dukes’ A cancers.  
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As shown in the above table, there were no significant differences found in tumour site, 
location, T stage, patient co-morbidity level, or deprivation level between interval and 
screen-detected Dukes’ A cancers. The only difference found was that significantly more 
screen-detected Dukes’ A cancers were managed with local excision. This is despite having 
comparable proportions of pT1 tumours (which could be used as a surrogate for polyp 
cancers). This outcome does not appear to be related to patients undergoing a major 
resection itself, as the 30 day mortality rate is the same for both groups. 
In the Kaplan-Meier curve below, patients who are diagnosed with a Dukes A cancer 
through screening have a superior survival rate compared to interval Dukes’ A cancers (Log 
Rank Mantel-Cox χ2=6.168, df=1, p=0.013). 
 
 
Figure 15.2 Survival Curve for Screen and Interval Cancers of Dukes’ A stage. 
15.2.2 Outcomes for Dukes’ B Cancers 
When the demographics and tumour details of the above groups for Dukes’ B cancers are 
reviewed, the only significant differences are found in mean age at diagnosis (screen-
detected = 64.9 years, interval = 66.0 years, t=2.29, p=0.023) and T stage (screen-detected 
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= 86.3% T3, interval = 70.6% T3, χ2=4.959, df=1, p=0.026). This difference in age is unlikely 
to be clinically significant. The greater proportion of T3 tumours (tumours invading through 
all bowel wall layers but not into adjacent structures) in the screen-detected group does 
not appear to have translated into a better survival, as may have been expected. Gender, 
ASA grade, deprivation level, tumour site, management (all resections), and 30 day 
mortality rate (nil for both groups) were not significantly different between screen and 
interval cancer groups. 
If we perform the same analysis as above for Dukes’ B cancers, then the survival rates 
between the two groups is equivalent (Log Rank Mantel-Cox χ2=0.117, df=1, p=0.732). 
 
Figure 15.3 Kaplan-Meier curve for interval and screen-detected Dukes’ B cancers. 
15.2.3 Outcomes for Dukes’ C Cancers 
Dukes’ C cancers are cancers of any T stage that have metastasised to regional lymph 
nodes. The patient demographics and tumour details for these cancers are shown in the 
table below. 
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Screen, n=89 
Interval, 
n=56 
Comparison, 
p Value 
Mean Age (Years) 65.49 65.77 NS 
Gender 
Male 66 (74.2%) 31 (55.4%) 
0.019 
Female 23 (25.8%) 25 (44.6%) 
ASA Grade 
1-2 65 (85.5%) 35 (77.8%) 
NS 
3-5 11 (14.5%) 10 (22.2%) 
Lives in 10% 
Most Deprived 
Areas In 
England 
Yes 8 (9.0%) 6 (10.7%) 
NS 
No 81 (91.0%) 50 (89.3%) 
Tumour 
Location 
Distal To Splenic 
Flexure 
69 (77.5%) 34 (60.7%) 
0.03 
Splenic Flexure and 
Proximal 
20 (22.5%) 22 (39.3%) 
T Stage 
pT0 0 (0.0%) 0 (0.0%) 
NS 
pT1 6 (6.7%) 3 (5.4%) 
pT2 11 (12.4%) 4 (7.1%) 
pT3 51 (57.3%) 28 (50.0%) 
pT4 20 (22.5%) 21 (37.5%) 
pTx 1 (1.1%) 0 (0.0%) 
Type of 
Procedure 
Resective 89 100.0%) 56 100.0%) 
NS 
Local Excision 0 (0.0%) 0 (0.0%) 
Palliative 0 (0.0%) 0 (0.0%) 
No Procedure 0 (0.0%) 0 (0.0%) 
30 Day 
Mortality 
Yes 1 (1.1%) 1 (1.8%) 
NS 
No 88 (98.9%) 55 (98.2%) 
Table 15.5 Demographics, tumour details and outcome for interval and screen-detected 
Dukes’ C cancers. 
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Figure 15.4 Kaplan-Meier curve for interval and screen-detected Dukes’ C cancers. 
 
As shown in the survival curve above, Dukes’ C screen-detected cancers do significantly 
better than those of interval cancers (Log Rank Mantel-Cox χ2= 6.051, df=1, p=0.014). 
Within the screen-detected cancer group, there were significantly more men with left sided 
tumours. A greater proportion of pT4 tumours was seen in the interval cancer group (37.5% 
vs. 22.5%), although this and the overall T stage profile was not significantly different 
between groups. There was no difference found in the ASA grade, deprivation level, 
modality of surgery, or 30-day mortality between groups. 
To determine the reasons behind this marked difference between these groups for Dukes’ 
C cancers, the lymph node status for each case was reviewed. A Dukes’ C cancer can be 
split into Dukes’ C1 (positive lymph nodes but negative apical node), and Dukes’ C2 
(positive apical lymph node). Dukes’ C2 cancers are associated with a worse prognosis 
compared with Dukes’ C1. The proportions of each of these are shown in Table 15.6. No 
significant differences were found between the proportions of these groups (χ2=0.2, df=1, 
p=0.66). 
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Dukes Stage Screen, n=89 Interval, n=56 
C1 80 (89.9%) 49 (87.5%) 
C2 9 (10.1%) 7 (12.5%) 
Table 15.6 Proportions of Dukes C1 and C2 for screen and interval cancers. 
 
 
Dukes Stage Mean Lymph Nodes Screen Interval t-test, p value 
 n=80 n=49  
C1 
Positive Lymph Nodes 2.90 3.61 NS 
Total Lymph Nodes 15.26 16.53 NS 
 
 n=9 n=7  
C2 
Positive Lymph Nodes 3.89 14.57 0.017 
Total Lymph Nodes 13.00 20.29 NS 
 
 n=89 n=56  
C Combined 
Positive Lymph Nodes 3.00 4.98 0.013 
Total Lymph Nodes 15.03 17.00 NS 
Table 15.7 Mean number of positive lymph nodes and total nodes harvested for each 
Dukes C stage. 
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Dukes Stage 
Total Number of Lymph 
Nodes Harvested 
Screen, n=89 Interval, n=56 
χ2 Comparison, 
p value 
C1 
<12 26 (32.5%) 12 (24.5%) 
NS 
>12 54 (67.5%) 37 (42.9%) 
C2 
<12 3 (33.3%) 3 (42.9%) 
NS 
>12 6 (66.7%) 4 (57.1%) 
 
C Combined 
<12 29 (32.6%) 15 (26.8%) 
NS 
>12 60 (67.4%) 41 (73.2%) 
Table 15.8 Number and percentage of each Dukes C cancer with less than or greater than 
12 lymph nodes harvested for screen and interval cancers. 
 
A value of 12 lymph nodes harvested is widely accepted as an adequate amount of nodes 
to enable accurate staging of a patient’s cancer [154]. Achieving this is related to both 
surgical and pathological skill. The implication of not harvesting 12 nodes or more is that a 
cancer may be under-staged, or positive lymph nodes may remain in situ post procedure. 
Table 15.8 above shows the proportion of cancers in which such an adequate clearance 
was achieved. As shown, Dukes’ stage C1, C2 and combined Dukes’ C cases had equivalent 
proportions where there were 12 or more lymph nodes harvested. 
When the survival curves are broken down into Dukes’ C1 and C2, tumour site, and gender, 
only screen-detected cancers of Dukes’ C2 stage have a significantly superior survival curve 
compared with the equivalent interval cancer group. The Kaplan-Meier curves for each 
subgroup are shown below. 
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Figures 15.5 a & b Kaplan-Meier survival curves for Dukes’ C1 and C2 cancers comparing interval vs. screen-detected groups 
 
 
 
 
Table 15.9 Log Rank (Mantel-Cox) test for survival curve equality for Dukes’ C1 and C2 cancers. 
Screen vs. Interval Cancers Chi-Square df Significance, p value 
Dukes C1 1.525 1 0.217 
Dukes C2 9.449 1 0.002 
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Figures 15.6 a & b. Kaplan-Meier survival curves for left and right sided cancers comparing interval vs. screen-detected groups. 
 
 
 
 
Table 15.10 Log Rank (Mantel-Cox) test for survival curve equality for left and right sided cancers. 
Screen vs. Interval Cancers Chi-Square df Significance, p value 
Splenic Flexure and Proximal 2.750 1 0.097 
Distal To Splenic Flexure 1.764 1 0.184 
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Figures 15.7 a & b. Kaplan-Meier survival curves for male and female gender comparing interval vs. screen-detected groups. 
 
 
 
 
Table 15.11 Log Rank (Mantel-Cox) test for survival curve equality for male and female gender. 
Screen vs. Interval Cancers Chi-Square df Significance, p value 
Male 3.321 1 0.068 
Female 1.662 1 0.197 
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15.2.4 Outcomes for Dukes’ D Cancers 
The table below shows the demographics and tumour details of patients with a Dukes D cancer in 
both the screen-detected and interval cancer groups.  
 
Screen, n=21 Interval, n=44 
Comparison, 
p Value 
Mean Age (Years) 64.05 65.24 NS 
Gender 
Male 15 (71.4%) 29 (65.9%) 
NS 
Female 6 (28.6%) 15 (34.1%) 
ASA Grade 
1-2 9 (75.0%) 9 (52.9%) 
NS 
3-5 3 (25.0%) 8 (47.1%) 
Lives in 10% Most 
Deprived Areas In 
England 
Yes 1 (4.8%) 6 (13.6%) 
NS 
No 20 (95.2%) 38 (86.4%) 
Tumour Location 
Distal To Splenic Flexure 16 (76.2%) 30 (68.2%) 
NS Splenic Flexure and 
Proximal 
5 (23.8%) 14 (31.8%) 
T Stage 
pT1 0 (0.0%) 0 (0.0%) 
NS 
pT2 1 (8.3%) 0 (0.0%) 
pT3 5 (41.7%) 4 (40.0%) 
pT4 6 (50.0%) 6 (60.0%) 
Type of 
Procedure 
Resective 12 (57.1%) 10 (22.7%) 
0.02 
Local Excision 0 (0.0%) 0 (0.0%) 
Palliative 3 (14.3%) 8 (18.2%) 
No Procedure 6 (28.6%) 26 (59.1%) 
30 Day Mortality 
Yes 0 (0.0%) 5 (11.4%) 
NS 
No 21 (100.0%) 39 (88.6%) 
Table 15.12 Demographics, tumour details and outcome for interval and screen-detected Dukes’ D 
cancers. 
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As shown, there is no difference in gender, ASA grade, deprivation level, tumour location or T stage. 
Although 11.4% of interval cancers died within the first 30 days post diagnosis compared to 0% of 
screen-detected cancers, this was not statistically significant on analysis. The only significant 
difference between groups is the rates of resective surgery for these cancers. 57.1% of screen-
detected cancers underwent a resection of their primary tumour, compared to 22.7% of interval 
cancers. Also, 28.6% of screen-detected cancers did not undergo any procedure, compared to 59.1% 
of interval cancers. 
Survival for these groups was found to be significantly different, with screen-detected cancers 
having a more favourable survival rate (Log Rank Mantel-Cox χ2= 11.479, df=1, p=0.001), as shown in 
Figure 15.8 below. 
 
Figure 15.8 Kaplan-Meier curve for interval and screen-detected Dukes’ D cancers. 
15.3 Interval Cancer Group vs. Control Group by Dukes Stage 
When the interval cancer group is compared against the control group for each Dukes stage, we 
might expect to see if the cancers at each stage behave differently to that of the general population. 
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This might explain why the interval cancer group does significantly worse for most Dukes’ stages 
compared to the screen-detected group. 
In comparing interval cancers against control group cancers for each Dukes stage, there were no 
significant differences found in any patient demographic, tumour characteristics and location, 
management choice and 30 day mortality rate. No significant differences were found between 
groups in the mean positive lymph nodes, mean total lymph nodes, and proportion of cases with 12 
or more nodes harvested for Dukes’ C1, C2 and Dukes’ C cancers. 
The survival curves for each of these Dukes’ stages are shown below in Figures 15.9 to 15.11. There 
were no significant differences found between the curves of these groups on analysis as shown in 
Table 15.13. 
 
 
Table 15.13 Tests of equality of survival distributions for interval vs. control cancer groups for each 
Dukes stage. 
 
Dukes Stage 
Log Rank (Mantel-Cox) 
Chi-Square df Significance, p value 
A 0.682 1 0.506 
B 0.128 1 0.958 
C 0.485 1 0.684 
D 2.547 1 0.156 
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Figure 15.9 Survival curve for interval and control cancers of Dukes Stage A. 
 
 
Figure15.10 Survival curve for interval and control cancers of Dukes Stage B. 
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Figure15.11 Survival curve for interval and control cancers of Dukes Stage C. 
 
Figure15.11 Survival curve for interval and control cancers of Dukes Stage D. 
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15.4 Role of Medication Use on FOBt Positivity 
To further understand the possible reasons behind the disproportionate positivity of the 
FOBt by gender and tumour site, an analysis of the role of medications was performed. 
Out of 514 patients with a screen or interval colorectal cancer, we received 346 proformas 
suitable for analysis (67.3%). This included 100% response rates for all the medication 
information, and a 98.6% response rate for data regarding pre-FOBt cholecystectomy. 120 
patients analysed were in the interval cancer group, with 226 in the screen-detected cancer 
group. 
32/346 (9.2%) patients had previously taken hormone replacement therapy. No patients 
were taking this at the time of completing the FOBt. This included 10.8% of patients (n=13) 
in the interval cancer group, and 8.4% of patients (n=19) in the screen-detected group. The 
difference in proportions between groups was not significantly significant (χ2=0.55, df=1, 
p=0.46). 
 
 
Group 
Total p value 
Interval Screen 
Ever Used 
Hormone 
Antagonists 
No 117 (97.5%) 218 (96.5%) 335 (96.8%) 
0.60 
Yes 3 (2.5%) 8 (3.5%) 11 (3.2%) 
  
Hormone 
Antagonist 
Use at Time of 
FOBt 
No 120 100.0%) 221 (97.8%) 341 (98.6%) 
0.10 
Yes 0 (0.0%) 5 (2.2%) 5 (1.4%) 
Table 15.14 Use of hormone antagonists at time and prior to carrying out FOBt. 
 
Table 15.14 summaries the use of hormone antagonists both pre-FOBt and at the time of 
test. No association with the use of hormonal medication and FOBt positivity was found. 
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Group 
Total p value 
Interval Screen 
NA-NSAID Use 
Within 2 
Months of 
FOBt 
No 115 (95.8%) 202 88.9%) 317 (91.6%) 
0.039 
Yes 5 (4.2%) 25 (10.6%) 29 (8.4%) 
 
Anticoagulant 
Use Within 2 
Months of 
FOBt 
No 103 (85.8%) 201 (88.9%) 304 (87.9%) 
0.40 
Yes 17 (14.2%) 25 (11.1%) 42 (12.1%) 
  
Aspirin Use 
Within 2 
Months of 
FOBt 
No 105 (87.5%) 203 (89.8%) 308 (89.0%) 
0.51 
Yes 15 (12.5%) 23 (10.2%) 38 (11.0%) 
Table 15.15 Use of Non-Aspirin Non-Steroidal Anti-Inflammatory Drugs (NA-NSAID), Anti-
Coagulants and Aspirin within two months of carrying out a FOBt.  
 
11 of 341 patients (3.2%) had undergone a cholecystectomy prior to carrying out their 
FOBt. 3/115 (2.5%) of patients belonged to the interval cancer group, with 8/215 (3.6%) 
having a screen-detected cancer. The difference in proportions was not found to be 
significant (χ2=0.27, df=1, p=0.60). Although, all 11 cholecystectomy patients had a tumour 
that was distal to the splenic flexure, this was not found to be significant (χ2=3.10, df=1, 
p=0.08). Significantly more women were found to have undergone a cholecystectomy than 
men (6.4% vs. 1.7%, χ2=5.24, df=1, p=0.02). 
The use of NA-NSAIDs appears to be associated with a positive FOBt. This effect does not 
appear to be the case for anti-coagulants (either aspirin or warfarin), or for aspirin alone. 
For the population who used NA-NSAID within two months of carrying out their FOBt, 
within both interval and screen-detected cancer groups, there was no significant 
differences in gender (p=0.97 & p=0.92 respectively), tumour location (p=0.65 & p=0.67), or 
stage of tumour (p=0.22 & p=0.36). 
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On univariate logistic regression analysis of factors that predict a positive result of the 
FOBt, male gender (p=0.003), NA-NSAID use within 2 months of test (p=0.047), and a 
location distal to the splenic flexure (p=0.003). 
The combination of tumour site & gender, NA-NSAID use & gender, and tumour site & NA-
NSAID use, do not appear to be predictors of a positive result (p=0.26, p=0.29, p=0.21 
respectively).  
On multivariate logistic regression analysis, NA-NSAID use and tumour site remained 
significant predictors of a positive FOBt result (p=0.047 & p=0.025). 
15.5 Chapter Conclusion 
This chapter has shown that the guaiac based faecal occult blood test is more effective at 
detecting cancers in the left colon and in men. Screen-detected cancers had a superior 
survival rate compared to the interval cancer group. 
On comparing these two groups for each individual Dukes stage, the screen-detected group 
was found to have a significantly better survival rate for Dukes’ A, C and D cancers. This is 
despite equivalent patient demographic proportions between groups. 
The interval cancer group and control group were found to have equivalent survival rates 
when analysed by Dukes stage. 
Non-aspirin non-steroidal anti-inflammatory medications (NA-NSAIDs) were found to be 
associated with a positive FOBt result, whereas anti-coagulant use and hormonal therapy 
was not.  
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Chapter 16 How Can the Screening 
Programme Be Improved? 
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16.1 Analysis of Window Positivity of First Returned FOBt Kit 
7.8% of interval cancers had a FOBt that was had between one and four windows positive 
in their first test. They then repeated two further tests, both of which had none of the six 
windows positive, giving them an overall normal (negative) result. 
When this group is compared against the interval cancer group with one normal test, there 
was no difference found in gender (χ2=1.286, df=1, p=0.257), ASA grade (χ2=0.007, df=1, 
p=0.933), deprivation level, (χ2=2.505, df=1, p=0.114), tumour location (χ2=1.302, df=1, 
p=0.254), Dukes stage (χ2=0.055, df=1, p=0.815) or survival (Log Rank Mantel-Cox, 
χ2=1.638, p=0.201). However, those with one unclear test were diagnosed with their 
cancer significantly sooner (7.5 vs. 12.8 months from completion of the FOB test, t=2.987, 
p=0.003). 
If consideration is taken to changing the criteria for an abnormal test to a lower number of 
positive windows, then the first test returned in all those who were diagnosed with a 
colorectal cancer must be reviewed. This must be ideally of one screening round, so as to 
get an accurate number of interval cancers after one round. Table 16.1 below shows the 
overall number of individuals who were invited for screening, divided into those who had a 
first round test and those who had taken part in a second round of screening. 9,861 
subjects (1.0%) had a screening test prior to the study period commencement. As we do 
not have data regarding cancer detection for this time period, these patients were not 
included in the analysis of the first round numbers. 
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1st Screening 
Round 
2nd Screening 
Round 
Total For Study 
Period (Apr 07-
Mar 10) 
Invitations Sent 
Male 433,495 38,726 472,221 
Female 441,158 40,923 482,081 
Total 874,653 79,649 954,302 
Returned Test 
Kits 
Male 232,904 21,914 254,818 
Female 255,425 24,019 279,444 
Total 488,329 45,933 534,262 
Kit Result: 
 
Normal 
Male 219,751 20,661 240,412 
Female 246,105 23,126 269,231 
Unclear, Normal 
x2 
Male 6,525 727 7,252 
Female 5,165 550 5,715 
Abnormal 
Male 703 54 757 
Female 362 40 402 
Unclear x2 
Male 2,938 233 3,171 
Female 1,710 144 1,854 
Unclear, 
Abnormal 
Male 335 26 361 
Female 169 8 177 
Unclear, Normal, 
Abnormal 
Male 44 6 50 
Female 38 4 42 
Unclear, Normal, 
Unclear 
Male 1,273 151 1,424 
Female 849 102 951 
Discharged 
Male 1,335 56 1,391 
Female 1,027 45 1,072 
Window 
Results:  
Only Returned 1 
Test Kit – 
Discharged 
+ve Spot x1 375 21 396 
+ve Spot x2 271 7 278 
+ve Spot x3 67 4 71 
+ve Spot x4 51 5 56 
 
Didn’t Complete 
All Offered 
Screening Tests - 
Discharged 
+ve Spot x1 318 11 329 
+ve Spot x2 188 14 202 
+ve Spot x3 38 1 39 
+ve Spot x4 41 1 42 
 
Completed 
Screening Tests 
(Number of First 
Kits Only) 
+ve Spot x1 10,251 1,091 11,342 
+ve Spot x2 6,189 616 6,805 
+ve Spot x3 1,466 143 1,609 
+ve Spot x4 1,129 112 1,241 
Abnormal Kits 
+ve Spot x5 721 48 769 
+ve Spot x6 932 90 1,022 
Table 16.1a Total number of individuals offered and taking up the FOB test and their 
results. 
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1st Screening 
Round 
2nd Screening 
Round 
Total For 
Study Period 
(Apr 07-Mar 
10) 
Outcomes After 
WP Result:  
Outcome After 
1+ve Test Kit 
Result 
Abnormal Result 129 11 140 
2nd Unclear 2,938 301 3239 
2x Normal 
Results 
7,184 779 7963 
Total 10,251 1,091 11,342 
    
 
Outcome After 
2+ve Test Kit 
Result 
Abnormal Result 166 16 182 
2nd Unclear 2,457 218 2,675 
2x Normal 
Results 
3,566 382 3948 
Total 6,189 616 6,805 
 
Outcome After 
3+ve Test Kit 
Result 
Abnormal Result 138 6 144 
2nd Unclear 782 73 855 
2x Normal 
Results 
546 64 610 
Total 1,466 143 1,609 
 
Outcome After 
4+ve Test Kit 
Result 
Abnormal Result 153 10 163 
2nd Unclear 588 48 636 
2x Normal 
Results 
388 54 442 
Total 1,129 112 1,241 
Table 16.1b Outcomes after an unclear first test result by number of positive windows. 
 
The table below (Table 16.2) shows which cancer group patients were classified in 
according the result of their first FOBt, in those who had not been offered screening in an 
earlier round (i.e. cancers in relation to the prevalent screening round).  As previously 
discussed, if patients did not complete the required number of FOBt kits before they were 
diagnosed with their cancer, then they fell into the control group. If they did not complete 
the required number of tests due to their own choice, and were later diagnosed with a 
cancer, then they belonged to the non-uptake group. 
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Control, 
n=19 
Non-Uptake, 
n=15 
Interval, 
n=185 
Screen, 
n=285 
First FOB Kit, 
Number of 
Windows 
Positive 
0 
11 
(57.9%) 
0 
(0.0%) 
170  
(91.9%) 
0 
(0.0%) 
1 
1 
(5.3%) 
5 
(33.3%) 
6 
(3.2%) 
62 
(21.7%) 
2 
1 
(5.3%) 
2 
(13.3%) 
5 
(2.7%) 
61 
(21.4%) 
3 
3 
(15.8%) 
5 
(33.3%) 
3 
(1.6%) 
50 
(17.4%) 
4 
1 
(5.3%) 
3 
(20.0%) 
1 
(0.5%) 
41 
(14.4%) 
5 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
21 
(7.4%) 
6 
2 
(10.5%) 
0 
(0.0%) 
0 
(0.0%) 
52 
(18.2%) 
Table 16.2 Number of cancers per number of positive windows for each cancer 
classification group. 
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Figure 16.1 Types of Non-Uptake by Positive Windows. 
 
Figure 16.1 shows the number of patients who did not complete a screening episode, after 
they had returned one FOB kit. It should be noted that, in the patients who had an initial 
abnormal test (five or six windows positive), all took up a screening colonoscopy.  
 
323 First Test 
Results 
1 Window 
Positive 
2 DNC FOBt 
3 Non-Uptake 
Colonoscopy 
2 Windows 
Positive 
1 DNC FOBt 
1 Non-Uptake 
Colonoscopy 
3 Windows 
Positive 
2 DNC FOBt 
2 Non-Uptake 
SSP 
Appointment 
1 Non-Uptake 
Colonoscopy 
4 Windows 
Positive 
2 DNC FOBt 
1 Non-Uptake 
Colonoscopy 
5 Windows 
Positive 
All took up 
colonoscopy 
6 Windows 
Positive 
All took up 
colonoscopy 
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Figure 16.2 Number of cancers in each group of positive first FOB test result. 
 
The above figure shows the percentage of colorectal cancers that are found in each degree 
of window positivity on a patient’s first test result. This shows the total number of cancers 
and the total number in those who completed the FOB screening test by each positive first 
kit result. The percentages shown are the predictive values for colorectal cancer by each 
degree of positive first test. This is for those who completed all the offered FOB tests, as 
well as those who just completed one test. The boxes highlighted in yellow correspond to 
three and four positive windows. Given the relatively high predictive level in the diagnosis 
of a colorectal cancer, a cut-off level of a minimum of three positive windows seems the 
most likely area for change. Figure 16.3 is a diagrammatic representation of the total 
number of invites, and the individual results based on the result of the first FOBt. A traffic 
Percentage of 
Cancers by 
Number of 
Windows 
Postive in All 
First Tests, and 
Patients Who 
Completed All 
Offered FOB 
test 
Total Number 
of Tests 
Returned To 
Screening Hub 
In Study 
Period 
Total Number 
of Cancers, 
and Total 
Number of 
Cancers in 
Patients Who 
Completed All 
Offered FOB 
Tests 
323 First Test 
Results 
1 Window 
Positive 
74 Cancers, 72 
Completed FOBt 
10,251 
Completed, 693 
DNC 
0.70% 
Completed, 
0.68% All 
2 Windows 
Positive 
69 Cancers, 68 
Completed FOBt 
6,189 Completed, 
479 DNC 
1.10% 
Completed, 
1.04% All 
3 Windows 
Positive 
61 Cancers, 59 
Completed FOBt 
1,466 Completed, 
105 DNC 
4.02% 
Completed, 
3.88% All 
4 Windows 
Positive 
46 Cancers, 44 
Completed FOBt 
1,129 Completed, 
92 DNC 
3.90% 
Completed, 
3.77% All 
5 Windows 
Positive 
21 Cancers 721 Completed 2.91% 
6 Windows 
Positive 
52 Cancers 932 Completed 5.58% 
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light colour scheme is used to show each cancer that was diagnosed according to their 
potential to be diagnosed through the screening programme. The green colour represents 
cancers that were diagnosed through screening, amber roughly corresponds to non-uptake 
and control group cancers, and red cancers are interval cancers. The rationale behind each 
allocation is explained in the discussion. The figures are for prevalent round cancers over 
the study period. 
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874,653 Invites 
Sent 
488,329 
Responded 
465,856 
Zero Windows 
+ve 
170 Interval 
Cancers 
11 Dx At Time 
of Returning 
Test 
10,944 
One Window +ve 
3,067 
Subsequent 
Abnormal or 
Unclear Result 
62 Screen-
detected 
 3 Non-Uptake 
of Scr 
Colonoscopy 
1 Dx Before 
Planned 
Screening Test 
7,184 
Subsequent 
Normal Tests 
6 Interval 
Cancers 
693 Did Not 
Complete 
Further Tests 
 2 Non-Uptake 
Cancers 
6,648 
Two Windows 
+ve 
2,623 
Subsequent 
Abnormal or 
Unclear Result 
61 Screen-
detected 
1 Non Uptake 
of Scr 
Colonoscopy 
1 Dx Before 
Planned 
Screening Test 
3,566 
Subsequent 
Normal Tests 
5 Interval 
Cancers 
449 Did Not 
Complete 
Further Tests 
1 Non-Uptake 
Cancer 
1,571 
Three Windows 
+ve 
920 Subsequent 
Abnormal or 
2nd Unclear 
Result 
50 Screen-
detected 
2 Non Uptake 
of SSP 
1 Non Uptake 
of Scr 
Colonoscopy 
2 Dx Before 
Planned 
Screeing Test 
546 Subsequent 
Normal Tests 
3 Interval 
Cancers 
105 Did Not 
Complete 
Further Tests 
2 Non-uptake  
Cancers 
1 Cancer Dx 
Before 
Planned SSP 
Apt. 
1,221 
Four Windows 
+ve 
741 Subsequent 
Abnormal or 
2nd Unclear 
Result 
41 Screen-
detected 
1 Non Uptake 
of Scr 
Colonoscopoy 
1 Dx Before 
Planned 
Screening Test 
388 Subsequent 
Normal Tests 
1 Interval 
Cancer 
92 Did Not 
Complete 
Further Tests 
2 Non Uptake 
Cancers 
721 
Five Windows 
+ve 
21 Screen-
detected 
932 
Six Windows +ve 
50 Screen-
detected 
2 Dx Before 
Planned 
Screening Test 
Figure 16.3 Outcomes of the first round of screening. 
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From the above figures, we have shown that the positive predictive values of patients with 
three and four positive windows on their first FOB test are high, compared to those with 
one or two positive windows. 
When outcomes are compared between these groups of window positivity on a screened 
individual’s first test, those with an unclear result have a significantly better survival rate 
compared with those with an abnormal test (both with screen-detected cancers), and the 
interval cancer group.  
 
 
Figure 16.4 Kaplan-Meier survival curves of screen-detected cancers with 1-4 & 5-6 
windows positive on first FOBt against interval cancer group. 
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Comparison, p value 1-4 5-6 Interval Cancers 
1-4  0.014 <0.001 
5-6 0.014  0.006 
Interval Cancers <0.001 0.006  
Table 16.3 Log rank (Mantel-Cox) test comparing groups of screen-detected cancers and 
interval cancers. 
 
 
When the unclear initial test group (1-4 positive windows) is split into 1-2 and 3-4, they 
were found to have equivalent survival rates as each other. 
 
 
Figure 16.5 Kaplan-Meier survival curves of screen-detected cancers with 1-2, 3-4 & 5-6 
windows positive on first FOBt against interval cancer group. 
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The p-values in the comparison of each group are shown in Table 16.4 below. 
 
Comparison, p 
value 
1-2 3-4 5-6 
Interval 
Cancers 
1-2  0.922 0.029 <0.001 
3-4 0.922  0.050 <0.001 
5-6 0.029 0.050  0.006 
Interval Cancers <0.001 <0.001 0.006  
Table 16.4 Log rank (Mantel-Cox) test comparing groups of screen-detected cancers and 
interval cancers. 
 
Table 16.5 below shows the patient, tumour and operative management variables for each 
subgroup of window positivity in the screen-detected group, when compared against each 
other, and the interval cancer group. 
The cancers detected after an abnormal test result have an equivalent overall stage profile 
to the interval cancer group (however with fewer Dukes’ D cancers), with similar patient 
demographics. 
The group with a 3-4 positive window first test, when compared against the interval cancer 
group, were found in a significantly greater proportion of men, distal to the splenic flexure, 
and had a more favourable stage profile (including 43.3% Dukes’ A cancers). 
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Table 16.5 Patient, tumour and management variables for each positive window on first FOBt and interval cancers, and Chi-squared comparisons.
 
Screen-detected Number of Positive Windows 
On 1st Test Interval 
Cancers 
Comparison, p value 
1-2 3-4 5-6 1-2 Vs. 3-4 1-4 Vs. 5-6 
3-4 Vs. 
Interval 
5-6 Vs. 
Interval 
Mean Age At Diagnosis (SEM) 64.83 (±0.28) 65.10(±0.35) 64.91(±0.40) 65.71(±0.21) NS NS NS NS 
Gender 
Male 85 (69.1%) 71 (78.0%) 52 (73.2%) 112 (60.5%) 
NS NS 0.004 NS 
Female 38 (30.9%) 20 (22.0%) 19 (26.8%) 73 (39.5%) 
Lives in 10% Most 
Deprived Areas In 
England 
Yes 16 (13.0%) 3 (3.3%) 9 (12.7%) 16 (8.6%) 
0.014 NS NS NS 
No 107 (87.0%) 88 (96.7%) 62 (87.3%) 169 (91.4%) 
ASA Grade 
Grouped 
1-2 70 (76.9%) 51 (82.3%) 46 (78.0%) 96 (73.3%) 
NS NS NS NS 
3-5 21 (23.1%) 11 (17.7%) 13 (22.0%) 35 (26.7%) 
Grouped Tumour 
Site 
Distal To Splenic 
Flexure 
102 (82.9%) 75 (82.4%) 50 (70.4%) 123 (66.5%) 
NS 0.026 0.006 NS 
Splenic Flexure and 
Proximal 
21 (17.1%) 16 (17.6%) 21 (29.6%) 62 (33.5%) 
Type of Surgery 
Resective 105 (85.4%) 70 (76.9%) 65 (91.5%) 146 (78.9%) 
NS NS <0.001 0.001 
Local Excision 15 (12.2%) 15 (16.5%) 5 (7.0%) 4 (2.2%) 
Palliative 2 (1.6%) 1 (1.1%) 0 (.0%) 9 (4.9%) 
No Procedure 1 (0.8%) 5 (5.5%) 1 (1.4%) 26 (14.1%) 
Dukes Stage 
A 57 (47.1%) 39 (43.3%) 14 (20.6%) 35 (19.4%) 
NS 0.003 <0.001 NS 
B 28 (23.1%) 19 (21.1%) 25 (36.8%) 50 (27.8%) 
C 31 (25.6%) 25 (27.8%) 23 (33.8%) 53 (29.4%) 
D 5 (4.1%) 7 (7.8%) 6 (8.8%) 42 (23.3%) 
30 Day Mortality 
Yes 0 (0.0%) 0 (0.0%) 1 (1.4%) 6 (3.2%) 
NS NS NS NS No 123 (100.0%) 91 (100.0%) 70 (98.6%) 179 (96.8%) 
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16.2 Implications of Changing the Minimum Criteria for an Abnormal 
Test to 3/6 Positive Windows 
As shown above, the aim of changing the criteria for an abnormal test to a lower number of 
positive windows on the first test would be to decrease the number of interval cancers. The 
benefits of this would be to detect cancers at an earlier stage, thereby improving survival 
rates for these patients. A change such as this would inevitably result in an increase in the 
number of nurse appointments, as well as screening colonoscopies. It would also save on 
the number of repeat test kits that would need to be issued, therefore decreasing the time 
from positive test result to screening colonoscopy. 
A secondary aim would be to decrease the number of patients who only complete one 
FOBt kit, before dropping out of the program. If the criteria for an abnormal test was to be 
lowered, then a subgroup of patients would only require one test to be completed, which 
would also decrease the time from test result to screening colonoscopy. 
Table 16.6 below shows the outcomes of each patient after they submitted one FOBt kit 
with each degree of positive windows (between one and four positive). It shows the 
number of patients that were discharged having not completed the screening episode, the 
number with a subsequent unclear or abnormal test, and the number who submitted two 
further tests which both had zero of six windows positive giving them an overall normal 
result. The numbers are for the prevalent round only. 
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Outcomes 
After WP 
Result: 
 
Discharged 
Normal 
Result 
Abnormal 
Result 
Outcome 
After 1+ve 
Test Kit 
Result 
Returned only 1 Kit 375 (3.4%) 
 
 
Did not complete all Kits 318 (2.9%) 
Abnormal Result 
 
129 (1.2%) 
2nd Unclear 2,938 (26.8%) 
2x Normal Results 7,184 (65.6%)  
Total 10,944 (100.0%) 
Outcome 
After 2+ve 
Test Kit 
Result 
Returned only 1 Kit 271 (4.1%)   
Did not complete all Kits 188 (2.8%)   
Abnormal Result   166 (2.5%) 
2nd Unclear   2,457 (37.0%) 
2x Normal Results  3,566 (53.6%)  
Total 6,648 (100.0%) 
Outcome 
After 3+ve 
Test Kit 
Result 
Returned only 1 Kit 67 (4.3%)   
Did not complete all Kits 38 (2.4%)   
Abnormal Result   138 (8.8%) 
2nd Unclear   782 (49.8%) 
2x Normal Results  546 (34.8%)  
Total 1,571 (100.0%) 
Outcome 
After 4+ve 
Test Kit 
Result 
Returned only 1 Kit 51 (4.2%)   
Did not complete all Kits 41 (3.4%)   
Abnormal Result   153 (12.5%) 
2nd Unclear   588 (48.2%) 
2x Normal Results  388 (31.8%)  
Total 1,221 (100.0%) 
Table 16.6 Outcomes after 1-4 positive windows on first FOBt in prevalent screening 
round. 
 
If the criteria for an abnormal test were set at a lower threshold, there are a maximum and 
minimum number of additional colorectal cancers that would have been detected. 
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The minimum number corresponds to the interval cancer group that had one to four 
positive windows on their first FOBt, who went on to submit two further normal tests (both 
zero windows positive). The total numbers by degree of positive windows is shown in Table 
16.7 below. If the non-uptake group is included in the additional number of potential 
cancers to be detected, then the percentage prevalence improves to the maximum number 
of cancers able to be detected. 
 
Table 16.7 Minimum and maximum numbers of additional cancers detected by number 
of positive windows on first FOBt kit. 
 
As shown in the tables above, an alteration to the minimum criterion for an abnormal test 
to three positive windows would give the greatest return in additional cancers detected, 
Number 
of 
Positive 
Windows 
on 1st Test 
 
Number 
of Cancers 
Number 
Affected 
By Test 
Result 
Prevalence (95% Confidence 
Interval) 
1 
Minimum 6 7184 0.084% (0.0167 to 0.1503) 
Maximum 12 7887 0.152% (0.0661 to 0.2382) 
 
2 
Minimum 5 3566 0.140% (0.0179 to 0.2630) 
Maximum 8 4015 0.199% (0.0613 to 0.3337) 
 
3 
Minimum 3 546 0.550% (-0.0706 to 1.1695) 
Maximum 11 651 1.690% (0.6996 to 2.6798) 
 
4 
Minimum 1 388 0.258% (-0.2468 to 0.7622) 
Maximum 5 480 1.042% (0.1333 to 1.9500) 
 
3 & 4 
Minimum 4 934 0.428% (0.0095 to 0.8471) 
Maximum 16 1131 1.415% (0.7264 to 2.1030) 
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whilst also being the most realistic to be achievable with the finite resources of the 
screening programme. Alteration to three positive windows would result in a reduction of 
total numbers of retest FOBt kits sent out (549-615 per year), with an increase in the 
number of SSP appointments and screening colonoscopies performed (311-377 per year). 
By using the figures published as part of the SCHARR report on FOBt (and FIT) cost-
effectiveness, it is possible to determine what the cost implications would be if the 
suggested alteration were carried out [155]. This is shown below in Table 16.8. An 
assumption of 100% uptake of a SSP appointment and screening colonoscopy was made. 
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Table 16.8 Net costs of alteration to different minimum numbers of positive windows on first FOBt. Cost for sending one retest kit=£3.19, cost of one 
SSP appointment=£15, cost for one screening colonoscopy with pathological analysis of specimen=£245.
Minimum 
Number of 
Positive 
Windows 
on 1st Test 
 
Number of 
Cancers 
Number of 
Persons 
Affected 
Net Cost of 
Sending Out 
Retest Kits 
(£) 
Net Cost of 
Additional SSP 
Appointments 
Net Cost of 
Additional 
Colonoscopies 
Total Cost 
Cost Per Cancer 
Detected (95% CI) 
1 
Minimum 15 11,684 -70,729 175,260 2,862,580 2,967,111 
£197,807 
(131,368 to 400,231) 
Maximum 36 13,033 -75,032 195,495 3,193,085 3,313,548 
£92,043 
(69,403 to 136,609) 
 
2 
Minimum 9 4,500 -34,548 67,500 1,102,500 1,135,452 
£126,161 
(76,337 to 363,242) 
Maximum 24 5,146 -36,640 77,190 1,260,770 1,301,320 
£54,221 
(38,743 to 90,242) 
 
3 
Minimum 4 934 -12,256 14,010 228,830 230,584 
£57,646  
(29,144 to 2,598,715) 
Maximum 16 1,131 -12,884 16,965 277,095 281,176 
£17,574 
(11,822 to 34,225) 
 
4 
Minimum 1 388 -5,257 5,820 95,060 106,137 
£106,137 
(35,889 to -107,705) 
Maximum 5 480 -5,551 7,200 117,600 119,249 
£23,850 
(12,740 to 186,373) 
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Table 16.8 above shows that altering the criteria for an abnormal test to a minimum of 
three positive windows gives the most cost-effective improvement per cancer detected, 
with a range of £17,574 to £57,646 for the minimum to maximum number of cancers 
potentially detectable with this change. 
It must be assumed that any additional cancers detected due to a change in classification of 
a test result would have an equivalent survival rate as that of those that are currently 
detected through screening, for each group of window positivity (e.g. 3-4 positive 
windows). When this takes place, lowering the minimum number of positive windows 
would equate to an approximately 20% improvement in survival rate over five years. The 
cost per life year gained is therefore £17,574 (95% CI £11,822 to £34,225) if all potentially 
detectable cancers are detected as part of the change in screening protocol. 
16.3 Chapter Conclusion 
Analysing the first round only, the total numbers of patients who returned a FOBt kit with 
an unclear (one to four positive windows) as their first test result are shown above. The 
outcomes after this result are presented, with the number of cancers that are detected 
with the current screening protocol, and the maximum possible number that could be 
detected, for each degree of positive window. 
The cost implications of changing the criteria for an abnormal test to a minimum of three 
windows (which gives the maximum yield of cancers potentially detectable) is shown. 
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Chapter 17 Discussion 
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17.1 Introduction 
Although this work began as a service evaluation, it became apparent that, as the project 
progressed, there were key research questions that needed to be answered. These 
research hypotheses have been described in Chapter 10 and relate to new knowledge that 
was generated from this work.  
This chapter discusses the impact of the screening programme: the effect that it has had as 
a whole on the stage profile and survival of patients against a control group who were not 
offered screening. This control group was analysed in detail to ensure that there was 
minimal bias secondary to the concurrent commencement of the programme. 
Although there is a vastly superior outcome for patients who have their cancer detected 
through screening, the programme does have significant limitations. The guaiac based 
faecal occult blood test has a miss rate of nearly 40% in the detection of a colorectal 
cancer, as determined by the interval cancer rate. If we include the advanced stage cancers 
that were detected in the second round of screening, after a negative first round test, this 
figure will increase. An explanation of reasons behind this significant miss rate, including 
the effect of medication use, is made below. Methods to minimise the proportion of 
missed cancers by altering the criteria for an abnormal FOBt kit result will be discussed. 
17.2 The Impact of the Screening Programme 
The availability of the control group was a serendipitous one. Having over 500 subjects 
suitable for comparison against those who were offered screening, of the same age group, 
and in the same study period, will not happen again within the life of the Bowel Cancer 
Screening Programme. A detailed review of the effect of demographic variables on the 
survival of patients within the control group was performed, which showed that the group 
behaved as would have been expected. I.e. No effect of gender on survival, but those with 
a greater level of comorbidities, and those from a more deprived background, having a 
significantly worse survival rate. As discussed, there were a small number of patients 
(n=19) who completed a FOBt (or part of), but were diagnosed out with the screening 
programme. These 3.7% may have a small amount of influence by their improved 
awareness of colorectal cancer, but this is does not appear to have affected the results as a 
whole. 
As shown in Chapters 12 and 13, the screening programme as a whole has produced a 
superior survival rate to that of the control group. The intervention group that was 
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diagnosed with a cancer was found to have equivalent levels of patient co-morbidities, 
gender proportions, and deprivation level. The effect of each of these on survival was 
equivalent for both groups. 
There were significantly more Dukes’ A cancers diagnosed in the intervention group (26% 
vs. 18%), that were managed via local excision. The intervention group was found to have a 
superior all-cause survival curve compared to the control group. 
When the intervention group is analysed by its three subgroups, the reasons behind the 
more favourable stage profile and survival rate is due to the outcomes of screen-detected 
cancers alone. The interval cancer group and non-uptake cancer group were found to have 
equivalent outcomes as the control group (and each other). 
Compared with the results from the Nottingham study, the proportion of cancers detected 
through screening has improved with implementation of the national programme, with a 
decrease in the proportion in non-responders [100]. This could be due to improved 
awareness of the screening programme through national media campaigns. This study also 
shows that nearly 40% of all screen-detected cancers are Dukes Stage A with an improved 
survival rate compared to the non-screen-detected cancer population. On initial review, 
the improved survival is likely to reflect the larger proportion of earlier stage tumours. This 
earlier stage profile in screen-detected cancers may represent the true prevalence of 
colorectal cancers within a population. The natural history of colorectal cancers (i.e. the 
long lag time associated with the adeno-carcinoma sequence) and the asymptomatic 
nature of early cancers mean that more advanced tumours are more likely to present 
through symptomatic services, as well as being present for a shorter duration before 
progressing to a more advanced stage (i.e. metastasising to nodes/distant organs). 
It is encouraging that after a screening colonoscopy there were no missed colorectal 
cancers detected. All cancers detected through a screening colonoscopy were either at the 
initial invite, or diagnosed at the planned surveillance colonoscopy. Recent post 
colonoscopy interval rates have been published as 1.8% within three years of initial 
negative procedure, and 4% within ten years [156]. Therefore, this study follow up may be 
too short to confirm this excellence in colonoscopy standard. As mentioned, the rates of 
local excisions for Dukes A cancers are significantly higher for those who had a screening 
colonoscopy. Assuming there is no systematic difference in size or morphology of Dukes’ A 
tumours between groups, this may be a reflection on the high level of ability in performing 
polypectomies for those accredited colonoscopists. 
 181 
  
17.3 Cancers in the Population who do not take up Screening 
At its outset, this research did not intend to look at the reasons for non-uptake of the 
offered screening tests. The proportion of colorectal cancers in the non-uptake group, out 
of the whole population who did not take up the screening test is minute (311 of 420,040 
invitations, 0.08%). However, the patient demographics of this cancer group are likely to 
represent the patient demographics of the non-uptake group as a whole, and not 
specifically the demographics of this cancer group. 
The higher proportion of unfit patients (ASA grades 3-5) in the non-uptake group may 
reflect the health beliefs of the non-uptake group in general. Patients from a higher level of 
social deprivation are less likely to engage with health promotion initiatives and have 
higher rates of smoking and alcohol consumption that may be a causative factor in their 
greater level of comorbidities. Smoking and alcohol consumption are also risk factors in the 
development of a colorectal cancer itself. These groups were also found to have a worse 
uptake of screening colonoscopy when analysed on a national basis [157]. Uptake of a 
screening colonoscopy varies from 89.5% in the least deprived areas to 86.4% in the most 
deprived areas. Other factors that influenced uptake were poor self-assessed health, non-
white ethnicity, population density and certain geographical regions. 
Despite the higher proportions of risk factors that are associated with a worse outcome in 
the non-uptake group, this has not resulted in an overall worse survival rate. This could be 
because of a potential counter-acting effect of the screening programme in raising 
awareness of colorectal cancer. Although this group of patients are less likely to complete 
the offered screening tool, they may have opted to seek advice from their general 
practitioner at an earlier stage. This may lead to an earlier referral to symptomatic services, 
and so increase the likelihood of the patient undergoing a curative resection. However, to 
confirm this, a qualitative study of patients diagnosed with a colorectal cancer, who did not 
take up the screening test, would need to take place. This would help to establish the effect 
of the offer of screening, in a patient’s willingness to seek medical advice for bowel related 
symptoms. 
If the uptake of screening as a whole improves with time, with a proportional decrease in 
non-uptake cancers and increase in screen-detected cancers, the poor prognostic effect of 
a more deprived, unhealthier population which then has their cancer detected through 
screening, may lead to a corresponding decrease in survival rate in this group. However, it 
is likely that the uptake rate would have to increase significantly for this to happen. 
Conversely, the cancer population from more deprived areas may continue to decline the 
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offer of screening, whereas the uptake rate in the more affluent areas may increase. This 
would potentially lead to a decrease in survival rate for the non-uptake group, as the 
deprivation level (and hence the proportion of ASA 3-5 patients) shifts towards the more 
deprived groups, and a further increase in the screen-detected survival rate as fitter 
patients (who will do better after treatment) are diagnosed with their cancer. 
17.4 The Effectiveness of the Faecal Occult Blood Test 
Of the 514 patients diagnosed with a colorectal cancer after completing a screening 
episode, 192 (37.4%) were missed by the guaiac based faecal occult blood test, a significant 
amount. There were also a group of patients who were diagnosed with a colorectal cancer 
in the incident (2nd) round of screening, having completed a normal FOBt in the prevalent 
round. 14 patients were diagnosed with either a Dukes C or Dukes D cancer in the 2nd round 
(all after submitting a normal FOBt in the 1st round). Given the time taken for a cancer to 
progress through each Dukes stage, it is likely that these cancers were present at the time 
of submitting their first test. They could therefore also be classed as interval cancers, 
bringing the total to 204 cancers (40.1%). 
This study found that the guaiac based faecal occult blood test appears to be more 
effective at detecting cancers in the left colon and in men. Reasons for the difference due 
to gender are unclear.  One possible explanation may be differing levels of oestrogen in 
women, and its effect on the stage of tumours at presentation (less advanced tumours 
associated with hormonal therapy) [158]. Combined hormonal therapy has also been used 
in treatment of angiodysplasia with its effects of improved endothelial integrity and 
shortened bleeding time. However, trial results using this therapy have been mixed [159]. 
With the median age of natural menopause being 49 years (interquartile range 45.0-51.0), 
the vast majority of women in the screening population will be post-menopausal [160]. 
Another possibility is the effect of non-steroidal anti-inflammatory drugs and anti-
coagulants by increasing the amount of bleeding from these tumours, whose effect will be 
discussed below. 
Brenner et al. compared incidence and mortality from colorectal cancer using several 
national databases from around the world [161]. Globally, women had an equivalent 
incidence rate and mortality rate as men, but between four and eight years later. Both 
Steele and Morris (whose papers are discussed below) noted that, as with this study, the 
proportion of men in the screen-detected group is significantly higher than all other cancer 
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groups, indicating that difference in incidence and prevalence between genders is not the 
sole reason behind this finding. 
Right sided tumours (cancers proximal to the splenic flexure) are more likely to be sessile 
and undergo fewer traumas from bowel motion as it moves through the colon (as it will be 
of a more liquid consistency) [162]. For these reasons, right colon cancers may bleed less 
than cancers in the distal colon, and therefore will be less likely to cause a positive result. 
The guaiac based faecal occult blood test detects the haem portion of haemoglobin. As this 
moves round the large bowel, haem will degrade and hence will be less likely to cause a 
positive result for proximal lesions. 
There have been two recent papers that have performed a similar analysis of the screening 
programme. The first is based on the pilot of the Scottish Bowel Cancer Screening 
Programme by Steele et al., which analysed the population screened between 2000 and 
2007 [163]. The second analyses results from the English Bowel Cancer Screening 
Programme between July 2006 and December 2008, on a national scale [164].  
Steele’s paper looked at screen-detected, interval and non-uptake cancers as part of the 
Scottish demonstration pilot. They report on results of those screened aged between 50 to 
69, with biennial guaiac-based faecal occult blood tests. They analysed results by screening 
round (3 rounds performed in total) and compared these against cancers diagnosed in the 
population not offered screening in the same time frame. 
Throughout the three screening rounds, screen-detected cancers have a consistently 
favourable stage profile, with 49.9% of cancers being of Dukes stage A in the first round, 
40.9% in the second round, and 38.8% in the third round. These results were reflected in 
this study. Similarly, the proportion of Dukes’ D cancers was consistently low (7.6%, 3.6%, 
and 2.3%). 
Interval cancers within Steele’s study had variable stage proportions for each screening 
round. After the first round, there was no significant difference between this group and the 
control group (χ2=6.783, df=3, p=0.079). After the second round, interval cancers had a 
significantly less favourable stage distribution secondary to 41.5% of interval cancers being 
of Dukes’ stage C compared to 29.1% in the non-screened group (χ2=14.422, df=3, 
p=0.002). Conversely, after the third round this effect is reversed, with interval cancers 
having a better stage distribution (χ2=19.682, df=3, p<0.001). Our current study 
encompasses a mix of the prevalent and incident screening rounds, although it primarily 
covers that of the first round. It is possible therefore, that if our current study was to 
continue, a change in the stage profile of the interval cancers may occur.  Despite these 
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variations in stage profile of interval cancers, in each of the three rounds, the Scottish 
interval cancer patients were found to have a significantly superior survival rate to the non-
screened population (p<0.001 for all rounds). In our research, we did not find this. We 
found no difference in overall survival when the interval cancer group was compared 
against the control group and non-uptake group. As interval cancers will have presented 
through symptomatic services, it stands to reason that they will have a similar stage profile 
to the non-screened population (non-uptake and control), and hence have a similar 
outcome to these. It also does not support the suggestion that aggressive, fast-growing 
tumours may disproportionately present as interval cancers after a negative FOB test 
result. 
Steele suggested that the interval cancer group are, by definition, more likely to engage 
with health professionals and hence have an overall better level of health. This would lead 
to a better outcome post cancer diagnosis. However, the ASA grade and deprivation level 
of the interval cancer group were not significantly different from the screen-detected 
group or the control group, and so this possible effect was not seen to be evident in our 
study. 
As seen in our study, Steele found significantly more screen-detected cancers found in men 
(χ2=29.046, p<0.001), and in the left colon (χ2=41.353, p<0.001) when compared against 
interval cancers. This effect was also seen by Morris et al. [164]. Morris used the National 
Cancer Data Repository linked with the national Bowel Cancer Screening Programme 
database to review the screening history of those offered screening, with those out with 
the screening programme. Screen-detected cancers were found more frequently in men 
(69.2%) compared with the interval cancer group (56.2%), non-participants (62.5%), and 
their control group of those never invited (61.0%). As seen in our study, the proportion of 
cancers in patients from the most deprived areas (by income) is greater in the non-
participant group, compared to those who underwent screening (23.9% vs. 13.8% for 
screen-detected cancers & 16.5% for interval cancers), and those who were never invited 
(15.2% in screening age range). 
The stage profile in Morris’ paper is again favourable for screen-detected cancers, with 
28.9% of cancers being of Dukes stage A. However, the paper suffers from a large amount 
of missing stage data (17.6%) for screen-detected cancers. Clearly it is not feasible to 
backfill this missing data item as was done in our study on a national level. It is likely that 
the unknown Dukes’ stages are a mix of polyp cancers that have not undergone a major 
surgical resection (and hence should be classed as Dukes stage A), along with patients who 
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were not fit for any procedure due to their co-morbidities or widespread disease 
dissemination (corresponding predominantly to Dukes stage D). Having a surgical resection 
means several points in the patient’s cancer timeline that their information could be fed 
into local, and therefore national, cancer registries. Therefore the number of patients with 
an unknown Dukes stage are unlikely to be of Stage B or C. This will likely have an impact 
on the true proportions of tumour stage within each group, and so their published results 
of a 28.9% stage A cancers in the screen-detected group may well be an underestimate. 
Morris also found that interval cancers had a similar 1 year survival compared to the 
control group (78.4% vs. 79.6%, p=0.548). This is more in keeping with our research and is 
likely to reflect the similar stage profiles between these two groups. 
Overall 7.8% of interval cancers were found in patients who had returned one unclear kit 
(one to four windows positive) followed by two normal tests, giving an overall negative 
result. Whilst this subgroup of cancers showed no significant difference in patient 
demographics, tumour stage or survival, this may be due to the small sample size. They 
were, however, diagnosed with their colorectal cancer significantly sooner post completion 
of the FOBt. This raises the question regarding re-testing at an earlier interval, or for testing 
with an alternate kit such as an immunohistochemical FOBt (iFOBt) which allows for a 
differential cut-off level for a positive result. 
The National Bowel Cancer Screening Programme in Scotland has adapted its test regime to 
incorporate the iFOBt. For the population who have an initial unclear test using the guaiac 
based FOB test, they are asked to repeat a faecal occult blood test using an iFOBt kit. Those 
with an abnormal iFOBt are invited for a colonoscopy as with the English programme. The 
results of this technique are yet unpublished. However, use of this test will only increase 
the sensitivity of a faecal occult blood test, it will not solve the issue of intermittent 
bleeding from a tumour. 
17.5 Outcomes of Screen and Interval Cancers by Dukes Stage 
The variable outcome between screen-detected and interval cancer groups for each Dukes 
stage is an interesting new finding. 
At the beginning of the analysis comparing these two groups, the improved survival curve 
for screen-detected cancers over interval cancers was expected to be secondary to a more 
favourable stage profile. In particular, as nearly 40% of screen-detected cancers were of 
Dukes Stage A seemed to be the logical explanation for the survival difference. 
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The significant difference in survival curves for cancers of Stage A, C and even D, between 
interval and screen-detected groups, requires an explanation. As is well documented in the 
literature, survival in intervention group as a whole was found to be influenced by the same 
variables as that of the control group; patient co-morbidity (using ASA grade as a 
surrogate), and deprivation level. Even though the proportions of these variables was 
found to be similar between groups, screen-detected cancers still had an improved survival 
curve. 
It has previously been postulated that interval cancers may develop between screening 
rounds, and hence be of an aggressive, fast-growing nature. They should therefore have a 
worse survival rate compared to a control group. However, for each stage of tumour, the 
survival curves for interval cancers and cancers within the control group were no different. 
An alternative explanation for the differences in outcomes for each stage of tumour, 
between interval and screen-detected groups is that, instead of interval cancer group being 
more aggressive, it is the screen-detected cancers that are more indolent. 
The improved survival for virtually all stages of tumours in the screen-detected group could 
be secondary to these tumours having a low potential for metastasis, and so reducing the 
risk of a patient having micro-metastases remaining in situ after initial cancer treatment. 
The significant difference in survival between screen-detected and interval cancers of 
Dukes A stage may be a Type II error secondary to the limited follow-up of cases. Dukes’ A 
cancers as a whole have an excellent survival rate, with published figures of a five-year 
relative survival rate of 93.2% in those diagnosed in England between 1996-2002 [2]. At the 
end of the follow up period in this study, 99.2% of screen-detected and 94.4% of interval 
cancers were still alive. As both groups have survival rates equivalent to national data, and 
as the survival curves appear to converge towards the end of the follow up period, it could 
be concluded that the differing rates of survival are not clinically significant. A longer term 
follow up (10 years or more) with larger patient numbers would help to elucidate any true 
differences in survival. 
There are several possible factors that could potentially explain the marked difference in 
survival for Dukes’ C cancers. A difference in proportion of Dukes C1 to Dukes C2 (i.e. 
involvement of the apical lymph node) between groups does not appear to be one of them. 
Both groups had a very similar mix of C1 and C2 stages. When survival of each of these 
groups was analysed, although both curves were more favourable for screen-detected 
cancers, there was only a significant difference found for C2 tumours (p=0.002). However, 
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given the small numbers within these groups (n=9 and 7), it is difficult to draw any firm 
conclusions from this. 
Another possibility for the difference between groups could lie in the surgical and 
pathological skill in harvesting an adequate number of lymph nodes for analysis. As 
mentioned, inadequate lymph node retrieval or identification could lead to under-staging 
of the tumour or leaving positive lymph nodes in situ. Again, the proportions of cases in 
which 12 or more nodes were harvested were equivalent between groups, meaning this is 
an unlikely cause for the survival difference. However, in the interval cancer group, for 
Dukes’ C2 cancers, there was a significantly greater mean number of positive lymph nodes 
found (15 vs. 4). An explanation for this may be because this subgroup of interval cancers 
was more aggressive in its regional lymph node spread, and hence outcomes were worse 
for this group. Although, as discussed above, the small numbers in this subgroup preclude 
definitive conclusions. 
The difference in survival for Dukes’ C cancers could, in part, be explained by the significant 
differences in tumour location. There have been three recent papers that have suggested 
that for Stage III cancer (American Joint Commission on Cancer (AJCC) Stage, nodal spread), 
survival is better for left-sided colon lesions (and worse for Stage II) [165-167]. The reasons 
for this are unclear, but it is thought to be secondary to differences in embryological origin 
of the colon (i.e. differences in blood supply), genetic, and environmental factors [166]. As 
there was a significantly greater proportion of distal cancers within the screen-detected 
cancer group (78% vs. 61%, p=0.03), this may explain the superior survival curve for this 
group. Further evidence to support this is the survival curves broken down by tumour site 
(for Dukes’ C cancers) are not significantly different (right-sided p=0.097, left-sided 
p=0.184).  
As with other stages of tumour, ASA grade and deprivation level for Dukes’ C cancers were 
found to be equivalent between groups. There was a difference between male and female 
proportions, with a greater proportion of men having a screen-detected cancer. The 
improved survival curve of screen-detected cancers is therefore contrary to the improved 
survival of women at all stages of cancer [2]. When outcomes between groups were broken 
down by gender, the screen-detected group continued to have a superior survival curve, 
although this difference was not found to be statistically significant. The lack of significant 
differences in survival curves between screen and interval cancer groups for Dukes’ C 
cancers when split into Dukes C1 and C2, tumour location and gender may be a Type I error 
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due to a small sample size. Further analysis is needed on this specific cancer group, with 
larger numbers. 
With regards to Dukes’ D tumours, the NORCCAG database does not hold details as to the 
management of each case of cancer metastasis. It is possible that those screen-detected 
patients with a Dukes D cancer, may have had a metastasis that was amenable to a surgical 
resection. A small proportion of liver or lung metastases from a colorectal cancer primary 
may be amenable for surgical resection, offering the patient a potential cure from their 
cancer. The significantly higher rate of resective surgery for the primary tumour suggests 
that this may be the case. If there was widespread dissemination of the cancer, the patient 
would have likely undergone a palliative procedure, or no procedure at all.  
The counter argument to the above discussion is that the differences in survival seen are all 
secondary to lead-time bias. To attempt to allow for this, an analysis of survival from 
invitation to screen (i.e. an intention to treat analysis) was performed. This showed that the 
differences in survival by stage were less marked and so ceased being significant in some 
stages. However, given the relatively small numbers in each group, an analysis with longer 
term follow up and larger numbers may prove or disprove the survival differences seen.  
17.6 Medication Use in Screen-Detected and Interval cancer Groups 
The effect of medication use and its effect on the positivity of the faecal occult blood test 
have not been previously published. 
For a postal survey to healthcare professionals, an average response rate of 57.5% has 
been previously published for surveys published between 1996-2005 [168]. The response 
rate of 67.3% in this thesis therefore appears to be acceptable.  
Although all patients who were using hormone antagonists at the time of test had a 
positive FOBt, the actual numbers are too small to draw any firm conclusions as to the 
significance of this result. This is likely further confounded by the mix of hormones that are 
being inhibited (testosterone and oestrogen, either directly or via precursors (aromatase 
inhibition and gonadotrophin releasing hormone, GnRH, agonists)). 
Use of non-steroidal anti-inflammatory drugs (NSAIDs) will cause an increase in colonic 
bleeding due to their action of non-selective inhibition of the enzyme cyclooxygenase 
(specifically COX-1), and therefore an inhibition of the mucosal-protective prostaglandins 
[169]. It is unsurprising that use of non-aspirin NSAIDs (NA-NSAIDs) at, or just before, 
completing the FOBt, was associated with a significantly higher rate of test positivity, 
compared to the population with a false negative test result (interval cancer group). No 
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other factors that were associated with a positive test result, as described above, differed 
between the screen-detected group and interval cancer group, in those who were taking 
NA-NSAIDs at the time of test. This suggests that it is the medication that has influenced 
the test result. 
Aspirin use has been shown to be associated with a lower neoplasia detection rate in 
patients with a positive FOBt, but its effect on the positivity of the FOBt in those with a CRC 
has not been established [170]. In this study, we did not find that aspirin, or other anti-
coagulants, influenced the FOBt result. This is despite similar proportions of use. This 
difference could be secondary to the differing mechanisms of action of aspirin and NA-
NSAIDs. Aspirin acts with non-selective inhibition of both COX-1 and COX-2, whereas NA-
NSAIDs (such as diclofenac) act by preferentially blocking COX-2, although it still has some 
COX-1 inhibition. 
The population who undergo a cholecystectomy, have an increased risk of colon cancer 
(119 vs. 86 per 100,000 person-years), with lithogenic bile having been postulated as the 
underlying mechanism [171]. We did not find a difference in tumour location related to a 
past history of cholecystectomy, although the total numbers of previous such operations is 
likely too small to detect such differences. The finding of a greater proportion of women 
having undergone a cholecystectomy is likely reflective of the higher prevalence of 
gallstones among women in a Western population [172]. 
This part of the study adds to our understanding as to why there is a significant rate of 
interval cancers as part of the screening programme. The bowel cancer screening 
programme evaluation committee is considering altering its database to include medication 
use as a key data item. With recent publications regarding the potential positive effects of 
aspirin in improving outcomes for patients at risk of developing a colorectal cancer, as well 
as those diagnosed with a cancer, a larger dataset with a longer follow-up period following 
users of these medications will help to establish their potential benefits. At present, the 
instructions provided with each test kit ask the screenee to avoid taking NSAIDs at the time 
of carrying out the test. This study has demonstrated the difficulties in detecting a cancer 
due to the low sensitivity of the FOBt, and the intermittent bleeding of colorectal cancers. 
To improve sensitivity (but potentially worsen specificity), removing this instruction from 
the patient leaflet may be beneficial. The risks associated if all screened individuals were 
asked to take a course of NSAID at the time of test, would likely outweigh the increase in 
cancer detection rate, but may be appropriate for those who are already using this group 
of medications. 
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17.7 Altering the parameters of an abnormal FOBT Result 
The main aim of altering the classification of what is an abnormal faecal occult blood test is 
to minimise on the number of missed cancers.  These occur when a screened individual has 
an initial unclear first test, followed by two normal tests, giving an overall negative result. 
By lowering the minimum criteria for an abnormal an abnormal test, it will mean a greater 
number that will be invited for a colonoscopy without the need to repeat any test kits. Due 
to the additional accreditation that screening endoscopists are required to achieve, a 
screening colonoscopy is a very effective and safe investigation. 
By reducing the number of repeat FOBt kits that the screening population need to carry 
out, it will also minimise the number of patients that drop out from the screening process 
after one test. Of the 22,410 screening episodes from the whole study group that returned 
an unclear (1-4 windows positive) first test result, 1,413 (6.3%) did not complete all 
required FOBt kits. The impact on a patient’s health perception in being advised to undergo 
a colonoscopy after one test kit should not be underestimated. The survival of those who 
have three or four positive windows on their first FOBt is significantly better than those 
who have five or six positive windows. Patients with an abnormal first test are more 
reflective of symptomatic interval and non-uptake cancers in their stage profile, whereas 
those with three or four positive windows have a more favourable stage profile, and so 
should be targeted specifically to improve outcomes of those cancers potentially 
detectable by FOB screening. 
The cost effectiveness analysis has shown that a change to the minimum number of 
positive windows to three, gives the best return for additional cancer detection, whilst 
being cost-effective in its implementation.  
It could be argued that the control cancers and the non-uptake cancers should not be 
included in the overall figures as they were not diagnosed through screening. However, the 
speed of diagnosis from FOBt result to screening colonoscopy is likely to improve with 
patients only having to submit one test. Therefore the control group may be able to 
complete the screening process. For non-uptake cancers, the impact of a patient hearing 
the test is abnormal and that they will be offered a clinic appointment for consideration of 
a colonoscopy, is likely to improve uptake. It is of note that no patients who had an 
abnormal test declined a screening colonoscopy. One of the main barriers to completing a 
FOBt screening episode is the process itself. By increasing the proportion of the population 
who only need to complete one FOBt kit, compliance with further aspects of the screening 
process are also likely to improve. 
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The number of additional cancers detected is unlikely to reach the maximum numbers 
presented in Chapter 16, however, even if the value lies between this and the minimum 
number, it is possible that the increased costs in such a change to the screening protocol 
will lie close to NICE’s willingness to pay threshold of £20,000 per quality adjusted life year 
(QALY). 
 
17.8 Limitations of Study 
17.8.1 Database Accuracy and Completeness 
The largest problem with a database study is always going to relate to the accuracy of the 
inputted data, as well as missing data. 
In this study, once the study group was identified and the relevant data extracted from the 
NORCCAG database, a large amount of time was spent validating the dataset. As described, 
this included reviewing the source hospital data for the majority of patients, filling in 
missing data as appropriate. 
NORRCAG is known not to be a complete dataset. The 2010 NBOCAP annual report 
described case ascertainment of approximately 81% for the North of England cancer 
network [173]. Its aims are to record all colorectal cancer patients known to the colorectal 
multi-disciplinary team meetings (MDT’s) in each region. Inherently, this may mean that 
patients who are not discussed in an MDT are missed from the database. This is likely to be 
less of a problem compared to the older age groups, as most patients will be suitable to 
undergo a form of treatment, be it surgical resection or palliative chemo/radiotherapy. At 
the least, possible treatment options will be discussed, which should trigger their 
information being recorded on the hospital cancer registry. With new advances into 
different chemotherapy regimes, the need for a tissue diagnosis so that the correct 
combination of therapeutic agents can be used, is increasing. This means that there are 
more cases of colonoscopies or liver biopsies being performed to obtain adequate samples 
to guide treatment. These interventions will increase the number of cases discussed at 
MDTs and therefore should improve completeness of the database. 
 Due to the large amount of missing data that was prevalent throughout the NORCCAG 
database, virtually all records were reviewed. This will have helped to minimise on the 
inaccuracies of the dataset. However, initial data entry to NBOCAP is performed by audit 
clerks who have no medical training or background, and therefore do not have the clinical 
knowledge to identify implausible data entries. NBOCAP has a small amount of inbuilt data 
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validation queries, such as no cancer may be classed as being located in the rectum if it’s 
height from the dentate line is greater than 15cm. However, these validation steps are not 
exhaustive, hence the need for more extensive validation queries to be written after 
importing the data into the NORCCAG database. 
The importing of data from multiple data sources and the combination of these is another 
possible source of data corruption. Although each record was reviewed for face validity, it 
is possible that one section of data from, for example, the BCSP database, may have been 
incorrectly linked with the corresponding data of the NORCCAG database. Without direct 
access to the screening database to validate all data entries, it is impossible to be sure of 
complete data accuracy. 
The most important method of improving the completeness of the dataset, to ensure all 
eligible patients are captured, is by triangulating data sources. There are several different 
methods that this could take place. The first is using a national cancer registry. The National 
Cancer Intelligence Network “provides a national repository for cancer datasets” [174]. This 
database was used by Morris et al. [175], but has the specific problem with missing data. As 
described, 17.6% of screen detected cancers had a missing Dukes’ stage. If this dataset 
were available for use, then I would expect that its role would be that of validation of the 
NORCCAG database, with the records that were complete. A similar database that could 
have been used would be that of “Hospital Episode Statistics (HES)”, provided by the Health 
and Social Care Information Centre [176]. Its role is that of a “data warehouse containing 
details of all admissions, outpatient appointments and A&E attendances at NHS hospitals in 
England”. Use of this dataset may minimise on any missing subjects, who will have received 
a form of treatment for their CRC. The third would be to use local hospital databases. 
Examples might be pathology databases for all with proven adenocarcinomas of a 
colorectal origin, or waiting-times data. 
The problem with using multiple sources is that it increases the complexity of permissions 
to obtain each of them. Appropriate consolidation of data must take place to avoid 
duplicate records. Adequate data security is also needed. 
For patients who had no surgical intervention, or for those who declined one part of the 
screening process, it was necessary to review patient letters. This allowed the actual route 
to diagnosis to be analysed, and for specific reasons as to why a patient did not undergo an 
operation. Missing from a database study are the qualitative aspects of the project. Access 
to databases was granted on the basis that there would be no direct patient contact, 
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therefore further permissions would have been required before any such study could take 
place.  
Given the effort put into ensuring that the extracted NORCCAG dataset was as complete as 
possible, use of additional databases would have been unlikely to significantly alter the 
dataset that was used for analysis. The only exception to this may have been that there 
were a small number of subjects that could have been included in the study group. 
However, I would anticipate that this would not have significantly changed the results 
found. 
 
17.8.2 Missing Cause of Deaths 
Within this thesis, an improved all-cause mortality rate has been shown for screen-
detected cancers over other cancer groups. Whilst NORCCAG collects dates of death via the 
Office of National Statistics, the database does not contain information regarding the cause 
of death. With the most recent update based on the Nottingham study showing no 
difference in all-cause mortality rates between intervention and control groups, but an 
improvement in colorectal cancer specific mortality, having an accurate validated cause of 
death would be extremely advantageous. As discussed, the risk factors and patient 
demographics that are associated with the development of a colorectal cancer (e.g. 
smoking, deprivation status, etc.), are also strongly associated other conditions and hence 
causes of death. Causes of death would have been of particular interest in the non-uptake 
group which was found to have higher proportions of these risk factors. If an analysis of 
cancer-specific mortality was performed, this may have potentially had a large impact on 
the survival curves seen. It may be that the non-uptake group has a better survival 
compared to the interval cancer group, which did not have these higher levels of risk 
factors. 
Having cancer-specific causes of death would help in the comparison between screen and 
interval cancers, when corrected for Dukes’ stage. If it is a cancer recurrence that is a 
primary cause of death in the interval cancer group, this would add to evidence of an 
aggressive interval cancer. This may also have implications as to how these cancers should 
be managed, either with a lower threshold for post-operative chemotherapy, or more 
aggressive management of early tumours with segmental bowel resection over local 
excisions. 
 
 194 
  
17.8.3 Variable Patient Management between Hospital Trusts 
Within the study location of the North East of England, there is a mix of district general 
hospitals and tertiary referral centres. Within each of these trusts, there is not always a 
screening colonoscopist. This may mean that for patients presenting through symptomatic 
services, they may have their cancer managed differently to that in other trusts. In 
particular, for T1 cancers, if the patient has a colonoscopy by a screening colonoscopist or 
by a consultant who performs TEMS procedures, they may be more likely undergo a local 
excision, without the need for a formal segmental bowel resection. Similarly, as we do not 
have the data regarding cause of death, there is a possibility of a missed cancer at 
endoscopy (screening or non-screening) which reflects the variable ability of the regions 
endoscopists. However, the chances of this happening are remote. 
With the increasing prevalence of polyp cancers being detected through the screening 
programme, the need for accurate histological assessment of these is crucial to their 
further management. Differences in abilities of histopathologists in being able to 
confidently report on completeness of excision of these cancers between trusts, may 
impact on whether the patient undergoes a resective procedure. The management of these 
polyp cancers has been shown to vary between hospital trusts [177]. 
 
17.8.4 Mix of Screening Rounds 
To date, the majority of screening research that has been published has concentrated on 
dividing the cancers detected by screening rounds. By doing this, the researcher can assess 
the impact that each screening round has on a population. The difficulty in doing this as 
part of the National Screening Programme, was the considerable time taken for the roll-out 
of the whole region. The extent of this delay was not expected initially, and hence the 
proportion of cancers that were included in the control group was higher than initially 
thought. The commencement of the study period in April 2007 was to allow two months of 
initial invites to circulate, expecting that this would be a significant number. In retrospect, 
the start of the study should have been at January or February 2007. This would have 
ensured that a complete screening round was captured. 
As each colorectal cancer within the Northern Colorectal Cancer Database is stored 
predominately by diagnosis date, this was the easiest data item to identify the study 
population. A three year study period therefore meant that there was a mix of cancers that 
were diagnosed from the prevalent (1st) round and incident (2nd) round. Although the vast 
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majority of cases were diagnosed after an offer of a patient’s first screening test, there 
were 5.6% (46 of 825) of cancers diagnosed in the incident round. 
The difficulty that having a mix of two screening rounds leads to is that there may be 
pathological, and therefore outcome, differences between cancers from the two rounds. As 
seen by Steele in the results of the Scottish Pilot data, the stage proportions, particularly of 
interval cancers, vary between screening rounds. Although their interval cancers were 
found to have an improved survival rate compared to their control group in each screening 
round, we did not find this in our study population. Isolating the prevalent from the 
incident screening round is at present unfeasible, as the North East of England population 
should be commencing the third round of screening between March 2011 and March 2012. 
This means that the most recent colorectal cancer cases will not be available for analysis 
until January 2013, after entry to regional and national registries. Adequate follow up of 
these cases to review patient outcomes will delay analysis further. 
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Chapter 18 Conclusions and Areas for 
Future Research 
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18.1 Conclusion 
This thesis demonstrates the impact of the bowel cancer screening programme within one 
region of England since it has been rolled out nationally. By using a combination of a 
regional colorectal cancer registry, as well as the regional bowel cancer screening database, 
it has been possible to identify the screening history for all patients diagnosed with a 
cancer, in the population eligible for screening.  
We have shown that, of the virtually one million screening invitations sent, with an uptake 
of 56%, there were 825 colorectal cancers diagnosed. What was not expected at the outset 
of the study, was the availability of a control group of 511 patients, who were in the same 
age range and diagnosed in the same time frame as those invited for screening. 
Of the 825 cancers diagnosed in those invited for screening, 311 (37.7%) were diagnosed in 
patients who did not take up or complete their screening episode. Of the 514 cancers 
diagnosed in those who completed a screening episode, 322 (67.6%) were detected 
through screening, and 192 (37.4%) were diagnosed between screening rounds after a 
negative episode (interval cancers). 
With its national implementation, the NHS BCSP exceeds the outcomes of the preliminary 
studies. In particular, the proportion of screen-detected cancers has improved compared to 
the Nottingham based studies, with a decrease in the proportion of non-uptake cancers. 
Screen-detected cancers had a favourable stage profile, and a far superior survival rate 
compared to the control group. 
However, there are still large numbers of cancers that are not detected through the guaiac-
based faecal occult blood test. In particular, failure of the current methods to detect right 
sided cancers and cancers in women requires further research as this group comprise a 
significant number of patients falsely reassured by their results. For these interval cancers, 
in contrast to earlier research, they have an equivalent tumour stage profile, and survival 
rate, compared to those who do not take up screening, or the control group. 
The earlier stage shift was not found to be the sole reason for the improved survival rates 
of screen-detected cancers over interval cancers. With an additional survival benefit for 
each Dukes stage of screen-detected cancers, it is possible that these cancers have a 
different biology to those previously seen. They bleed more, and appear to be more 
indolent in nature. Further research is needed to confirm this suggestion. 
Non-aspirin non-steroidal anti-inflammatory use within two months of carrying out a FOBt 
has been shown to be associated with a positive test result. This effect has not previously 
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been demonstrated, and suggests that removing the instructions to avoid their use from 
the patient information may be beneficial in terms of cancer detection. 
For the population who undergo screening, an argument has been made for altering the 
criteria for an abnormal faecal occult blood test from a minimum of five (out of six) positive 
windows, to a minimum of three. A cost-effectiveness analysis has shown that such an 
amendment to the screening pathway may be feasible. Suggestions for further research are 
described below. 
18.2 Areas for Future Research 
There are several areas that would benefit for future research on the basis of the results in 
this study. These are described below. 
 
18.2.1 Cohort Study into Change to FOBt Result Classification 
As discussed above, there may be a benefit in altering the criteria for an abnormal FOBt to 
a lower cut-off in the number of positive windows. Due to the small size numbers and the 
heterogeneity of the groups that had an initial unclear FOBt kit result, further research is 
needed to validate the findings described in Chapter 16. 
An analysis of the national bowel cancer screening database along with national cancer 
registries would mean a larger sample size suitable for analysis. However, larger sample 
sizes would be inherently more challenging to match each patient to each FOB kit result.   
An alternative would be a randomised controlled trial. The sample group of patients would 
be those who had three or four positive windows on their first FOBt, followed by two 
normal (0/6 windows positive) FOBt’s, giving them an overall normal result under current 
guidelines. In one arm the subjects would be offered a colonoscopy, whereas no 
investigation would be offered to the other group. The second arm would be followed up 
to see if they were diagnosed through symptomatic services before the next screening 
round, and also the result of their subsequent screening episode. A comparison between 
these two groups would aim to identify all possible pathology that would have normally not 
have been detected under current screening practice. The cost-effectiveness of such a 
change in practice would be crucial to any potential alteration of the screening pathway. 
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18.2.2 Histological Analysis of Post-FOBt Interval Cancers and Screen-detected Cancers 
As discussed in the interval cancer chapter, there are associations between a range of 
genetic abnormalities and the development of interval colorectal cancers. However, these 
studies have predominantly been based on post-colonoscopy interval cancers. As the 
sensitivity of a colonoscopy is extremely high at detecting a colorectal cancer, this will 
increase the likelihood that there will be histological differences in these cancers compared 
to one picked up through symptomatic or screening services. To date, there have been no 
studies that have performed this type of analysis on post-FOBt interval cancers. From the 
results of this study, we know that the FOBt appears to be more effective at detecting 
cancers in the left colon and in men. Do these interval cancers have the same overall 
macroscopic appearance? Do they have the same degree of microsatellite instability, or 
associated genetic abnormalities? Are there any differences in the vascularity of screen and 
interval cancers that lead one group to bleed more and hence improve detection rates 
using the faecal occult blood test? This analysis could take place on the cohort identified 
within this study and would add valuable information as to the relatively high rates of 
interval cancers within the bowel cancer screening programme.  
This histological analysis should also include that of the screen-detected cancers. As 
suggested, patients with these cancers have a better survival rate with equivalent stage of 
tumour. Of particular interest would be the gross structure of these tumours, their 
histological subtypes and any associated genetic differences to that of a control group, and 
the interval cancers. 
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18.2.3 Qualitative Study with Interval Cancer Patients 
There has been, and is, on-going research into the reasons behind why a large population 
do not take up the offer of FOBt screening. However, there have been no published articles 
on the health values of patients who are diagnosed with a colorectal cancer, after a normal 
FOBt. A qualitative study could be carried out on the impact of being diagnosed with a 
cancer after been given the ‘all-clear’ by the screening programme. The effects of a false 
negative in a screening programme can be split into the medical outcomes (morbidity and 
mortality, which have been covered in this study), the psychological outcomes, the 
economic outcomes and the legal outcomes. A systematic review was carried out in 2000 
that looked at the above issues however colorectal cancer screening was not covered 
[178]. 
18.3 Personal Reflection on this Research 
General surgical training has changed significantly over the past few years. Previously, 
doctors wishing to go into surgical practice would spend prolonged periods at a senior 
house officer (SHO) grade. During this time, they would gain valuable operative experience 
and improve their CV in preparation for gaining a registrar post and national training 
number. With the advent of modernising medical careers (MMC), this route into surgical 
training has gone. Current training is much more “stream-lined” with two years core 
surgical training after completion of the mandatory two foundation years. The application 
process for gaining a training number is now a national procedure, which means you are 
competing for places with a nationwide cohort. Therefore, to score highly on the relevant 
stations, an applicant must have an outstanding portfolio. 
It was with this in mind that I decided to apply for and carry out this project. I feel I have 
gained a great deal from this MD research degree. It has helped me develop an analytical 
view point. I have changed the way in which I approach my surgical practice. I now 
frequently review the current literature and guidelines to develop my skills as an evidence-
based practitioner. I have further developed my knowledge of statistical analysis of 
quantitive research, and would feel confident in applying its principles in future work. 
The hardest challenge for me during the past two years has been gaining access to each 
hospital trust, in order to validate the dataset. This process took over 6 months from initial 
contact with the trusts to gaining access to all of them. I found it particularly frustrating 
when passed from department to department, with each contact denying any 
responsibility for helping with the project. There was a large discrepancy between trusts, 
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with some responding very quickly and allowing access almost immediately, and others 
taking 6 months of discussion, form filling, and meetings before approval. This difference 
made the process even more trying. If I were to repeat the process again, however, I feel I 
would be able to gain complete access quicker. Face to face meetings with research and 
development teams, as opposed to correspondence via email, would have been the most 
beneficial step in speeding up the process. 
This project has highlighted areas for future research, based on this project. I plan to be 
involved with these, allowing me to further develop my skills as an academic surgeon.       
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Appendix 1 Database Variables 
Creation 
 
Imported into Access the following data sheets: 
 NORCCAG 
 BCSP 
o Invites and FOB test 
o SSP Appointments 
o Colonoscopy Data 
 Postcode and Deprivation Data 
Using Study number as identifier from each – merged all records 
 Duplicate entries removed 
Data then extracted to Excel and put into SPSS. 
SPSS Editing: 
 Combination of study groups 
o Control vs. Intervention (screen, non-uptake & interval) 
o Uptake of FOBt (screen & interval vs. non-uptake) 
o Screen vs. non-uptake and interval groups 
 Group in prevalent round of screening 
 Deprivation quintile group created 
 Type of non-uptake group 
o Non-uptake of FOBt 
o Non-uptake of screening nurse appointment 
o Non-uptake of screening colonoscopy 
 Age at diagnosis created 
 Age when first sent FOB test created 
 Created binned variables for IMD and Health Rank 
 Created variables identifying cases into both IMD and Health worst 
10%/15%/20%/25% most deprived areas 
 ASA grouped 1-2, 3-5 
 Coded ASA grade, converting all “99” codes to missing values 
 Coded variable of PCT name 
 Coded gender 
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 Overall FOB Episode types numerically coded 
o Grouping of positive windows from 1st returned FOBt kit 
 Created new variable – earlier FOB test? 
 Created new variable – date of earlier FOB 
 Time from completion of FOBt kits to diagnosis and from invitation 
 Calculated mean number of positive windows over all FOB tests per 
episode 
 Each medication coded for use at any time, and within two months of 
carrying out test kit 
 Recoded reason as to why no operation into 5 categories 
o Advanced disease 
o Patient refused 
o Unfit for surgery 
o Died before treatment commenced 
o Unknown 
 Coded cancer unit 
 Created date of final screening colonoscopy 
 Calculated time between final screening colonoscopy and diagnosis date  
 Coded tumour site: distal or proximal to the splenic flexure 
 Coded urgency of operation and streamlined into elective, emergency and 
unknown 
 Coded surgical access 
 Coded operation type 
o Streamlined incorporating all total/subtotal colectomies into one 
category 
o All local excisions together 
o All palliative procedures together 
 New variable grouping operation types into resective surgery, local 
excision, palliative and no procedure 
 Coded stoma type and intension (temp/perm) 
 Coded grade of senior operating surgeon 
 Coded Pathological Dukes Stage 
 Created Updated Dukes stage, incorporating all Dukes’ D cancers and 
combining C1 and C2 cancers together (to form Dukes’ C) 
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 Created screen vs. interval variable for each Dukes stage 
 Created interval vs. control variable for each Dukes stage 
 Coded T and N Stage 
 Cross-referenced TNM stage vs. recorded Dukes stage – one error found – 
corrected 
 Calculated length of inpatient stay 
 Compared positive number of lymph nodes vs. Dukes stage – 1 error found 
– corrected 
 Coded peri-operative death 
 Created 30-day mortality variable 
 Created end date for follow up (31st Dec 2010) to calculate survival/follow 
up length 
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Appendix 2 Sample Proforma 
 
GP 
Practice: 
THE 
DENSHAM 
SURGERY 
THE HEALTH 
CENTRE  
NHS 
Number: 
012345678 
 
Date of 
Death:  
 
 
Medication Action 
Group:  
Yes 
 
No 
 
Name of 
Drug(s):  
Date 
Started:  
Date 
Finished: 
           
           
HRT 
          
           
           
           
           
NSAIDs 
          
           
           
           
           
Hormone 
Antagonists           
           
           
           
           
Anti-Coagulants 
          
           
           
           
           
           
Past Medical 
History:  
Yes 
 
No 
 
Date of 
Procedure:     
           
           
Cholecystectomy? 
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Appendix 3 1st Medication Request 
Letter 
 
Wolfson Research Institute 
Durham University Queen's Campus 
University Boulevard Stockton on Tees 
TS17 6BH 
Dear Colleague, 
We are seeking your help with a study of people diagnosed with colorectal cancer through the 
Bowel Cancer Screening Programme. As you know, the NHS Bowel Cancer Screening Programme 
involves biennial faecal occult blood tests (FOBt) followed by a colonoscopy for positive results. The 
main aim of the programme is to detect colorectal cancer. A secondary aim is to identify adenomas 
and remove them. 
We are studying all of the colorectal cancers diagnosed within the North East of England between 
April 2007 and March 2010 which fall into 3 distinct groups: 
 Screen-detected Cancers 
 Interval Cancers 
o A cancer diagnosed between screening rounds, after a negative FOB 
 Non-Uptake Cancers 
o A cancer in the population who decline screening 
Patients diagnosed with an interval cancer are significantly more likely to be women and have 
tumours in the right colon (proximal to the splenic flexure). The reasons as to why the FOBt is worse 
at detecting right -sided tumours and in women are not fully understood. One possibility is that 
medication or surgery may have an effect on the positivity of a FOBt in someone with a cancer. 
Specifically: oestrogen therapy (e.g. HRT), NSAIDs/aspirin and cholecystectomy may have an effect. 
We need your help in obtaining the medication history for patients within your practice who have 
been diagnosed with a colorectal cancer within (or outwith) the screening programme. 
We have enclosed a Proforma with edited details of the patients we are interested in who are 
registered at your practice. Only the NHS number has been used as a patient identifiable data item. 
We would be extremely grateful if you or your practice manager could fill in the appropriate details 
on medication history and previous cholecystectomy, and return it in the enclosed stamped 
addressed envelope. The average number of patients per practice is less than two (range 1-8) so we 
hope that this will not take up too much of your time to complete. 
The project has been given ethical approval by the School of Medicine and Health at Durham 
University and forms part of the work of a postgraduate research degree. Ethical approval has been 
waived by the NHS Research and Ethics Committee as the project is classed as a service evaluation. If 
you have any further queries, please do not hesitate to contact us by letter or email. 
Many thanks for your help in advance, 
Yours sincerely, 
 
Mr Mike Gill  Prof Greg Rubin   Prof Mike Bramble 
SpR Surgery  Professor of General Practice Consultant Gastroenterologist 
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Appendix 4 2nd Medication Request 
Letter 
 
 
Wolfson Research Institute 
Durham University Queen's Campus 
University Boulevard Stockton on Tees 
TS17 6BH 
m.gill@nhs.net  
5
th
 March 2012 
Dear Colleague, 
 
We wrote to you on the 7
th
 February 2012 regarding a study of people diagnosed with colorectal 
cancer through the Bowel Cancer Screening Programme. Specifically, we are looking at possible 
reasons why the biennial faecal occult blood test (FOBt) appears to be worse at detecting cancers in 
women and in the right colon (proximal to the splenic flexure).  
One possibility is that medication or surgery may have an effect on the positivity of a FOBt in 
someone with a cancer. Specifically: oestrogen therapy (e.g. HRT), NSAIDs/aspirin and 
cholecystectomy may have an effect. We need your help in obtaining the medication history for 
patients within your practice who have been diagnosed with a colorectal cancer within (or outwith) 
the screening programme. 
To date, we have not yet received the copy of the proforma that was enclosed with the initial letter 
sent to your practice. We would be extremely grateful if you could follow this up. If you find it easier, 
we are happy to receive a full print-out of the relevant patient’s medication list. 
Our records for patient dates of death are accurate to the 1
st
 November 2011. Any patient who has 
died after this will not have their date of death recorded in the relevant box on the proforma. 
Therefore, please can you include all inactive patients on your IT system when searching for each 
patient. 
If you no longer have a copy of the proforma, please contact Mr Mike Gill on the email address 
below and we will be happy to email you a new copy. Please accept our apologies if you have 
recently sent your response. If you have any further queries, please do not hesitate to contact us by 
letter or email: m.gill@nhs.net.  
Many thanks for your help in advance, 
Yours sincerely, 
 
Mr Mike Gill  Prof Greg Rubin   Prof Mike Bramble 
SpR Surgery  Professor of General Practice Consultant Gastroenterologist 
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Appendix 5 3rd Medication Request 
Letter 
 
 
Wolfson Research Institute 
Durham University Queen's Campus 
University Boulevard Stockton on Tees 
TS17 6BH 
m.gill@nhs.net  
15
th
 May 2012 
Dear Colleague, 
 
We wrote to you on the 7
th
 February and the 5
th
 March 2012 regarding a study of people diagnosed 
with colorectal cancer through the Bowel Cancer Screening Programme. Specifically, we are looking 
at possible reasons why the biennial faecal occult blood test (FOBt) appears to be worse at detecting 
cancers in women and in the right colon (proximal to the splenic flexure).  
One possibility is that medication or surgery may have an effect on the positivity of a FOBt in 
someone with a cancer. Specifically: oestrogen therapy (e.g. HRT), NSAIDs/aspirin and 
cholecystectomy may have an effect. We need your help in obtaining the medication history for 
patients within your practice who have been diagnosed with a colorectal cancer within (or outwith) 
the screening programme. 
To date, we have not yet received the copy of the proforma that was enclosed with the initial letter 
sent to your practice. We would be extremely grateful if you could follow this up. If you find it easier, 
we are happy to receive a full print-out of the relevant patient’s medication list, in particular if the 
relevant patient has had multiple PRN prescriptions of non-steroidals, for example. This is now 
extremely important as even with a low response rate there are indications that the FOB test 
performs better in patients taking NSAIDs. 
Our records for patient dates of death are accurate to the 1
st
 November 2011. Any patient who has 
died after this will not have their date of death recorded in the relevant box on the proforma. 
Therefore, please can you include all inactive patients on your IT system when searching for each 
patient. 
To date, we have only had a 53% response rate from all practices which has generated interesting 
but not definitive results due to the relatively small number of patients that were taking medications 
(specifically NSAIDs). We really need to increase the completeness of the data to see if the results 
are significant or not. A response rate of 70 -80% would be sufficient, and this is one of those 
projects where primary care involvement is crucial and can make a significant difference to the 
research findings. We need your support. 
Many thanks for your help in advance, 
Yours sincerely, 
 
Mr Mike Gill  Prof Greg Rubin   Prof Mike Bramble 
SpR Surgery  Professor of General Practice Consultant Gastroenterologist 
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